

第 1 章 miRNA 在三阴性乳腺癌中的作用:诊断、预后和治疗

- Adams BD, Wali VB, Cheng CJ, Inukai S, Booth CJ, Agarwal S, Rimm DL, Györfy B, Santarpia L, Pusztai L, Saltzman WM, Slack FJ (2016) miR-34a silences c-SRC to attenuate tumor growth in triple-negative breast cancer. *Cancer Res* 76:927–939
- Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhai S, Wood MJ (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nat Biotechnol* 29:341–345
- Bar I, Merhi A, Abdel-Sater F, Ben Addi A, Sollennita S, Canon J-L, Delrée P (2017) The MicroRNA miR-210 is expressed by cancer cells but also by the tumor microenvironment in triple-negative breast cancer. *J Histochem Cytochem* 65:335–346
- Baumann V, Winkler J (2014) miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. *Future Med Chem* 6:1967–1984
- Berber U, Yilmaz I, Narli G, Haholu A, Kucukodaci Z, Demirel D (2014) miR-205 and miR-200c: predictive micro RNAs for lymph node metastasis in triple negative breast cancer. *J Breast Cancer* 17:143–148
- Bhardwaj A, Singh H, Rajapakshe K, Tachibana K, Ganesan N, Pan Y, Gunaratne PH, Coarfa C, Bedrosian I (2017) Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer. *Oncotarget* 8:19645–19660
- Biswas S, Mandal G, Roy Chowdhury S, Purohit S, Payne KK, Anadon C, Gupta A, Swanson P, Yu X, Conejo-Garcia JR (2019) Exosomes produced by mesenchymal stem cells drive differentiation of myeloid cells into immunosuppressive M2-polarized macrophages in breast cancer. *J Immunol* 203:3447–3460
- Bolandghamat Pour Z, Nourbakhsh M, Mousavizadeh K, Madjd Z, Ghorbanhosseini SS, Abdolvahabi Z, Hesari Z, Ezzati Mobasser S (2019) Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin. *BMC Cancer* 19:1–13
- Borri F, Granaglia A (2021) Pathology of triple negative breast cancer. In: *Seminars in cancer biology*. Elsevier, London
- Browne G, Dragon JA, Hong D, Messier TL, Gordon JA, Farina NH, Boyd JR, VanOudenhove JJ, Perez AW, Zaidi SK (2016) MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells. *Tumour Biol* 37:8825–8839
- Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J (2011) microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. *Cancer Res* 71:5635–5645
- Cao Z-G, Li J-J, Yao L, Huang Y-N, Liu Y-R, Hu X, Song C-G, Shao Z-M (2016) High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer. *Oncotarget* 7:64900
- Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM (2013) Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. *PLoS One* 8:e55910
- Chakkaravarthi K, Ramesh R, Palaniyandi T, Baskar G, Viswanathan S, Wahab MRA,

- Surendran H, Ravi M, Sivaji A (2023) Prospectives of mirna gene signaling pathway in triple-negative breast cancer. *Pathol Res Pract* 248:154658
- Chaudhary P, Gibbs LD, Maji S, Lewis CM, Suzuki S, Vishwanatha JK (2020) Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis. *Breast Cancer Res* 22:1–15
- Chen H, Pan H, Qian Y, Zhou W, Liu X (2018a) MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2. *Mol Cancer* 17:1–11
- Chen X, Zhao M, Huang J, Li Y, Wang S, Harrington CA, Qian DZ, Sun XX, Dai MS (2018b) MicroRNA-130a suppresses breast cancer cell migration and invasion by targeting FOSL1 and upregulating ZO-1. *J Cell Biochem* 119:4945–4956
- Dass SA, Tan KL, Selva Rajan R, Mokhtar NF, Mohd Adzmi ER, Wan Abdul Rahman WF, Tengku Din TADA-A, Balakrishnan V (2021) Triple negative breast cancer: a review of present and future diagnostic modalities. *Medicina* 57:62
- de Faria BJ, Marta GN (2022) Triple-negative breast cancer and radiation therapy. *Rep Pract Oncol Radiother* 27:545–551
- Deng X, Cao M, Zhang J, Hu K, Yin Z, Zhou Z, Xiao X, Yang Y, Sheng W, Wu Y (2014) Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. *Biomaterials* 35:4333–4344
- Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. *Clin Cancer Res* 13:4429–4434
- Di Leone A, Franco A, Zotta F, Scardina L, Sicignano M, Di Guglielmo E, Castagnetta V, Magno S, Terribile D, Sanchez AM, Franceschini G, Masetti R (2023) Local treatment of triple-negative breast cancer: is mastectomy superior to breast-conserving surgery? *J Pers Med* 13
- Dioufa N, Clark AM, Ma B, Beckwitt CH, Wells A (2017) Bi-directional exosome-driven inter-communication between the hepatic niche and cancer cells. *Mol Cancer* 16:1–14
- Eades G, Wolfson B, Zhang Y, Li Q, Yao Y, Zhou Q (2015) lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6. *Mol Cancer Res* 13:330–338
- Encarnación-Medina J, Godoy L, Matta J, Ortiz-Sánchez C (2023) Identification of Exo-miRNAs: a summary of the efforts in translational studies involving triple-negative breast cancer. *Cells* 12
- Fu Y, Yang Q, Yang H, Zhang X (2023) New progress in the role of microRNAs in the diagnosis and prognosis of triple negative breast cancer. *Front Mol Biosci* 10:1162463
- García-García F, Salinas-Vera YM, García-Vázquez R, Marchat LA, Rodríguez-Cuevas S, López-González JS, Carlos-Reyes Á, Ramos-Payán R, Aguilar-Medina M, Pérez-Plasencia C (2019) miR-145-5p is associated with pathological complete response to neoadjuvant chemotherapy and impairs cell proliferation by targeting TGFβR2 in breast cancer. *Oncol Rep* 41:3527–3534
- Gong C, Tian J, Wang Z, Gao Y, Wu X, Ding X, Qiang L, Li G, Han Z, Yuan Y (2019) Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy. *J Nanobiotechnol* 17:1–18
- Gong W, Zhu C, Liu Y, Muckenhuber A, Bronger H, Scorilas A, Kiechle M, Dorn J, Magdolen V, Dreyer T (2021) Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer. *Am J Transl Res* 13:1594
- Grimaldi AM, Nuzzo S, Condorelli G, Salvatore M, Incoronato M (2020) Prognostic and clinicopathological significance of MiR-155 in breast cancer: a systematic review. *Int J Mol Sci* 21:5834
- Grimaldi AM, Salvatore M, Incoronato M (2021) miRNA-based therapeutics in breast cancer: a

- systematic review. *Front Oncol* 11:668464
- Guz M, Jeleniewicz W, Cybulski M (2023) Interactions between circRNAs and miR-141 in cancer: from pathogenesis to diagnosis and therapy. *Int J Mol Sci* 24:11861
- Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. *J Clin Oncol* 24:5652–5657
- Halsted CP, Benson JR, Jatoi I (2014) A historical account of breast cancer surgery: beware of local recurrence but be not radical. *Future Oncol* 10:1649–1657
- Hamam R, Ali AM, Alsaleh KA, Kassem M, Alfayez M, Aldahmash A, Alajez NM (2016) microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. *Sci Rep* 6:25997
- Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). *Arch Pathol Lab Med* 134:e48–e72
- Han J, Yu J, Li J, Guo M, Song J, Zhou X (2019) Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway. *Bosn J Basic Med Sci* 19:52
- Hata A, Kashima R (2016) Dysregulation of microRNA biogenesis machinery in cancer. *Crit Rev Biochem Mol Biol* 51:121–134
- Hidalgo-Miranda A, Romero-Cordoba S, Rodriguez-Cuevas S, Rebollar-Vega R, Tagliabue E, Iorio M, D'Ippolito E, Baroni S (2016) A microRNA signature identifies subtypes of triple-negative breast cancer and reveals MIR-342-3P as regulator of a lactate metabolic pathway. In: *Human genomics*. Biomed Central, London
- Higginbotham JN, Zhang Q, Jeppesen DK, Scott AM, Manning HC, Ochieng J, Franklin JL, Coffey RJ (2016) Identification and characterization of EGF receptor in individual exosomes by fluorescence-activated vesicle sorting. *J Extracell Vesicles* 5:29254
- Hong Z, Hong C, Ma B, Wang Q, Zhang X, Li L, Wang C, Chen D (2019) MicroRNA-126-3p inhibits the proliferation, migration, invasion, and angiogenesis of triple-negative breast cancer cells by targeting RGS3. *Oncol Rep* 42:1569–1579
- Hossain F, Majumder S, David J, Miele L (2021) Precision medicine and triple-negative breast cancer: current landscape and future directions. *Cancers* 13:3739
- Hu J, Xu J, Wu Y, Chen Q, Zheng W, Lu X, Zhou C, Jiao D (2015) Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer. *Tumour Biol* 36:251–258
- Ji H, Sang M, Liu F, Ai N, Geng C (2019) miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer. *Pathol Res Pract* 215:697–704
- Jia Z, Liu Y, Gao Q, Han Y, Zhang G, Xu S, Cheng K, Zou W (2016) miR-490-3p inhibits the growth and invasiveness in triple-negative breast cancer by repressing the expression of TNKS2. *Gene* 593:41–47
- Kahraman M, Röske A, Laufer T, Fehlmann T, Backes C, Kern F, Kohlhaas J, Schrörs H, Saiz A, Zabler C, Ludwig N, Fasching PA, Strick R, Rübner M, Beckmann MW, Meese E, Keller A, Schrauder MG (2018) MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer. *Sci Rep* 8:11584
- Kaviani A, Sodagari N, Sheikhabahaei S, Eslami V, Hafezi-Nejad N, Safavi A, Noparast M, Fitoussi A (2013) From radical mastectomy to breast-conserving therapy and oncoplastic breast surgery: a narrative review comparing oncological result, cosmetic outcome, quality of life, and health

economy. *ISRN Oncol* 2013:742462

- Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Børresen-Dale A-L, Santarpia L (2015) A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. *Clin Cancer Res* 21:1207–1214
- Kumar R, Sharma A, Tiwari RK (2012) Application of microarray in breast cancer: an overview. *J Pharm Bioallied Sci* 4:21
- Kunej T, Obsteter J, Pogacar Z, Horvat S, Calin GA (2014) The decalog of long non-coding RNA involvement in cancer diagnosis and monitoring. *Crit Rev Clin Lab Sci* 51:344–357
- Lee JU, Kim WH, Lee HS, Park KH, Sim SJ (2019) Quantitative and specific detection of exosomal miRNAs for accurate diagnosis of breast cancer using a surface-enhanced Raman scattering sensor based on plasmonic head-flocked gold nanopillars. *Small* 15:1804968
- Lee SJ, Jeong J-H, Lee J, Park HY, Jung JH, Kang J, Kim EA, Park NJ-Y, Park J-Y, Lee IH (2021) MicroRNA-496 inhibits triple negative breast cancer cell proliferation by targeting Del-1. *Medicine* 100
- Leidinger P, Backes C, Rheinheimer S, Keller A, Meese E (2015) Towards clinical applications of blood-borne miRNA signatures: the influence of the anticoagulant EDTA on miRNA abundance. *PLoS One* 10:e0143321
- Li W, Liu C, Zhao C, Zhai L, Lv S (2016) Downregulation of $\beta 3$ integrin by miR-30a-5p modulates cell adhesion and invasion by interrupting Erk/Ets-1 network in triple-negative breast cancer corrigendum in/10.3892/ijo. 2021.5169. *Int J Oncol* 48:1155–1164
- Li H-Y, Liang J-L, Kuo Y-L, Lee H-H, Calkins MJ, Chang H-T, Lin F-C, Chen Y-C, Hsu T-I, Hsiao M (2017a) miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. *Breast Cancer Res* 19:1–14
- Li HY, Liang JL, Kuo YL, Lee HH, Calkins MJ, Chang HT, Lin FC, Chen YC, Hsu TI, Hsiao M, Ger LP, Lu PJ (2017b) miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. *Breast Cancer Res* 19:133
- Li Z, Meng Q, Pan A, Wu X, Cui J, Wang Y, Li L (2017c) MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24. *Oncotarget* 8:19455
- Li C, Miao K, Chen Y, Liu L, Zhao G, Lin M, Jiang C (2018) Jagged2 promotes cancer stem cell properties of triple negative breast cancer cells and paclitaxel resistance via regulating microRNA-200. *Eur Rev Med Pharmacol Sci* 22:6008–6014
- Li P-P, Li R-G, Huang Y-Q, Lu J-P, Zhang W-J, Wang Z-Y (2021) LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple negative breast cancer by regulation of miR-26a-5p/MTDH pathway-mediated autophagy and genomic instability. *Aging (Albany NY)* 13:24171
- Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y (2022) Recent advances in therapeutic strategies for triple-negative breast cancer. *J Hematol Oncol* 15:121
- Liang Z, Ahn J, Guo D, Votaw JR, Shim H (2013) MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. *Pharm Res* 30:1008–1016
- Lin Y, Liu AY, Fan C, Zheng H, Li Y, Zhang C, Wu S, Yu D, Huang Z, Liu F (2015) MicroRNA-33b inhibits breast cancer metastasis by targeting HMGA2, SALL4 and Twist1. *Sci Rep* 5:9995
- Liu Y, Cai Q, Bao P-P, Su Y, Cai H, Wu J, Ye F, Guo X, Zheng W, Zheng Y (2015a) Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes. *Breast Cancer Res Treat* 152:183–191
- Liu X, Tang H, Chen J, Song C, Yang L, Liu P, Wang N, Xie X, Lin X, Xie X (2015b) MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer. *Oncotarget* 6:20070

- Liu C, Zhang S, Wang Q, Zhang X (2017) Tumor suppressor miR-1 inhibits tumor growth and metastasis by simultaneously targeting multiple genes. *Oncotarget* 8:42043
- Liu M, Gong C, Xu R, Chen Y, Wang X (2019) MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2. *Cell Mol Biol Lett* 24:1–11
- Liu Y, Gong W, Panoutsopoulou K, Singer-Cornelius T, Augustin K, Bronger H, Kiechle M, Dorn J, Scorilas A, Avgeris M, Magdolen V, Dreyer T (2023) Association of high miR-27a, miR-206, and miR-214 expression with poor patient prognosis and increased chemoresistance in triple-negative breast cancer. *Am J Cancer Res* 13:2471–2487
- Lv ZD, Kong B, Liu XP, Jin LY, Dong Q, Li FN, Wang HB (2016) miR-655 suppresses epithelial-to-mesenchymal transition by targeting Prrx1 in triple-negative breast cancer. *J Cell Mol Med* 20:864–873
- Lytle JR, Yario TA, Steitz JA (2007) Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. *Proc Natl Acad Sci* 104:9667–9672
- Malla RR, Kumari S, Gavara MM, Badana AK, Gugalavath S, Kumar DKG, Rokkam P (2019) A perspective on the diagnostics, prognostics, and therapeutics of microRNAs of triple-negative breast cancer. *Biophys Rev* 11:227–234
- Mao H, Cao Y, Zou Z, Xia J, Zhao J (2023) An enzyme-powered microRNA discriminator for the subtype-specific diagnosis of breast cancer. *Chem Sci* 14:2097–2106
- Matamala N, Vargas MT, Gonzalez-Campora R, Minambres R, Arias JI, Menendez P, Andres-Leon E, Gomez-Lopez G, Yanowsky K, Calvete-Candenas J (2015) Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. *Clin Chem* 61:1098–1106
- Mathe A, Scott RJ, Avery-Kiejda KA (2015) MiRNAs and other epigenetic changes as biomarkers in triple negative breast cancer. *Int J Mol Sci* 16:28347–28376
- Mollah F, Varamini P (2021) Overcoming therapy resistance and relapse in TNBC: emerging technologies to target breast cancer-associated fibroblasts. *Biomedicines* 9:1921
- Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K (2007) Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's surveillance, epidemiology, and end results database. *Cancer* 110:876–884
- Naorem LD, Muthaiyan M, Venkatesan A (2019) Identification of dysregulated miRNAs in triple negative breast cancer: a meta-analysis approach. *J Cell Physiol* 234:11768–11779
- Nassar FJ, Chamandi G, Tfaily MA, Zgheib NK, Nasr R (2020) Peripheral blood-based biopsy for breast cancer risk prediction and early detection. *Front Med* 7:28
- Nie J, Jiang H-C, Zhou Y-C, Jiang B, He W-J, Wang Y-F, Dong J (2019) MiR-125b regulates the proliferation and metastasis of triple negative breast cancer cells via the Wnt/ β -catenin pathway and EMT. *Biosci Biotechnol Biochem* 83:1062–1071
- Niedźwiecki S, Piekarski J, Szymańska B, Pawłowska Z, Jeziorski A (2018) Serum levels of circulating miRNA-21, miRNA-10b and miRNA-200c in triple-negative breast cancer patients. *Ginekol Pol* 89:415–420
- Obidiro O, Battogtokh G, Akala EO (2023) Triple negative breast cancer treatment options and limitations: future outlook. *Pharmaceutics* 15
- O'Brien K, Lowry MC, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RA, O'Driscoll L (2015) miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. *Oncotarget* 6:32774
- Onyeagucha B, Rajamanickam S, Subbarayalu P, Bansal B, Bansal H, Chang Y, Timilsina S,

- Abdelfaltah N, Eedunuri V, Rao M (2016) Abstract P2-03-04: down-regulation of Bcl2-related ovarian killer (BOK) by miR-296-5p protects breast cancer cells from paclitaxel-induced apoptosis. *Cancer Res* 76:P2-03-04-P02-03-04
- Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W, Chang G, Li X, Li Q, Wang S (2014) MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. *PLoS One* 9:e96228
- Paszek S, Gabło N, Barnaś E, Szybka M, Morawiec J, Kołacińska A, Zawlik I (2017) Dysregulation of microRNAs in triple-negative breast cancer. *Ginekolog* 88:530–536
- Perez EA, Cortés J, Gonzalez-Angulo AM, Bartlett JM (2014) HER2 testing: current status and future directions. *Cancer Treat Rev* 40:276–284
- Perou CM, Sørli T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA (2000) Molecular portraits of human breast tumours. *Nature* 406:747–752
- Phan B, Majid S, Ursu S, de Semir D, Nosrati M, Bezrookove V, Kashani-Sabet M, Dar AA (2016) Tumor suppressor role of microRNA-1296 in triple-negative breast cancer. *Oncotarget* 7:19519
- Piasecka D, Braun M, Kordek R, Sadej R, Romanska H (2018) MicroRNAs in regulation of triple-negative breast cancer progression. *J Cancer Res Clin Oncol* 144:1401–1411
- Piombino C, Mastrolia I, Omarini C, Candini O, Dominici M, Piacentini F, Toss A (2021) The role of exosomes in breast cancer diagnosis. *Biomedicines* 9:312
- Poggio M, Hu T, Pai C-C, Chu B, Belair CD, Chang A, Montabana E, Lang UE, Fu Q, Fong L (2019) Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. *Cell* 177: 414–427. e413
- Qattan A (2020) Novel miRNA targets and therapies in the triple-negative breast cancer microenvironment: an emerging hope for a challenging disease. *Int J Mol Sci* 21
- Qattan A, Al-Tweigeri T, Alkhayal W, Suleman K, Tulbah A, Amer S (2021) Clinical identification of dysregulated circulating microRNAs and their implication in drug response in triple negative breast cancer (TNBC) by target gene network and meta-analysis. *Genes (Basel)* 12
- Ritter A, Hirschfeld M, Berner K, Rücker G, Jäger M, Weiss D, Medl M, Nöthling C, Gassner S, Asberger J, Erbes T (2020) Circulating non-coding RNA-biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer? *Int J Oncol* 56:47–68
- Rodríguez-Martínez A, de Miguel-Pérez D, Ortega FG, García-Puche JL, Robles-Fernández I, Exposito J, Martorell-Marugan J, Carmona-Sáez P, Garrido-Navas MC, Rolfo C (2019) Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy. *Breast Cancer Res* 21:1–9
- Saatci O, Kaymak A, Raza U, Ersan PG, Akbulut O, Banister CE, Sikirzhyski V, Tokat UM, Aykut G, Ansari SA, Dogan HT, Dogan M, Jandaghi P, Isik A, Gundogdu F, Kosemehmetoglu K, Dizdar O, Aksoy S, Akyol A, Uner A, Buckhaults PJ, Riazalhosseini Y, Sahin O (2020) Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. *Nat Commun* 11:2416
- Sabit H, Cevik E, Tombuloglu H, Abdel-Ghany S, Tombuloglu G, Esteller M (2021) Triple negative breast cancer in the era of miRNA. *Crit Rev Oncol Hematol* 157:103196
- Saifi O, Chahrour MA, Li Z, Hoballah J, Panoff J, Vallow LA, Zeidan YH (2022) Is breast conservation superior to mastectomy in early stage triple negative breast cancer? *Breast* 62: 144–151
- Sánchez-González I, Bobien A, Molnar C, Schmid S, Strotbek M, Boerries M, Busch H, Olayioye MA (2020) miR-149 suppresses breast cancer metastasis by blocking paracrine interactions with macrophages. *Cancer Res* 80:1330–1341

- Schopp JG, Polat DS, Arjmandi F, Hayes JC, Ahn RW, Sullivan K, Sahoo S, Porembka JH (2023) Imaging challenges in diagnosing triple-negative breast cancer. *Radiographics* 43:e230027
- Shi Y, Wang J, Tao S, Zhang S, Mao L, Shi X, Wang W, Cheng C, Shi Y, Yang Q (2023) miR-142-3p improves paclitaxel sensitivity in resistant breast cancer by inhibiting autophagy through the GNB2-AKT-mTOR pathway. *Cell Signal* 103:110566
- Shin VY, Siu JM, Cheuk I, Ng EK, Kwong A (2015) Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. *Br J Cancer* 112:1751–1759
- Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. *CA Cancer J Clin* 69:7–34
- Song G-Q, Zhao Y (2015) MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells' growth and migration. *Tumour Biol* 36:5001–5009
- Stevic I, Müller V, Weber K, Fasching PA, Karn T, Marmé F, Schem C, Stickeler E, Denkert C, van Mackelenbergh M (2018) Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. *BMC Med* 16:1–16
- Sueta A, Fujiki Y, Goto-Yamaguchi L, Tomiguchi M, Yamamoto-Ibusuki M, Iwase H, Yamamoto Y (2021) Exosomal miRNA profiles of triple-negative breast cancer in neoadjuvant treatment. *Oncol Lett* 22:1–10
- Sugita BM, Pereira SR, de Almeida RC, Gill M, Mahajan A, Duttargi A, Kirolikar S, Fadda P, de Lima RS, Urban CA (2019) Integrated copy number and miRNA expression analysis in triple negative breast cancer of Latin American patients. *Oncotarget* 10:6184
- Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N (2021) Triple-negative breast cancer: promising prognostic biomarkers currently in development. *Expert Rev Anticancer Ther* 21:135–148
- Sun X, Li Y, Zheng M, Zuo W, Zheng W (2016) MicroRNA-223 increases the sensitivity of triple-negative breast cancer stem cells to TRAIL-induced apoptosis by targeting HAX-1. *PLoS One* 11:e0162754
- Svoronos AA, Engelman DM, Slack FJ (2016) OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. *Cancer Res* 76:3666–3670
- Tang Q, Ouyang H, He D, Yu C, Tang G (2019) MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer. *Artif Cells Nanomed Biotechnol* 47:2800–2809
- Thakur S, Grover RK, Gupta S, Yadav AK, Das BC (2016) Identification of specific miRNA signature in paired sera and tissue samples of Indian women with triple negative breast cancer. *PLoS One* 11:e0158946
- Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK (2018) Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles* 7:1535750
- Todorova VK, Byrum SD, Gies AJ, Haynie C, Smith H, Reyna NS, Makhoul I (2022) Circulating exosomal microRNAs as predictive biomarkers of neoadjuvant chemotherapy response in breast cancer. *Curr Oncol* 29:613–630
- Triantafyllou A, Dovrolis N, Zografos E, Theodoropoulos C, Zografos GC, Michalopoulos NV, Gazouli M (2022) Circulating miRNA expression profiling in breast cancer molecular subtypes: applying machine learning analysis in bioinformatics. *Cancer Diagn Prognosis* 2:739
- Wang C, Zheng X, Shen C, Shi Y (2012) MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. *J Exp Clin Cancer Res* 31:1–8

- Wang J, Tsouko E, Jonsson P, Bergh J, Hartman J, Aydogdu E, Williams C (2014) miR-206 inhibits cell migration through direct targeting of the actin-binding protein coronin 1C in triple-negative breast cancer. *Mol Oncol* 8:1690–1702
- Wang Y, Zhang Z, Wang J (2018) MicroRNA-384 inhibits the progression of breast cancer by targeting ACVR1. *Oncol Rep* 39:2563–2574
- Wang D-Y, Gendoo DM, Ben-David Y, Woodgett JR, Zacksenhaus E (2019a) A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling. *Breast Cancer Res* 21:1–13
- Wang DY, Gendoo DMA, Ben-David Y, Woodgett JR, Zacksenhaus E (2019b) A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling. *Breast Cancer Res* 21:18
- Wang C, Xu C, Niu R, Hu G, Gu Z, Zhuang Z (2019c) MiR-890 inhibits proliferation and invasion and induces apoptosis in triple-negative breast cancer cells by targeting CD147. *BMC Cancer* 19:1–11
- Wang B, Zhang Y, Ye M, Wu J, Ma L, Chen H (2019d) Cisplatin-resistant MDA-MB-231 cell-derived exosomes increase the resistance of recipient cells in an exosomal miR-423-5p-dependent manner. *Curr Drug Metab* 20:804–814
- Wang F, Zuroske T, Watts JK (2020) RNA therapeutics on the rise. *Nat Rev Drug Discov* 19:441–442
- Wang D, Nie Y, Wang P, Ma Q (2023) In situ synthesis of Cu nanoclusters/CeO(2) nanorod as aggregated induced ECL probe for triple-negative breast cancer detection. *Talanta* 258:124400
- Weaver JW, Zhang J, Rojas J, Musich PR, Yao Z, Jiang Y (2022) The application of exosomes in the treatment of triple-negative breast cancer. *Front Mol Biosci* 9:1022725
- Wijesinghe KM, Kanak MA, Harrell JC, Dhakal S (2022) Single-molecule sensor for high-confidence detection of miRNA. *ACS Sens* 7:1086–1094
- Won KA, Spruck C (2020) Triple-negative breast cancer therapy: current and future perspectives (review). *Int J Oncol* 57:1245–1261
- Wu H-J, Chu P-Y (2022) Current and developing liquid biopsy techniques for breast cancer. *Cancers* 14:2052
- Wu Q, Chen Z, Zhang G, Zhou W, Peng Y, Liu R, Chen C, Feng J (2018) EZH2 induces the expression of miR-1301 as a negative feedback control mechanism in triple negative breast cancer. *Acta Biochim Biophys Sin* 50:693–700
- Wu X, Chen H, Wu M, Peng S, Zhang L (2020a) Downregulation of miR-182-5p inhibits the proliferation and invasion of triple-negative breast cancer cells through regulating TLR4/NF- κ B pathway activity by targeting FBXW7. *Ann Transl Med* 8
- Wu H, Wang Q, Zhong H, Li L, Zhang Q, Huang Q, Yu Z (2020b) Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next-generation sequencing. *Oncol Rep* 43:240–250
- Xiong H, Yan T, Zhang W, Shi F, Jiang X, Wang X, Li S, Chen Y, Chen C, Zhu Y (2018) miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer. *Cell Signal* 44:33–42
- Xu J, Wu K-j, Jia Q-j, Ding X-f (2020) Roles of miRNA and lncRNA in triple-negative breast cancer. *J Zhejiang Univ Sci B* 21:673
- Xu H, Fang M, Zuo B, Yao W, Ren J, Zhang Y (2023) circAR-E2E4-miR-665-STAT3 axis is a potential regulatory network in triple-negative breast cancer. *Heliyon* 9:e12654
- Yan L-X, Huang X-F, Shao Q, Huang M-Y, Deng L, Wu Q-L, Zeng Y-X, Shao J-Y (2008) MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical

- stage, lymph node metastasis and patient poor prognosis. *RNA* 14:2348–2360
- Yan H, Huang W, Chen C, Zhang X, Zhu K, Yuan J (2023) MiR-133a/CD47 axis is a novel prognostic biomarker to promote triple negative breast cancer progression. *Pathol Res Pract* 244:154400
- Yang F, Zhang W, Shen Y, Guan X (2015) Identification of dysregulated microRNAs in triple-negative breast cancer. *Int J Oncol* 46:927–932
- Ye J, Xu M, Tian X, Cai S, Zeng S (2019) Research advances in the detection of miRNA. *J Pharm Anal* 9:217–226
- Yin J, Zhu C, Wang G, Gu J (2022) Treatment for triple-negative breast cancer: an umbrella review of meta-analyses. *Int J Gen Med* 15:5901–5914
- Yu H, Li H, Qian H, Jiao X, Zhu X, Jiang X, Dai G, Huang J (2014) Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer. *Med Oncol* 31:1–6
- Zeng H, Wang L, Wang J, Chen T, Li H, Zhang K, Chen J, Zhen S, Tuluhong D, Li J (2018) microRNA-129-5p suppresses Adriamycin resistance in breast cancer by targeting SOX2. *Arch Biochem Biophys* 651:52–60
- Zeng C, Fan D, Xu Y, Li X, Yuan J, Yang Q, Zhou X, Lu J, Zhang C, Han J (2020) Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis. *Biochem Pharmacol* 174:113795
- Zhang KJ, Hu Y, Luo N, Li X, Chen FY, Yuan JQ, Guo L (2020) miR-574-5p attenuates proliferation, migration and EMT in triple-negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis. *Int J Oncol* 56:1240–1251
- Zhao Z, Li L, Du P, Ma L, Zhang W, Zheng L, Lan B, Zhang B, Ma F, Xu B (2019) Transcriptional downregulation of miR-4306 serves as a new therapeutic target for triple negative breast cancer. *Theranostics* 9:1401
- Zhong W, Zhang Y, Zhao H, Liang Z, Shi J, Ma Q (2023) High electrochemical active Au-NP/2D zinc-metal organic frameworks heterostructure-based ECL sensor for the miRNA-522 detection in triple negative breast cancer. *Talanta* 265:124875

第2章 乳腺癌免疫学和免疫治疗方法

- Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Card D, Zhao J, Karantza V, Cortes J (2017) Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. *J Clin Oncol* 35:1008. https://doi.org/10.1200/JCO.2017.35.15_suppl.1008
- Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthi S, Grosso JF et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med* 366:2455–2465. <https://doi.org/10.1056/NEJMoa1200694>
- Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dausies T, Fetting J, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V et al (2014) A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. *Cancer Immunol Res* 2:949–961. <https://doi.org/10.1158/2326-6066.CIR-14-0058>
- Cohen EP (2000) Cancer therapy with DNA-based vaccines. *Immunol Lett* 74:59–65. [https://doi.org/10.1016/S0165-2478\(00\)00250-9](https://doi.org/10.1016/S0165-2478(00)00250-9)
- Corti C, Venetis K, Sajjadi E, Zattoni L, Curigliano G, Fusco N (2022) CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. *Expert Opin Investig Drugs* 31:593–605. <https://doi.org/10.1080/13543784.2022.2054326>
- Dees S, Ganesan R, Singh S, Grewal IS (2020) Emerging CAR-T cell therapy for the treatment of triple-negative breast cancer. *Mol Cancer Ther* 19:2409–2421. <https://doi.org/10.1158/1535-7163.MCT-20-0385>
- Disis MLN, Guthrie KA, Liu Y, Coveler AL, Higgins DM, Childs JS, Dang Y, Salazar LG (2023) Safety and outcomes of a plasmid DNA vaccine encoding the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer: a phase 1 nonrandomized clinical trial. *JAMA Oncol* 9:71–78. <https://doi.org/10.1001/jamaoncol.2022.5143>
- Dols A, Meijer SL, Smith JW 2nd, Fox BA, Urba WJ (2003) Allogeneic breast cancer cell vaccines. *Clin Breast Cancer* 3(Suppl 4):S173–S180. <https://doi.org/10.3816/cbc.2003.s.008>
- Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. *Proc Natl Acad Sci U S A* 90:3539–3543. <https://doi.org/10.1073/pnas.90.8.3539>
- Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik SVP, Laiko M, Levi J, Daphtary MM, Biedrzycki BA, Wolff AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, Davidson NE, Jaffee EM (2009) Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. *J Clin Oncol* 27(35):5911–5918
- Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* 144:646–674.

<https://doi.org/10.1016/j.cell.2011.02.013>

- Kagihara JA, Andress M, Diamond JR (2020) Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions. *Expert Rev Precis Med Drug Dev* 5:59–65. <https://doi.org/10.1080/23808993.2020.1730694>
- Keenan BP, Jaffee EM (2012) Whole cell vaccines – past progress and future strategies. *Semin Oncol* 39:276–286. <https://doi.org/10.1053/j.seminoncol.2012.02.007>
- Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N Engl J Med* 373:23–34. <https://doi.org/10.1056/NEJMoa1504030>
- Li J, Burgess DJ (2020) Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment. *Acta Pharm Sin B* 10:2110–2124. <https://doi.org/10.1016/j.apsb.2020.05.008>
- Lopes A, Vandermeulen G, Pr  at V (2019) Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. *J Exp Clin Cancer Res* 38:146. <https://doi.org/10.1186/s13046-019-1154-7>
- Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, Cherif H, Uddin S, Steinhoff M, Marincola FM, Dermime S (2023) CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. *Mol Cancer* 22:20. <https://doi.org/10.1186/s12943-023-01723-z>
- Mittal S, Brown NJ, Holen I (2018) The breast tumor microenvironment: role in cancer development, progression and response to therapy. *Expert Rev Mol Diagn* 18:227–243. <https://doi.org/10.1080/14737159.2018.1439382>
- Mizutani N, Luo Y, Mizutani M, Reisfeld RA, Xiang R (2004) DNA vaccines suppress angiogenesis and protect against growth of breast cancer metastases. *Breast Dis* 20:81–91. <https://doi.org/10.3233/bd-2004-20110>
- Nanda R, Chow LQM, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, Karantza V, Buisseret L (2016) Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. *J Clin Oncol Off J Am Soc Clin Oncol* 34:2460–2467. <https://doi.org/10.1200/JCO.2015.64.8931>
- Nasiri F, Kazemi M, Mirarefin SMJ, Mahboubi Kancha M, Ahmadi Najafabadi M, Salem F, Dashti Shokoohi S, Evazi Bakhshi S, Safarzadeh Kozani P, Safarzadeh Kozani P (2022) CAR-T cell therapy in triple-negative breast cancer: hunting the invisible devil. *Front Immunol* 13:1018786. <https://doi.org/10.3389/fimmu.2022.1018786>
- NCT00729664 (2015) Multiple ascending dose (MDX1105-01) (Anti-PDL1). <https://clinicaltrials.gov/ct2/show/NCT00729664>
- NCT01570036 (2013) Combination immunotherapy with herceptin and the HER2 vaccine NeuVax. <https://clinicaltrials.gov/ct2/show/NCT01570036>
- NCT01730118 (2013) Ad/HER2/Neu dendritic cell cancer vaccine testing. <https://clinicaltrials.gov/ct2/show/NCT01730118>
- NCT01837602 (2018) cMet CAR RNA T cells targeting breast cancer. <https://clinicaltrials.gov/ct2/show/NCT01837602>
- NCT02349724 (2014) A clinical research of CAR T cells targeting CEA positive cancer. <https://clinicaltrials.gov/ct2/show/NCT02349724>
- NCT02414269 (2015) Malignant pleural disease treated with autologous T cells genetically engineered to target the cancer-cell surface antigen mesothelin. <https://clinicaltrials.gov/ct2/>

show/NCT02414269

- NCT02425891 (2022) A study of atezolizumab in combination with nab-paclitaxel compared with placebo with nab-paclitaxel for participants with previously untreated metastatic triple-negative breast cancer (IMpassion130). <https://clinicaltrials.gov/ct2/show/NCT02425891>
- NCT02447003 (2020) Study of pembrolizumab (MK-3475) monotherapy for metastatic triple-negative breast cancer (MK-3475-086/KEYNOTE-086). <https://clinicaltrials.gov/ct2/show/NCT02447003>
- NCT02580747 (2018) Treatment of relapsed and/or chemotherapy refractory advanced malignancies by CART-meso. <https://clinicaltrials.gov/ct2/show/NCT02580747>
- NCT02587689 (2015) Phase I/II study of anti-mucin1 (MUC1) CAR T cells for patients with MUC1+ advanced refractory solid tumor <https://clinicaltrials.gov/ct2/show/NCT02587689>
- NCT02706392 (2021) Genetically modified T-cell therapy in treating patients with advanced ROR1+ malignancies. <https://clinicaltrials.gov/ct2/show/NCT02706392>
- NCT02792114 (2023) T-cell therapy for advanced breast cancer. <https://clinicaltrials.gov/ct2/show/NCT02792114>
- NCT02915445 (2016) EpCAM CAR-T for treatment of advanced solid tumors. <https://clinicaltrials.gov/ct2/show/NCT02915445>
- NCT03060356 (2020) Autologous T cells expressing MET scFv CAR (RNA CART-cMET). <https://clinicaltrials.gov/ct2/show/NCT03060356>
- NCT03635632 (2019) C7R-GD2.CART cells for patients with relapsed or refractory neuroblastoma and other GD2 positive cancers (GAIL-N). <https://clinicaltrials.gov/ct2/show/NCT03635632>
- NCT03682744 (2018) CAR-T intraperitoneal infusions for CEA-expressing adenocarcinoma peritoneal metastases or malignant ascites (IPC). <https://www.clinicaltrials.gov/ct2/show/NCT03682744>
- NCT03696030 (2018) HER2-CAR T cells in treating patients with recurrent brain or leptomeningeal metastases <https://clinicaltrials.gov/ct2/show/NCT03696030>
- NCT03740256 (2023) Binary oncolytic adenovirus in combination with HER2-specific autologous CAR VST, advanced HER2 positive solid tumors (VISTA). <https://clinicaltrials.gov/ct2/show/NCT03740256>
- NCT04020575 (2020) Autologous huMNC2-CAR44 T cells for breast cancer targeting cleaved form of MUC1 (MUC1*). <https://clinicaltrials.gov/ct2/show/NCT04020575>
- NCT04025216 (2019) A study of CART-TnMUC1 in patients with TnMUC1-positive advanced cancers. <https://clinicaltrials.gov/ct2/show/NCT04025216>
- NCT04107142 (2019) Haplo/allogeneic NKG2DL-targeting chimeric antigen receptor-grafted $\gamma\delta$ T cells for relapsed or refractory solid tumour. <https://clinicaltrials.gov/ct2/show/NCT04107142>
- NCT04348643 (2020) Safety and efficacy of CEA-targeted CAR-T therapy for relapsed/refractory CEA+ cancer. <https://www.clinicaltrials.gov/ct2/show/NCT04348643>
- NCT04427449 (2020) 4SCAR-CD44v6 T cell therapy targeting cancer. <https://clinicaltrials.gov/ct2/show/NCT04427449>
- NCT04430595 (2020) Multi-4SCAR-T therapy targeting breast cancer. <https://clinicaltrials.gov/ct2/show/NCT04430595>
- NCT04511871 (2023) A phase I trial of CCT303-406 in patients with relapsed or refractory HER2 positive solid tumors. <https://clinicaltrials.gov/ct2/show/NCT04511871>
- NCT04650451 (2020) Safety and activity study of HER2-targeted dual switch CAR-T cells (BPX-603) in subjects with HER2-positive solid tumors. <https://clinicaltrials.gov/ct2/show/record/NCT04650451>

- Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H (2006) Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. *J Clin Oncol Off J Am Soc Clin Oncol* 24:4721–4730. <https://doi.org/10.1200/JCO.2005.05.5335>
- Nicolás-Morales ML, Luisa-Sanjuan A, Gutiérrez-Torres M, Vences-Velázquez A, Ortuño-Pineda C, Espinoza-Rojo M, Navarro-Tito N, Cortés-Sarabia K (2022) Peptide-based vaccines in clinical phases and new potential therapeutic targets as a new approach for breast cancer: a review. *Vaccine* 10. <https://doi.org/10.3390/vaccines10081249>
- Noh M-G, Kim SS, Kim YJ, Jung T-Y, Jung S, Rhee J-H, Lee J-H, Lee J-S, Cho J-H, Moon K-S, Park H, Lee K-H (2021) Evolution of the tumor microenvironment toward immune-suppressive seclusion during brain metastasis of breast cancer: implications for targeted therapy. *Cancers (Basel)* 13. <https://doi.org/10.3390/cancers13194895>
- O'Donnell JS, Teng MWL, Smyth MJ (2019) Cancer immunoediting and resistance to T cell-based immunotherapy. *Nat Rev Clin Oncol* 16:151–167. <https://doi.org/10.1038/s41571-018-0142-8>
- Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 12:252–264. <https://doi.org/10.1038/nrc3239>
- Peres LP, da Luz FAC, Pultz BA, Brígido PC, de Araújo RA, Goulart LR, Silva MJB (2015) Peptide vaccines in breast cancer: the immunological basis for clinical response. *Biotechnol Adv* 33:1868–1877. <https://doi.org/10.1016/j.biotechadv.2015.10.013>
- Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im S-A, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med* 379:2108–2121. <https://doi.org/10.1056/NEJMoa1809615>
- Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M et al (2022) Event-free survival with pembrolizumab in early triple-negative breast cancer. *N Engl J Med* 386:556–567. <https://doi.org/10.1056/NEJMoa2112651>
- Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science* 331:1565–1570. <https://doi.org/10.1126/science.1203486>
- Shahgolzari M, Dianat-Moghadam H, Yavari A, Fiering SN, Hefferon K (2022) Multifunctional plant virus nanoparticles for targeting breast cancer tumors. *Vaccine* 10. <https://doi.org/10.3390/vaccines10091431>
- Shumway NM, Ibrahim N, Ponniah S, Peoples GE, Murray JL (2009) Therapeutic breast cancer vaccines: a new strategy for early-stage disease. *BioDrugs* 23:277–287. <https://doi.org/10.2165/11313490-000000000-00000>
- Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, Hauda KM, Beck LA, Leiferman KM, Owens AHJ, Piantadosi S, Dranoff G, Mulligan RC, Pardoll DM, Marshall FF (1997) Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. *Cancer Res* 57:1537–1546
- Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G et al (1998) Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. *Proc Natl Acad Sci U S A* 95:13141–13146.

<https://doi.org/10.1073/pnas.95.22.13141>

- Thomas MC, Greten TF, Pardoll DM, Jaffee EM (1998) Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. *Hum Gene Ther* 9:835–843. <https://doi.org/10.1089/hum.1998.9.6-835>
- Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen Y-C, Huang L-Q, Laheru DA, Goggins M, Hruban RH, Jaffee EM (2004) Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. *J Exp Med* 200:297–306. <https://doi.org/10.1084/jem.20031435>
- WHO (2022) Fact sheets: cancer
- WHO (2023) Global breast cancer initiative implementation framework: assessing, strengthening and scaling-up of services for the early detection and management of breast cancer
- Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon R-A, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE et al (2013) Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med* 369:122–133. <https://doi.org/10.1056/NEJMoa1302369>
- Yang B, Jeang J, Yang A, Wu TC, Hung C-F (2014) DNA vaccine for cancer immunotherapy. *Human Vaccine Immunother* 10:3153–3164. <https://doi.org/10.4161/21645515.2014.980686>
- Yang Y-H, Liu J-W, Lu C, Wei J-F (2022) CAR-T cell therapy for breast cancer: from basic research to clinical application. *Int J Biol Sci* 18:2609–2626. <https://doi.org/10.7150/ijbs.70120>
- You Z, Zhou W, Weng J, Feng H, Liang P, Li Y, Shi F (2021) Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis. *Cancer Cell Int* 21:489. <https://doi.org/10.1186/s12935-021-02187-1>
- Zupančič E, Silva J, Videira MA, Moreira JN, Florindo HF (2014) Development of a novel nanoparticle-based therapeutic vaccine for breast cancer immunotherapy. *Proc Vaccinol* 8: 62–67. <https://doi.org/10.1016/j.provac.2014.07.011>

第3章 乳腺癌的分子遗传学:从机制到治疗方法

- Aldea M, Andre F, Marabelle A, Dogan S, Barlesi F, Soria JC (2021) Overcoming resistance to tumor-targeted and immune-targeted therapies. *Cancer Discov* 11(4):874–899. <https://doi.org/10.1158/2159-8290.CD-20-1638>
- American Cancer Society. Breast Cancer Survival Rates. Available at: <https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html>. Accessed on 7 December 2023
- Anstey EH, Shoemaker ML, Barrera CM, O’Neil ME, Verma AB, Holman DM (2017) Breastfeeding and breast cancer risk reduction: implications for black mothers. *Am J Prev Med* 53(3S1):S40–S46. <https://doi.org/10.1016/j.amepre.2017.04.024>
- Arnold M, Morgan E, Rungay H et al (2022) Current and future burden of breast cancer: global statistics for 2020 and 2040. *Breast* 66:15–23. <https://doi.org/10.1016/j.breast.2022.08.010>
- Chang YJ, Hou YC, Chen LJ et al (2017) Is vegetarian diet associated with a lower risk of breast cancer in Taiwanese women? *BMC Public Health* 17(1):800. Published 2017 Oct 10. <https://doi.org/10.1186/s12889-017-4819-1>
- Corso G, Figueiredo J, De Angelis SP et al (2020) E-cadherin deregulation in breast cancer. *J Cell Mol Med* 24(11):5930–5936. <https://doi.org/10.1111/jcmm.15140>
- Costa B, Amorim I, Gärtner F, Vale N (2020) Understanding breast cancer: from conventional therapies to repurposed drugs. *Eur J Pharm Sci* 151:105401. <https://doi.org/10.1016/j.ejps.2020.105401>
- Dall GV, Britt KL (2017) Estrogen effects on the mammary gland in early and late life and breast cancer risk. *Front Oncol* 7:110. Published 2017 May 26. <https://doi.org/10.3389/fonc.2017.00110>
- Debien V, De Caluwé A, Wang X et al (2023) Immunotherapy in breast cancer: an overview of current strategies and perspectives. *NPJ Breast Cancer* 9(1):7. Published 2023 Feb 13. <https://doi.org/10.1038/s41523-023-00508-3>
- Dey S, Boffetta P, Mathews A, Brennan P, Soliman A, Mathew A (2009) Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum, South India. *Int J Cancer* 125(7):1663–1670. <https://doi.org/10.1002/ijc.24460>
- Dumitrescu RG, Shields PG (2005) The etiology of alcohol-induced breast cancer. *Alcohol* 35(3):213–225. <https://doi.org/10.1016/j.alcohol.2005.04.005>
- Eklund M, Broglio K, Yau C, Connor JT, Stover Fiscallini A, Esserman LJ (2019) The WISDOM personalized breast cancer screening trial: simulation study to assess potential bias and analytic approaches. *JNCI Cancer Spectr* 2(4):pky067. Published 2019 Jan 8. <https://doi.org/10.1093/jncics/pky067>
- Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology* 19(5):403–410. <https://doi.org/10.1111/j.1365-2559.1991.tb00229.x>
- Evans DGR, van Veen EM, Harkness EF et al (2022) Breast cancer risk stratification in women of screening age: incremental effects of adding mammographic density, polygenic risk, and a gene panel. *Genet Med* 24(7):1485–1494. <https://doi.org/10.1016/j.gim.2022.03.009>
- Fachal L, Aschard H, Beesley J et al (2020) Fine-mapping of 150 breast cancer risk regions

- identifies 191 likely target genes. *Nat Genet* 52(1):56–73. <https://doi.org/10.1038/s41588-019-0537-1>
- Fedele M, Cerchia L, Chiappetta G (2017) The epithelial-to-mesenchymal transition in breast cancer: focus on basal-like carcinomas. *Cancers (Basel)* 9(10):134. Published 2017 Sept 30. <https://doi.org/10.3390/cancers9100134>
- Filippini SE, Vega A (2013) Breast cancer genes: beyond BRCA1 and BRCA2. *Front Biosci (Landmark Ed)* 18(4):1358–1372. Published 2013 June 1. <https://doi.org/10.2741/4185>
- Fortner RT, Sisti J, Chai B et al (2019) Parity, breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the nurses' health studies. *Breast Cancer Res* 21(1):40. Published 2019 Mar 12. <https://doi.org/10.1186/s13058-019-1119-y>
- Gasperskaja E, Kučinskas V (2017) The most common technologies and tools for functional genome analysis. *Acta Med Litu* 24(1):1–11. <https://doi.org/10.6001/actamedica.v24i1.3457>
- Ginter PS, Idress R, Alfonso TMD, Fineberg S, Jaffer S, Sattar AK et al (2021) Histologic grading of breast carcinoma: a multi-institution study of interobserver variation using virtual microscopy. *Mod Pathol* 34(4):701–709. <https://doi.org/10.1038/s41379-020-00698-2>. Epub 2020 Oct 19
- Giuliano AE, Edge SB, Hortobagyi GN (2018) Eighth edition of the AJCC cancer staging manual: breast cancer. *Ann Surg Oncol* 25:1783–1785. <https://doi.org/10.1245/s10434-018-6486-6>
- Graffeo R, Rana HQ, Conforti F et al (2022) Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. *Breast* 65:32–40. <https://doi.org/10.1016/j.breast.2022.06.003>
- Guo W, Key TJ, Reeves GK (2018) Adiposity and breast cancer risk in postmenopausal women: results from the UK biobank prospective cohort. *Int J Cancer* 143(5):1037–1046. <https://doi.org/10.1002/ijc.31394>
- Harkness EF, Astley SM, Evans DG (2020) Risk-based breast cancer screening strategies in women. *Best Pract Res Clin Obstet Gynaecol* 65:3–17. <https://doi.org/10.1016/j.bpobgyn.2019.11.005>
- Hortobagyi GN, Buzdar AU (1988) Management of locally advanced breast cancer. *Am J Clin Oncol* 11(5):597–601. <https://doi.org/10.1097/00000421-198810000-00018>
- Hu ZI, McArthur HL (2018) Immunotherapy in breast cancer: the new frontier. *Curr Breast Cancer Rep* 10(2):35–40. <https://doi.org/10.1007/s12609-018-0274-y>
- Huber-Keener KJ (2022) Cancer genetics and breast cancer. *Best Pract Res Clin Obstet Gynaecol* 82:3–11. <https://doi.org/10.1016/j.bpobgyn.2022.01.007>
- Johnson KS, Conant EF, Soo MS (2021) Molecular subtypes of breast cancer: a review for breast radiologists. *J Breast Imaging* 3:12–24. <https://doi.org/10.1093/jbi/wbaa110>
- Kaur RP, Vasudeva K, Kumar R, Munshi A (2018) Role of p53 gene in breast cancer: focus on mutation spectrum and therapeutic strategies. *Curr Pharm Des* 24(30):3566–3575. <https://doi.org/10.2174/1381612824666180926095709>
- Khodarahmi M, Azadbakht L (2014) The association between different kinds of fat intake and breast cancer risk in women. *Int J Prev Med* 5(1):6–15
- Liu Y, Nguyen N, Colditz GA (2015) Links between alcohol consumption and breast cancer: a look at the evidence. *Womens Health (Lond)* 11(1):65–77. <https://doi.org/10.2217/whe.14.62>
- Łukasiewicz S, Czezelewski M, Forma A, Baj J, Sitarz R, Stanisławek A (2021) Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. *Cancers (Basel)* 13(17):4287. Published 2021 Aug 25. <https://doi.org/10.3390/cancers13174287>
- Marvalim C, Datta A, Lee SC (2023) Role of p53 in breast cancer progression: an insight into p53

- targeted therapy. *Theranostics* 13(4):1421–1442. Published 2023 Feb 27. <https://doi.org/10.7150/thno.81847>
- Mavaddat N, Michailidou K, Dennis J et al (2019) Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. *Am J Hum Genet* 104(1):21–34. <https://doi.org/10.1016/j.ajhg.2018.11.002>
- Melhem-Bertrandt A, Bojadzieva J, Ready KJ et al (2012) Early onset HER2-positive breast cancer is associated with germline TP53 mutations [published correction appears in *Cancer*. 2012 May 1;118(9):2561]. *Cancer* 118(4):908–913. <https://doi.org/10.1002/cncr.26377>
- Meyer JS, Alvarez C, Milikowski C, Olson L, Russo I, Russo J et al (2005) Breast carcinoma malignancy grading by Bloom–Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. *Mod Pathol* 2005(18):1067–1078. <https://doi.org/10.1038/modpathol.3800388>
- Michailidou K, Lindström S, Dennis J et al (2017) Association analysis identifies 65 new breast cancer risk loci. *Nature* 551(7678):92–94. <https://doi.org/10.1038/nature24284>
- Moo TA, Sanford R, Dang C, Morrow M (2018) Overview of breast cancer therapy. *PET Clin* 13(3):339–354. <https://doi.org/10.1016/j.cpet.2018.02.006>
- Muranen TA, Morra A, Khan S et al (2023) PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants. *NPJ Breast Cancer* 9(1):37. Published 2023 May 12. <https://doi.org/10.1038/s41523-023-00546-x>
- Nassar A, Zekri AN, Kamel MM et al (2022) Frequency of pathogenic germline mutations in early and late onset familial breast cancer patients using multi-gene panel sequencing: an Egyptian study. *Genes (Basel)* 14(1):106. Published 2022 Dec 29. <https://doi.org/10.3390/genes14010106>
- Park JH, Jonas SF, Bataillon G et al (2019) Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. *Ann Oncol* 30(12):1941–1949. <https://doi.org/10.1093/annonc/mdz395>
- Perou C, Sørli T, Eisen M et al (2000) Molecular portraits of human breast tumours. *Nature* 406:747–752. <https://doi.org/10.1038/35021093>
- Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM (2017) Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention. *CA Cancer J Clin* 67(5):378–397. <https://doi.org/10.3322/caac.21405>
- Pilewskie M, Jochelson M, Gooch JC, Patil S, Stempel M, Morrow M (2016) Is preoperative axillary imaging beneficial in identifying clinically node-negative patients requiring axillary lymph node dissection? *J Am Coll Surg* 222(2):138–145. <https://doi.org/10.1016/j.jamcollsurg.2015.11.013>
- Pradella LM, Evangelisti C, Ligorio C et al (2014) A novel deleterious PTEN mutation in a patient with early-onset bilateral breast cancer. *BMC Cancer* 14:70. Published 2014 Feb 6. <https://doi.org/10.1186/1471-2407-14-70>
- Renwick A, Thompson D, Seal S et al (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. *Nat Genet* 38(8):873–875. <https://doi.org/10.1038/ng1837>
- Rizvi SAA, Saleh AM (2018) Applications of nanoparticle systems in drug delivery technology. *Saudi Pharm J* 26(1):64–70. <https://doi.org/10.1016/j.jsps.2017.10.012>
- Roberts E, Howell S, Evans DG (2023) Polygenic risk scores and breast cancer risk prediction. *Breast* 67:71–77. <https://doi.org/10.1016/j.breast.2023.01.003>
- Roux A, Cholerton R, Sicsic J et al (2022) Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the “My Personal Breast Screening” (MyPeBS) randomised clinical trial. *BMC Cancer* 22(1):

507. Published 2022 May 6. <https://doi.org/10.1186/s12885-022-09484-6>
- Sajjadi E, Venetis K, Piciotti R et al (2021) Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling. *BMC Cancer* 21(1):1152. Published 2021 Oct 28. <https://doi.org/10.1186/s12885-021-08889-z>
- Satish S, Moore JF, Littlefield JM, Bishop IJ, Rojas KE et al (2023) Breast Cancer (Dove Med Press) 15:227–235. Published 2023 Mar 22. <https://doi.org/10.2147/BCTT.S390664>
- Sawaki M, Shien T, Iwata H (2019) TNM classification of malignant tumors (Breast Cancer Study Group). *Jpn J Clin Oncol* 49:228–231. <https://doi.org/10.1093/jjco/hyy182>
- Shah PD (2021) Polygenic risk scores for breast cancer-can they deliver on the promise of precision medicine? *JAMA Netw Open* 4(8):e2119333. Published 2021 Aug 2. <https://doi.org/10.1001/jamanetworkopen.2021.19333>
- Sidransky D, Tokino T, Helzlsouer K et al (1992) Inherited p53 gene mutations in breast cancer. *Cancer Res* 52(10):2984–2986
- Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. *CA Cancer J Clin* 72(1): 7–33. <https://doi.org/10.3322/caac.21708>
- Sohail SK, Sarfraz R, Imran M, Kamran M, Qamar S (2020) Estrogen and progesterone receptor expression in breast carcinoma and its association with clinicopathological variables among the Pakistani population. *Cureus* 12(8):e9751. <https://doi.org/10.7759/cureus.9751>
- Starek-Świechowicz B, Budziszewska B, Starek A (2023) Alcohol and breast cancer. *Pharmacol Rep* 75(1):69–84. <https://doi.org/10.1007/s43440-022-00426-4>
- Sud A, Turnbull C, Houlston R (2021) Will polygenic risk scores for cancer ever be clinically useful? *NPJ Precis Oncol* 5(1):40. Published 2021 May 21. <https://doi.org/10.1038/s41698-021-00176-1>
- Surakasula A, Nagarjunapu GC, Raghavaiah KV (2014) A comparative study of pre- and post-menopausal breast cancer: risk factors, presentation, characteristics and management. *J Res Pharm Pract* 3(1):12–18. <https://doi.org/10.4103/2279-042X.132704>
- Suzuki Y, Tsunoda H, Kimura T, Yamauchi H (2017) BMI change and abdominal circumference are risk factors for breast cancer, even in Asian women. *Breast Cancer Res Treat* 166(3): 919–925. <https://doi.org/10.1007/s10549-017-4481-4>
- Tan SH, Wolff AC (2007) Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. *Clin Breast Cancer* 7(6):455–464. <https://doi.org/10.3816/CBC.2007.n.002>
- Torabi Dalivandan S, Plummer J, Gayther SA (2021) Risks and function of breast cancer susceptibility alleles. *Cancers (Basel)* 13(16):3953. Published 2021 Aug 5. <https://doi.org/10.3390/cancers13163953>
- Torres-de la Roche LA, Acevedo-Mesa A, Lizarazo IL et al (2023) Hormonal contraception and the risk of breast cancer in women of reproductive age: a meta-analysis. *Cancers (Basel)* 15(23): 5624. Published 2023 Nov 28. <https://doi.org/10.3390/cancers15235624>
- Tsang JYS, Tse GM (2020) Molecular classification of breast cancer. *Adv Anat Pathol* 27(1): 27–35. <https://doi.org/10.1097/PAP.0000000000000232>
- Van Dooijeweert C, van Diest PJ, Ellis IO (2022) Grading of invasive breast carcinoma: the way forward. *Virchows Arch* 480(1):33–43. <https://doi.org/10.1007/s00428-021-03141-2>
- Waks AG, Stover DG, Guerriero JL, et al. (2019) The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy. *Clin Cancer Res* 25(15):4644–4655. <https://doi.org/10.1158/1078-0432.CCR-19-0173>
- Wilson JR, Bateman AC, Hanson H et al (2010) A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations [published correction appears in *J Med Genet*. 2011

- Mar;48(3):216]. *J Med Genet* 47(11):771–774. <https://doi.org/10.1136/jmg.2010.078113>
- Yadav S, Boddicker NJ, Na J et al (2023) Contralateral breast cancer risk among carriers of germline pathogenic variants in *ATM*, *BRCA1*, *BRCA2*, *CHEK2*, and *PALB2*. *J Clin Oncol* 41(9):1703–1713. <https://doi.org/10.1200/JCO.22.01239>
- Yanes T, McInerney-Leo AM, Law MH, Cummings S (2020) The emerging field of polygenic risk scores and perspective for use in clinical care. *Hum Mol Genet* 29(R2):R165–R176. <https://doi.org/10.1093/hmg/ddaa136>
- Yin L, Duan JJ, Bian XW, Yu S (2020) Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Res* 22:61. <https://doi.org/10.1186/s13058-020-01296-5>
- Zhou X, Yu L, Wang L et al (2022) Alcohol consumption, blood DNA methylation and breast cancer: a Mendelian randomisation study. *Eur J Epidemiol* 37(7):701–712. <https://doi.org/10.1007/s10654-022-00886-1>

第4章 白细胞介素在乳腺癌发生发展中的作用

- Ahmad N, Ammar A, Storr SJ, Green AR, Rakha E, Ellis IO, Martin SG (2017) IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. *Cancer Immunol Immunother* 67:537–549. <https://doi.org/10.1007/s00262-017-2106-8>
- Al-Rawi MA, Rmali K, Mansel RE, Jiang WG (2004) Interleukin 7 induces the growth of breast cancer cells through a wortmannin-sensitive pathway. *Br J Surg* 91:61–68. <https://doi.org/10.1002/bjs.4449>
- Aziz MA, Akter T, Sarwar MS, Islam MS (2022) The first combined meta-analytic approach for elucidating the relationship of circulating resistin levels and RETN gene polymorphisms with colorectal and breast cancer. *Egypt J Med Hum Genet* 23:27. <https://doi.org/10.1186/s43042-022-00240-w>
- Baker KJ, Houston A, Brint E (2019) IL-1 family members in cancer; two sides to every story. *Front Immunol* 10:1197. <https://doi.org/10.3389/fimmu.2019.01197>
- Balasubramanian SP, Azmy IA, Higham SE, Wilson AG, Cross SS, Cox A, Brown NJ, Reed MW (2006) Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. *BMC Cancer* 6:188. <https://doi.org/10.1186/1471-2407-6-188>
- Bankaitis KV, Fingleton B (2015) Targeting IL4/IL4R for the treatment of epithelial cancer metastasis. *Clin Exp Metastasis* 32:847–856. <https://doi.org/10.1007/s10585-015-9747-9>
- Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvisé M, Castañón E, Melero I (2019) Cytokines in clinical cancer immunotherapy. *Br J Cancer* 120:6–15. <https://doi.org/10.1038/s41416-018-0328-y>
- Boesch M, Onder L, Cheng HW, Novkovic M, Mörbe U, Sopper S, Gastl G, Jochum W, Ruhstaller T, Knauer M, Ludewig B (2018) Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of tumor cell stemness. *Onco Targets Ther* 7:e1414129. <https://doi.org/10.1080/2162402X.2017.1414129>
- Chavey C, Bibeau F, Gourgou-Bourgade S, Burlincho S, Boissière F, Laune D, Roques S, Lazennec G (2007) Oestrogen receptor negative breast cancers exhibit high cytokine content. *Breast Cancer Res* 9:15. <https://doi.org/10.1186/bcr1648>
- Chen WC, Lai YH, Chen HY, Guo HR, Su IJ, Chen HHW (2013a) Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. *Histopathology* 63:225–233. <https://doi.org/10.1111/his.12156>
- Chen YY, Li CF, Yeh CH, Chang MS, Hsing CH (2013b) Interleukin-19 in breast cancer. *Clin Dev Immunol* 2013:29432. <https://doi.org/10.1155/2013/294320>
- Chu CN, Wang YC, Chang WS, Wang ZH, Liu LC, Wang SC, Lin CC, Liu TY, Chang JG, Tsai CW, Yu CC, Bau DT (2020) Association of interleukin-4 polymorphisms with breast cancer in Taiwan. *In Vivo* 34:1111–1116. <https://doi.org/10.21873/invivo.11882>
- Collison LW, Chaturvedi V, Henderson AL, Giacomini PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA, Rehg JE, Jones ML, Ni HT, Artis D, Turk MJ, Vignali DA (2010) IL-35-mediated induction of a potent regulatory T cell population. *Nat Immunol* 11:1093–10101. <https://doi.org/10.1038/ni.1952>
- Coughlin SS (2019) Epidemiology of breast cancer in women. *Adv Exp Med Biol* 1152:9–29. https://doi.org/10.1007/978-3-030-20301-6_2

- Cui M, Zhang Q, Qiu X, Jin F (2016) The role of IL-11 and IL-Ra in angiogenesis of breast cancer. *Int J Clin Exp Pathol* 9:11682–11687
- De Larco JE, Wuertz BR, Rosner KA, Erickson SA, Gamache DE, Manivel JC, Furcht LT (2001) A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. *Am J Pathol* 158:639–646. [https://doi.org/10.1016/S0002-9440\(10\)64005-9](https://doi.org/10.1016/S0002-9440(10)64005-9)
- Dittmer J, Leyh B (2015) The impact of tumor stroma on drug response in breast cancer. *Semin Cancer Biol* 31:3–15. <https://doi.org/10.1016/j.semcancer.2014.05.006>
- Dmitrieva OS, Shilovskiy IP, Khaitov MR, Grivennikov SI (2016) Interleukins 1 and 6 as main mediators of inflammation and cancer. *Biochemist* 81:80–90. <https://doi.org/10.1134/S0006297916020024>
- Ekmekcioglu S, Kurzrock R, Grimm EA (2008) Hematopoietic growth factors and cytokines. In: *The molecular basis of cancer*. Elsevier, Amsterdam, pp 605–619
- Escobar P, Bouclier C, Serret J, Bièche I, Brigitte M, Caicedo A, Sanchez E, Vacher S, Vignais ML, Bourin P, Geneviève D, Molina F, Jorgensen C, Lazennec G (2015) IL-1 β produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production. *Oncotarget* 6:9–12. <https://doi.org/10.18632/oncotarget.4732>
- Fasoulakis Z, Kolios G, Papamanolis V, Kontomanolis EN (2018) Interleukins associated with breast cancer. *Cureus* 10:e3549. <https://doi.org/10.7759/cureus.3549>
- Filippi I, Carraro F, Naldini A (2015) Interleukin-1 β affects MDAMB231 breast cancer cell migration under hypoxia: role of HIF-1 α and NF κ B transcription factors. *Mediat Inflamm* 2015:789414. <https://doi.org/10.1155/2015/789414>
- Gaggianesi M, Turdo A, Chinnici A, Lipari E, Apuzzo T, Benfante A, Sperduti I, Di Franco S, Meraviglia S, Lo Presti E, Dieli F, Caputo V, Militello G, Vieni S, Stassi G, Todaro M (2017) IL4 primes the dynamics of breast cancer progression via DUSP4 inhibition. *Cancer Res* 77:3268–3279. <https://doi.org/10.1158/0008-5472>
- Gangemi S, Minciullo P, Adamo B, Franchina T, Ricciardi GR, Ferraro M, Briguglio R, Toscano G, Saitta S, Adamo V (2012) Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. *J Cell Biochem* 113:2122–2125. <https://doi.org/10.1002/jcb.24083>
- García-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M (2004) Interleukin-2 and its receptor complex (alpha, beta and gamma chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study. *Breast Cancer Res* 6:1–7. <https://doi.org/10.1186/bcr730>
- Green AR, Green VL, White MC, Speirs V (1997) Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. *Int J Cancer* 72:937–941. [https://doi.org/10.1002/\(SICI\)1097-0215\(19970917\)72:6%3C937::AID-IJC3%3E3.0.CO;2-Q](https://doi.org/10.1002/(SICI)1097-0215(19970917)72:6%3C937::AID-IJC3%3E3.0.CO;2-Q)
- Hanavadi S, Martin TA, Watkins G, Mansel RE, Jiang WG (2006) Expression of interleukin 11 and its receptor and their prognostic value in human breast cancer. *Ann Surg Oncol* 13:802–808. <https://doi.org/10.1245/ASO.2006.05.028>
- Hao S, Chen X, Wang F, Shao Q, Liu J, Zhao H, Yuan C, Ren H, Mao H (2018) Breast cancer cell-derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells. *Carcinogenesis* 39:1488–1496. <https://doi.org/10.1093/carcin/bgy136>
- Holen I, Lefley DV, Francis SE, Rennicks S, Bradbury S, Coleman RE, Ottewell P (2016) IL-1 drives breast cancer growth and bone metastasis in vivo. *Oncotarget* 7(46):75571–75584. <https://doi.org/10.18632/oncotarget.12289>

- Hou L, Xie S, Li G, Xiong B, Gao Y, Zhao X, Hu J, Deng S, Jiang J (2018) IL-6 triggers the migration and invasion of oestrogen receptor-negative breast cancer cells via regulation of hippo pathways. *Basic Clin Pharmacol Toxicol* 123:549–557. <https://doi.org/10.1111/bcpt.13042>
- Hsing CH, Cheng HC, Hsu YH, Chan CH, Yeh CH, Li CF, Chang MS (2012) Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome. *Clin Cancer Res* 18:713–725. <https://doi.org/10.1158/1078-0432.CCR-11-1532>
- Hsu YH, Hsing CH, Li CF, Chan CH, Chang MC, Yan JJ, Chang MS (2012) Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models. *J Immunol* 188:1981–1991. <https://doi.org/10.4049/jimmunol.1102843>
- Hu XB, Ouyang LZ, Tang LL (2013) Interleukin-2 gene polymorphisms and prognosis of breast cancer. *Genet Test Mol Biomarkers* 17:453–457. <https://doi.org/10.1089/gtmb.2012.0494>
- Hu F, Song D, Yan Y, Huang C, Shen C, Lan J, Chen Y, Liu A, Wu Q, Sun L, Xu F, Hu F, Chen L, Luo X, Feng Y, Huang S, Hu J, Wang G (2021) IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation. *Nat Commun* 12:3651. <https://doi.org/10.1038/s41467-021-23923-1>
- Irawan C, Atmakusumah D, Siregar NC, Tean TB, Kong LW, Kiat OC, Abdulmuthalib A, Harahap A, Mansyur M (2016) Expression of biomarkers CXCR4, IL11-RA, TFF1, MLF1P in advanced breast cancer patients with bone metastatic: a diagnostic study. *Acta Med Indones* 48:261–268
- Jafarzadeh A, Minaee K, Farsinejad AR, Nemati M, Khosravimashizi A, Daneshvar H, Mohammadi MM, Sheikhi A, Ghaderi A (2015) Evaluation of the circulating levels of IL-12 and IL-33 in patients with breast cancer: influences of the tumor stages and cytokine gene polymorphisms. *Iran J Basic Med Sci* 18:1189–1198
- Jiang XP, Yang DC, Elliott RL, Head JF (2011) Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells. *Anticancer Res* 31:2899–2906
- Johnstone CN, Chand A, Putoczki TL, Ernst M (2015) Emerging roles for IL-11 signaling in cancer development and progression: focus on breast cancer. *Cytokine Growth Factor Rev* 26:489–498. <https://doi.org/10.1016/j.cytogfr.2015.07.015>
- Joimel U, Gest C, Soria J, Pritchard LL, Alexandre J, Laurent M, Blot E, Cazin L, Vannier JP, Varin R, Li H, Soria C (2010) Stimulation of angiogenesis resulting from cooperation between macrophages and MDA-MB-231 breast cancer cells: proposed molecular mechanism and effect of tetrathiomolybdate. *BMC Cancer* 10:375. <https://doi.org/10.1186/1471-2407-10-375>
- König A, Vilsmaier T, Rack B, Friese K, Janni W, Jeschke U, Andergassen U, Trapp E, Jückstock J, Jäger B, Alunni-Fabbroni M, Friedl T, Weissenbacher T (2016) SUCCESS STUDY GROUP. Determination of interleukin-4,-5,-6,-8 and-13 in serum of patients with breast cancer before treatment and its correlation to circulating tumor cells. *Anticancer Res* 36:3123–3130
- Kozłowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ (2003) Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. *RoczAkad Med Białymst* 48:82–84
- Kuan EL, Ziegler SF (2018) A tumor-myeloid cell axis, mediated via the cytokines IL-1alpha and TSLP, promotes the progression of breast cancer. *Nat Immunol* 19:366–374. <https://doi.org/10.1038/s41590-018-0066-6>
- Lai EW, Joshi BH, Martiniova L, Dogra R, Fujisawa T, Leland P, de Krijger RR, Lubensky IA, Elkahoul AG, Morris JC, Puri RK, Pacak K (2009) Overexpression of interleukin-13 receptor- $\alpha 2$ in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy. *J Clin Endocrinol Metab* 94:2952–2957. <https://doi.org/10.1210/jc.2009-0309>

- Li A, Dubey S, Varney ML, Dave BJ, Singh RK (2003) IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. *J Immunol* 170:3369–3376. <https://doi.org/10.4049/jimmunol.170.6.3369>
- Li M, Yue C, Zuo X, Jin G, Wang G, Guo H, Wu F, Huang S, Zhao X (2020) The effect of interleukin 10 polymorphisms on breast cancer susceptibility in Han women in Shaanxi Province. *PLoS One* 15:e0232174. <https://doi.org/10.1371/journal.pone.0232174>
- Lin S, Gan Z, Han K, Yao Y, Min D (2015) Interleukin-6 as a prognostic marker for breast cancer: a meta-analysis. *Tumori* 101:535–541. <https://doi.org/10.5301/tj.5000357>
- Liu J, Shen JX, Hu JL, Huang WH, Zhang GJ (2014) Significance of interleukin-33 and its related cytokines in patients with breast cancers. *Front Immunol* 5:141. <https://doi.org/10.3389/fimmu.2014.00141>
- Liu S, Lee JS, Jie C, Park MH, Iwakura Y, Patel Y, Soni M, Reisman D, Chen H (2018) HER2 overexpression triggers an $\text{IL-1}\alpha$ proinflammatory circuit to drive tumorigenesis and promote chemotherapy resistance. *Cancer Res* 78:2040–2051. <https://doi.org/10.1158/0008-5472.CAN-17-2761>
- Lv Z, Liu M, Shen J, Xiang D, Ma Y, Ji Y (2018) Association of serum interleukin-10, interleukin-17A and transforming growth factor- α levels with human benign and malignant breast diseases. *Exp Ther Med* 15:5475–5480. <https://doi.org/10.3892/etm.2018.6109>
- Lyon DE, McCain NL, Walter J, Schubert C (2008) Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. *Nurs Res* 57:51–58. <https://doi.org/10.1097/01.NNR.0000280655.58266.6c>
- Maroni P, Bendinelli P, Ferraretto A, Lombardi G (2021) Interleukin 11 (IL-11): role(s) in breast cancer bone metastases. *Biomedicine* 9:659. <https://doi.org/10.3390/biomedicines9060659>
- Masjedi A, Hashemi V, Hojjat-Farsangi M, Ghalamfarsa G, Azizi G, Yousefi M, Jadidi-Niaragh F (2018) The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. *Biomed Pharmacother* 108:1415–1424. <https://doi.org/10.1016/j.biopha.2018.09.177>
- Méndez-García LA, Nava-Castro KE, Ochoa-Mercado TL, Palacios-Arreola MI, Ruiz-Manzano RA, Segovia-Mendoza M, Solleiro-Villavicencio H, Cázarez-Martínez C, Morales-Montor J (2019) Breast cancer metastasis: are cytokines important players during its development and progression? *J Interf Cytokine Res* 39:39–55. <https://doi.org/10.1089/jir.2018.0024>
- Momenimovahed Z, Salehiniya H (2019) Epidemiological characteristics of and risk factors for breast cancer in the world. *Breast Cancer* 11:151–164. <https://doi.org/10.2147/BCTT.S176070>
- Muraro E, Martorelli D, Turchet E, Miolo G, Scalone S, Comaro E, Talamini R, Mastorci K, Lombardi D, Perin T, Carbone A, Veronesi A, Crivellari D, Dolcetti R (2011) A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. *Breast Cancer Res* 13:117. <https://doi.org/10.1186/bcr3060>
- Murugaiyan G, Saha B (2009) Protumor vs antitumor functions of IL-17. *J Immunol* 183:4169–4175. <https://doi.org/10.4049/jimmunol.0901017>
- Oh K, Lee OY, Park Y, Seo MW, Lee DS (2016) IL-1 β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells. *BMC Cancer* 16:724. <https://doi.org/10.1186/s12885-016-2746-7>
- Perrier S, Caldefie-Chézet F, Vasson MP (2009) IL-1 family in breast cancer: potential interplay with leptin and other adipocytokines. *FEBS Lett* 583:259–265. <https://doi.org/10.1016/j.febslet.2008.12.030>
- Sanguinetti A, Santini D, Bonafè M, Taffurelli M, Avenia N (2015) Interleukin-6 and pro inflam-

- matory status in the breast tumor microenvironment. *World J Surg Onc* 13:129. <https://doi.org/10.1186/s12957-015-0529-2>
- Shabnaz S, Ahmed MU, Islam MS, Islam MR, Al-Mamun MM, Islam MS, Hasnat A (2016) Breast cancer risk in relation to TP53 codon 72 and CDH1 gene polymorphisms in the Bangladeshi women. *Tumour Biol* 37:7229–7237. <https://doi.org/10.1007/s13277-015-4612-7>
- Sheng S, Zhang J, Ai J, Hao X, Luan R (2018) Aberrant expression of IL-23/IL-23R in patients with breast cancer and its clinical significance. *Mol Med Rep* 17:4639–4644. <https://doi.org/10.3892/mmr.2018.8427>
- Sloot YJE, Smit JW, Joosten LAB, Netea-Maier RT (2018) Insights into the role of IL-32 in cancer. *Semin Immunol* 38:24–32. <https://doi.org/10.1016/j.smim.2018.03.004>
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 71:209–249. <https://doi.org/10.3322/caac.21660>
- Taher MY, Davies DM, Maher J (2018) The role of the interleukin (IL)-6/IL-6 receptor axis in cancer. *Biochem Soc Trans* 46:1449–1462. <https://doi.org/10.1042/BST20180136>
- Todorović-Raković N, Milovanović J (2013) Interleukin-8 in breast cancer progression. *J Interf Cytokine Res* 33:563–570. <https://doi.org/10.1089/jir.2013.0023>
- Venmar KT, Fingleton B (2014) Lessons from immunology: IL4R directly promotes mammary tumor metastasis. *Onco Targets Ther* 3:955373. <https://doi.org/10.4161/21624011.2014.955373>
- Vitiello GAF, Losi Guembarovski R, Amarante MK, Ceribelli JR, Carmelo ECB, Watanabe MAE (2018) Interleukin 7 receptor alpha Thr244Ile genetic polymorphism is associated with susceptibility and prognostic markers in breast cancer subgroups. *Cytokine* 103:121–126. <https://doi.org/10.1016/j.cyto.2017.09.019>
- Wang S, Chen F, Tang L (2014) IL 32 promotes breast cancer cell growth and invasiveness. *Oncol Lett* 9:305–307. <https://doi.org/10.3892/ol.2014.2641>
- Wang LN, Cui YX, Ruge F, Jiang WG (2015) Interleukin 21 and its receptor play a role in proliferation, migration and invasion of breast cancer cells. *Cancer Genomics Proteomics* 12:211–221
- Wang S, Yao Y, Yao M, Fu P, Wang W (2018) Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways. *Biochem Biophys Res Commun* 503:1605–1609. <https://doi.org/10.1016/j.bbrc.2018.07.088>
- Weichand B, Popp R, Dziu mb la S, Mora J, Strack E, Elwakeel E, Frank AC, Scholich K, Pierre S, Syed SN, Olesch C, Ringleb J, Ören B, Döring C, Savai R, Jung M, von Knethen A, Levkau B, Fleming I, Weigert A, Brüne B (2017) S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1beta. *J Exp Med* 214:2695–2713. <https://doi.org/10.1084/jem.20160392>
- Welte T, Zhang XHF (2015) Interleukin-17 could promote breast cancer progression at several stages of the disease. *Mediat Inflamm* 2015:804347. <https://doi.org/10.1155/2015/804347>
- Yang Y, Cheon S, Jung MK, Song SB, Kim D, Kim HJ, Park H, Bang SI, Cho D (2015) Interleukin-18 enhances breast cancer cell migration via down-regulation of claudin-12 and induction of the p38 MAPK pathway. *Biochem Biophys Res Commun* 459:379–386. <https://doi.org/10.1016/j.bbrc.2015.02.108>
- Zhang Y, Liu C, Gao J, Shao S, Cui Y, Yin S, Pan B (2020) IL-22 promotes tumor growth of breast cancer cells in mice. *Aging (Albany NY)* 12:13354–13364. <https://doi.org/10.18632/aging.103439>

第5章 化学因子受体塑造三阴性乳腺癌的免疫格局并影响其临床结局

- Adeshakin AO, Liu W, Adeshakin FO, Afolabi LO, Zhang M, Zhang G, Wang L, Li Z, Lin L, Cao Q, Yan D, Wan X (2021) Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy. *Cell Immunol* 362:104286
- Adrover JM, Del Fresno C, Crainiciuc G, Cuartero MI, Casanova-Acebes M, Weiss LA, Huerga-Encabo H, Silvestre-Roig C, Rossaint J, Cossio I, Lechuga-Vieco AV, Garcia-Prieto J, Gomez-Parrizas M, Quintana JA, Ballesteros I, Martin-Salamanca S, Aroca-Crevillen A, Chong SZ, Evrard M, Balabanian K, Lopez J, Bidzhekov K, Bachelier F, Abad-Santos F, Munoz-Calleja C, Zarbock A, Soehnlein O, Weber C, Ng LG, Lopez-Rodriguez C, Sancho D, Moro MA, Ibanez B, Hidalgo A (2019) A neutrophil timer coordinates immune defense and vascular protection. *Immunity* 50(390–402):e310
- Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A (2008) Pathways connecting inflammation and cancer. *Curr Opin Genet Dev* 18:3–10
- Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, McKenna KM, Ho PY, Cheng RZ, Chen JY, Barkal LJ, Ring AM, Weissman IL, Maute RL (2018) Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. *Nat Immunol* 19:76–84
- Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, Krishnan V, Hatakeyama J, Dorigo O, Barkal LJ, Weissman IL (2019) CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. *Nature* 572:392–396
- Barker TH, Baneyx G, Cardó-Vila M, Workman GA, Weaver M, Menon PM, Dedhar S, Rempel SA, Arap W, Pasqualini R, Vogel V, Sage EH (2005) SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. *J Biol Chem* 280:36483–36493
- Bayik D, Zhou Y, Park C, Hong C, Vail D, Silver DJ, Lauko A, Roversi G, Watson DC, Lo A, Alban TJ, McGraw M, Sorensen M, Grabowski MM, Otvos B, Vogelbaum MA, Horbinski C, Kristensen BW, Khalil AM, Hwang TH, Ahluwalia MS, Cheng F, Lathia JD (2020) Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner. *Cancer Discov* 10:1210–1225
- Belgiovine C, D’Incalci M, Allavena P, Frapolli R (2016) Tumor-associated macrophages and anti-tumor therapies: complex links. *Cell Mol Life Sci* 73:2411–2424
- Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. *Nat Med* 24:541–550
- Borregaard N (2010) Neutrophils, from marrow to microbes. *Immunity* 33:657–670
- Braso-Maristany F, Sanso M, Chic N, Martinez D, Gonzalez-Farre B, Sanfeliu E, Ghiglione L, Carcelero E, Garcia-Corbacho J, Sanchez M, Soy D, Jares P, Peg V, Saura C, Munoz M, Prat A, Vivancos A (2021) Case report: a case study documenting the activity of Atezolizumab in a PD-L1-negative triple-negative breast cancer. *Front Oncol* 11:710596

- Brummer G, Fang W, Smart C, Zinda B, Alissa N, Berkland C, Miller D, Cheng N (2020) CCR2 signaling in breast carcinoma cells promotes tumor growth and invasion by promoting CCL2 and suppressing CD154 effects on the angiogenic and immune microenvironments. *Oncogene* 39:2275–2289
- Casanova-Acebes M, Pitaval C, Weiss LA, Nombela-Arrieta C, Chevre R, González NA, Kunisaki Y, Zhang D, van Rooijen N, Silberstein LE, Weber C, Nagasawa T, Frenette PS, Castrillo A, Hidalgo A (2013) Rhythmic modulation of the hematopoietic niche through neutrophil clearance. *Cell* 153:1025–1035
- Cassetta L, Pollard JW (2018) Targeting macrophages: therapeutic approaches in cancer. *Nat Rev Drug Discov* 17:887–904
- Cassetta L, Fraggogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P, Lin EY, Fidanza A, Lopez-Yrigoyen M, Millar MR, Urman A, Ai Z, Spellman PT, Hwang ES, Dixon JM, Wiechmann L, Coussens LM, Smith HO, Pollard JW (2019) Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. *Cancer Cell* 35:588–602 e510
- Chen Q, Zhang XH, Massagué J (2011) Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. *Cancer Cell* 20:538–549
- Chen Y, Zhang S, Wang Q, Zhang X (2017a) Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. *J Hematol Oncol* 10:36
- Chen P, Zuo H, Xiong H, Kolar MJ, Chu Q, Saghatelian A, Siegwart DJ, Wan Y (2017b) Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. *Proc Natl Acad Sci U S A* 114:580–585
- Chinnaiyan AM, Hanna WL, Orth K, Duan H, Poirier GG, Froelich CJ, Dixit VM (1996) Cytotoxic T-cell-derived granzyme B activates the apoptotic protease ICE-LAP3. *Curr Biol* 6:897–899
- Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M, Hawinkels L, Jonkers J, de Visser KE (2015) IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. *Nature* 522:345–348
- Coffelt SB, Wellenstein MD, de Visser KE (2016) Neutrophils in cancer: neutral no more. *Nat Rev Cancer* 16:431–446
- Condamine T, Mastio J, Gabrilovich DI (2015a) Transcriptional regulation of myeloid-derived suppressor cells. *J Leukoc Biol* 98:913–922
- Condamine T, Ramachandran I, Youn JI, Gabrilovich DI (2015b) Regulation of tumor metastasis by myeloid-derived suppressor cells. *Annu Rev Med* 66:97–110
- Cox TR, Rumney RMH, Schoof EM, Perryman L, Høye AM, Agrawal A, Bird D, Latif NA, Forrest H, Evans HR, Huggins ID, Lang G, Linding R, Gartland A, Erler JT (2015) The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. *Nature* 522:106–110
- De Palma M, Lewis CE (2013) Macrophage regulation of tumor responses to anticancer therapies. *Cancer Cell* 23:277–286
- Donato C, Kunz L, Castro-Giner F, Paasinen-Sohns A, Strittmatter K, Szczerba BM, Scherrer R, Di Maggio N, Heusermann W, Biehlmaier O, Beisel C, Vetter M, Rochlitz C, Weber WP, Banfi A, Schroeder T, Aceto N (2020) Hypoxia triggers the Intravasation of clustered circulating tumor cells. *Cell Rep* 32:108105
- Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. *Cancer Cell* 16:183–194
- Gabrilovich DI (2017) Myeloid-derived suppressor cells. *Cancer Immunol Res* 5:3–8

- Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. *Nat Rev Immunol* 12:253–268
- Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fucikova J, Gabrielovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jager D, Kalinski P, Karre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautes-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G (2014) Classification of current anticancer immunotherapies. *Oncotarget* 5:12472–12508
- Gatti-Mays ME, Balko JM, Gameiro SR, Bear HD, Prabhakaran S, Fukui J, Disis ML, Nanda R, Gulley JL, Kalinsky K, Abdul Sater H, Sparano JA, Cescon D, Page DB, McArthur H, Adams S, Mittendorf EA (2019) If we build it they will come: targeting the immune response to breast cancer. *NPJ Breast Cancer* 5:37
- Germano G, Allavena P, Mantovani A (2008) Cytokines as a key component of cancer-related inflammation. *Cytokine* 43:374–379
- Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, Johnson SF, Carrasco RD, Lazo S, Bronson RT, Davis SP, Lobera M, Nolan MA, Letai A (2017) Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. *Nature* 543:428–432
- Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. *Cancer Cell* 21:309–322
- Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* 144:646–674
- Harney AS, Arwert EN, Entenberg D, Wang Y, Guo P, Qian BZ, Oktay MH, Pollard JW, Jones JG, Condeelis JS (2015) Real-time imaging reveals local, transient vascular permeability, and tumor cell Intravasation stimulated by TIE2hi macrophage-derived VEGFA. *Cancer Discov* 5:932–943
- Hartley G, Regan D, Guth A, Dow S (2017) Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF- α . *Cancer Immunol Immunother* 66:523–535
- Hartley GP, Chow L, Ammons DT, Wheat WH, Dow SW (2018) Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation. *Cancer Immunol Res* 6:1260–1273
- He HX, Gao Y, Fu JC, Zhou QH, Wang XX, Bai B, Li PF, Huang C, Rong QX, Ping LQ, He YX, Mao JY, Chen X, Huang HQ (2021) VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma. *Onco Targets Ther* 10:1907059
- Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrín A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature* 515:563–567
- Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, Kaplan RN, Mackall CL (2014) Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. *Sci*

- Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmed L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D (2015) Tumour exosome integrins determine organotropic metastasis. *Nature* 527:329–335
- Høye AM, Erler JT (2016) Structural ECM components in the premetastatic and metastatic niche. *Am J Physiol Cell Physiol* 310:C955–C967
- Huang YK, Busuttill RA, Boussioutas A (2021) The role of innate immune cells in tumor invasion and metastasis. *Cancers (Basel)* 13:5885
- Hughes R, Qian BZ, Rowan C, Muthana M, Keklikoglou I, Olson OC, Tazzyman S, Danson S, Addison C, Clemons M, Gonzalez-Angulo AM, Joyce JA, De Palma M, Pollard JW, Lewis CE (2015) Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. *Cancer Res* 75:3479–3491
- Hussain SM, Kansal RG, Alvarez MA, Hollingsworth TJ, Elahi A, Miranda-Carboni G, Hendrick LE, Pingili AK, Albritton LM, Dickson PV, Deneve JL, Yakoub D, Hayes DN, Kurosu M, Shibata D, Makowski L, Glazer ES (2021) Role of TGF-beta in pancreatic ductal adenocarcinoma progression and PD-L1 expression. *Cell Oncol (Dordr)* 44:673–687
- Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A (2020) Neutrophil diversity and plasticity in tumour progression and therapy. *Nat Rev Cancer* 20:485–503
- Jiang Y, Chen M, Nie H, Yuan Y (2019) PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. *Hum Vaccin Immunother* 15:1111–1122
- Jing W, Guo X, Wang G, Bi Y, Han L, Zhu Q, Qiu C, Tanaka M, Zhao Y (2020) Breast cancer cells promote CD169(+) macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages. *Int Immunopharmacol* 78:106012
- Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P, Schmid MC, Pink M, Winkler DG, Rausch M, Palombella VJ, Kutok J, McGovern K, Frazer KA, Wu X, Karin M, Sasik R, Cohen EE, Varner JA (2016) PI3Kγ is a molecular switch that controls immune suppression. *Nature* 539:437–442
- Karpova D, Brauninger S, Wiercinska E, Kramer A, Stock B, Graff J, Martin H, Wach A, Escot C, Douglas G, Romagnoli B, Chevalier E, Dembowski K, Hooftman L, Bonig H (2017) Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial. *J Transl Med* 15:2
- Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. *Cell* 141:52–67
- Kitamura T, Qian BZ, Soong D, Cassetta L, Noy R, Sugano G, Kato Y, Li J, Pollard JW (2015) CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. *J Exp Med* 212:1043–1059
- Knowles HJ, Harris AL (2007) Macrophages and the hypoxic tumour microenvironment. *Front Biosci* 12:4298–4314
- Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L, Wei S, Zou L, Machelon V, Emilie D, Terrassa M, Lackner A, Curiel TJ, Carmeliet P, Zou W (2005) CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. *Cancer Res* 65:465–472

- Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. *J Exp Med* 203:871–881
- Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. *Nat Rev Mol Cell Biol* 15:178–196
- Laoui D, Van Overmeire E, Di Conza G, Aldeni C, Keirsse J, Morias Y, Movahedi K, Houbracken I, Schouppe E, Elkrim Y, Karroum O, Jordan B, Carmeliet P, Gysemans C, De Baetselier P, Mazzone M, Van Ginderachter JA (2014) Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. *Cancer Res* 74:24–30
- Lawrence SM, Corriden R, Nizet V (2018) The ontogeny of a neutrophil: mechanisms of Granulopoiesis and homeostasis. *Microbiol Mol Biol Rev* 82:e00057-17
- Lee JM, Seo JH, Kim YJ, Kim YS, Ko HJ, Kang CY (2012) The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment. *Int J Cancer* 131:741–751
- Li K, Yuan Z, Lyu J, Ahn E, Davis SJ, Ahmed R, Zhu C (2021) PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition. *Nat Commun* 12:2746
- Lim YW, Coles GL, Sandhu SK, Johnson DS, Adler AS, Stone EL (2021) Single-cell transcriptomics reveals the effect of PD-L1/TGF-beta blockade on the tumor microenvironment. *BMC Biol* 19:107
- Lin Y, Xu J, Lan H (2019) Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. *J Hematol Oncol* 12:76
- Long AH, Highfill SL, Cui Y, Smith JP, Walker AJ, Ramakrishna S, El-Etriby R, Galli S, Tsokos MG, Orentas RJ, Mackall CL (2016) Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. *Cancer Immunol Res* 4:869–880
- Lu X, Yang R, Zhang L, Xi Y, Zhao J, Wang F, Zhang H, Li Z (2019) Macrophage Colony-stimulating factor mediates the recruitment of macrophages in triple negative breast cancer. *Int J Biol Sci* 15:2859–2871
- Lyes MA, Payne S, Ferrell P, Pizzo SV, Hollenbeck ST, Bachelder RE (2019) Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence. *Breast Cancer Res Treat* 174:413–422
- Mantovani A, Allavena P (2015) The interaction of anticancer therapies with tumor-associated macrophages. *J Exp Med* 212:435–445
- Mantovani A, Pierotti MA (2008) Cancer and inflammation: a complex relationship. *Cancer Lett* 267:180–181
- Mantovani A, Sica A, Locati M (2005) Macrophage polarization comes of age. *Immunity* 23:344–346
- Mantovani A, Allavena P, Sica A, Balkwill F (2008a) Cancer-related inflammation. *Nature* 454:436–444
- Mantovani A, Marchesi F, Portal C, Allavena P, Sica A (2008b) Linking inflammation reactions to cancer: novel targets for therapeutic strategies. *Adv Exp Med Biol* 610:112–127
- Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. *Nat Rev Clin Oncol* 14:399–416
- Miao M, De Clercq E, Li G (2020) Clinical significance of chemokine receptor antagonists. *Expert Opin Drug Metab Toxicol* 16:11–30
- Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. *Nature* 410:50–56

- Nagarsheth N, Wicha MS, Zou W (2017) Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. *Nat Rev Immunol* 17:559–572
- Niu M, Valdes S, Naguib YW, Hursting SD, Cui Z (2016) Tumor-associated macrophage-mediated targeted therapy of triple-negative breast cancer. *Mol Pharm* 13:1833–1842
- Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. *Immunity* 41:49–61
- Oner G, Altintas S, Canturk Z, Tjalma W, Verhoeven Y, Van Berckelaer C, Berneman Z, Peeters M, Pauwels P, van Dam PA (2019) Triple-negative breast cancer-role of immunology: a systemic review. *Breast J* 26:995–999
- Orimo A, Weinberg RA (2006) Stromal fibroblasts in cancer: a novel tumor-promoting cell type. *Cell Cycle* 5:1597–1601
- Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. *Cell* 121:335–348
- Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, Bent EH, Schwamb J, Iliopoulou B, Kutsch N, van Rooijen N, Frenzel LP, Wendtner CM, Heukamp L, Kreuzer KA, Hallek M, Chen J, Hemann MT (2014) Sensitizing protective tumor microenvironments to antibody-mediated therapy. *Cell* 156:590–602
- Pauken KE, Wherry EJ (2015) Overcoming T cell exhaustion in infection and cancer. *Trends Immunol* 36:265–276
- Peng SY, Chen L, Deng RH, Li H, Liu XH, Zheng DW, Wu CC, Liu CJ, Sun ZJ, Zhang XZ (2021) Non-depleting reformation of immunosuppressive myeloid cells to broaden the application of anti-PD therapy. *Nanoscale* 13:4420–4431
- Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia J, Wach A, Barker D, Fung S, Romagnoli B, Cortes J (2018) Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. *Lancet Oncol* 19:812–824
- Plava J, Cihova M, Burikova M, Matuskova M, Kucerova L, Miklikova S (2019) Recent advances in understanding tumor stroma-mediated chemoresistance in breast cancer. *Mol Cancer* 18:67
- Quintero-Fabián S, Arreola R, Becerril-Villanueva E, Torres-Romero JC, Arana-Argáez V, Lara-Riegos J, Ramírez-Camacho MA, Alvarez-Sánchez ME (2019) Role of matrix metalloproteinases in angiogenesis and cancer. *Front Oncol* 9:1370
- Raman D, Baugher PJ, Thu YM, Richmond A (2007) Role of chemokines in tumor growth. *Cancer Lett* 256:137–165
- Rice CM, Davies LC, Subleski JJ, Maio N, Gonzalez-Cotto M, Andrews C, Patel NL, Palmieri EM, Weiss JM, Lee JM, Annunziata CM, Rouault TA, Durum SK, McVicar DW (2018) Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression. *Nat Commun* 9:5099
- Rodell CB, Arlauckas SP, Cuccarese MF, Garriss CS, Li R, Ahmed MS, Kohler RH, Pittet MJ, Weissleder R (2018) TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. *Nat Biomed Eng* 2:578–588
- Sagiv JY, Michaeli J, Assi S, Mishalian I, Kisos H, Levy L, Danti P, Lumbroso D, Polyansky L, Sionov RV, Ariel A, Hovav AH, Henke E, Fridlender ZG, Granot Z (2015) Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. *Cell Rep* 10:562–573
- Sangaletti S, Talarico G, Chiodoni C, Cappetti B, Botti L, Portararo P, Gulino A, Consonni FM,

- Sica A, Randon G, Di Nicola M, Tripodo C, Colombo MP (2019) SPARC is a new myeloid-derived suppressor cell marker licensing suppressive activities. *Front Immunol* 10:1369
- Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA, Investigators IM (2020) Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 21:44–59
- Shaul ME, Fridlender ZG (2019) Tumour-associated neutrophils in patients with cancer. *Nat Rev Clin Oncol* 16:601–620
- Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, Li Y, Chen H, Yang H, Hsu PH, Van Allen EM, Freeman GJ, De Carvalho DD, He HH, Sharpe AH, Shi Y (2018) LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. *Cell* 174:549–563 e519
- Sica A, Allavena P, Mantovani A (2008) Cancer related inflammation: the macrophage connection. *Cancer Lett* 267:204–215
- Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J, Kellokumpu-Lehtinen PL, Lauttia S, Tynnenen O, Joensuu H, Heymann D, Määttä JA (2015) Human breast cancer cells educate macrophages toward the M2 activation status. *Breast Cancer Res* 17:101
- Tcyganov E, Mastio J, Chen E, Gabrilovich DI (2018) Plasticity of myeloid-derived suppressor cells in cancer. *Curr Opin Immunol* 51:76–82
- Teijeira A, Garasa S, Gato M, Alfaro C, Migueliz I, Cirella A, de Andrea C, Ochoa MC, Otano I, Etxeberria I, Andueza MP, Nieto CP, Resano L, Azpilikueta A, Allegretti M, de Pizzol M, Ponz-Sarvisé M, Rouzaut A, Sanmamed MF, Schalper K, Carleton M, Mellado M, Rodriguez-Ruiz ME, Berraondo P, Perez-Gracia JL, Melero I (2020) CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. *Immunity* 52(856–871):e858
- Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* 515:568–571
- Veglia F, Perego M, Gabrilovich D (2018) Myeloid-derived suppressor cells coming of age. *Nat Immunol* 19:108–119
- Veglia F, Sanseviero E, Gabrilovich DI (2021) Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. *Nat Rev Immunol* 21:485–498
- Wang N, Liu W, Zheng Y, Wang S, Yang B, Li M, Song J, Zhang F, Zhang X, Wang Q, Wang Z (2018) CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF- κ B/SOX4 signaling. *Cell Death Dis* 9:880
- Yin T, Zhao ZB, Guo J, Wang T, Yang JB, Wang C, Long J, Ma S, Huang Q, Zhang K, Ma X, Liu C, Liu S, Lian ZX, Yang Z (2019) Aurora A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in breast cancer. *Cancer Res* 79:3431–3444
- Zhang D, Chen G, Manwani D, Mortha A, Xu C, Faith JJ, Burk RD, Kunisaki Y, Jang JE, Scheiermann C, Merad M, Frenette PS (2015) Neutrophil ageing is regulated by the microbiome. *Nature* 525:528–532
- Zhang WJ, Wang XH, Gao ST, Chen C, Xu XY, Sun Q, Zhou ZH, Wu GZ, Yu Q, Xu G, Yao YZ, Guan WX (2018) Tumor-associated macrophages correlate with phenomenon of epithelial-

- mesenchymal transition and contribute to poor prognosis in triple-negative breast cancer patients. *J Surg Res* 222:93–101
- Zhang J, Pang Y, Xie T, Zhu L (2019) CXCR4 antagonism in combination with IDO1 inhibition weakens immune suppression and inhibits tumor growth in mouse breast cancer bone metastases. *Onco Targets Ther* 12:4985–4992
- Zhou J, Nefedova Y, Lei A, Gabrilovich D (2018) Neutrophils and PMN-MDSC: their biological role and interaction with stromal cells. *Semin Immunol* 35:19–28
- Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG (2014) CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. *Cancer Res* 74:5057–5069
- Zurlo IV, Schino M, Strippoli A, Calejari MA, Cocomazzi A, Cassano A, Pozzo C, Di Salvatore M, Ricci R, Barone C, Bria E, Tortora G, Larocca LM, Basso M, Martini M (2022) Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. *Cancer Immunol Immunother* 71:45–55

第6章 肿瘤浸润性淋巴细胞对乳腺癌预后的影响

- Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. *J Clin Oncol* 32(27):2959–2966
- Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, Earl HM, Poole CJ, Hiller L, Dunn JA, Bowden SJ, Twelves C, Bartlett JM, Mahmoud SM, Rakha E, Ellis IO, Liu S, Gao D, Nielsen TO, Pharoah PD, Caldas C (2014) Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. *Ann Oncol* 25(8):1536–1543
- Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR (2017) *AJCC cancer staging manual*, 8th edn. Springer International Publishing, Cham
- Angelico G, Broggi G, Caltabiano R, Santoro A, Spadola S, D'Alessandris N, Scaglione G, Valente M, Arciuolo D, Sanchez AM, Franceschini G, Masetti R, Mulè A, Zannoni GF (2021) Histopathological evaluation of tumor-infiltrating lymphocytes (TILs) as predictive biomarker for hormone receptors status, proliferative activity and clinical outcome in her-2 positive breast cancer. *Appl Sci* 11(15):6788
- Asano Y, Kashiwagi S, Goto W, Takada K, Takahashi K, Hatano T, Noda S, Takashima T, Onoda N, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M (2017) Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden. *BMC Cancer* 17(1):888
- Badr NM, Berditchevski F, Shaaban AM (2020) The immune microenvironment in breast carcinoma: predictive and prognostic role in the neoadjuvant setting. *Pathobiology* 87(2):61–74
- Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T, Zare P (2020) Tumor microenvironment complexity and therapeutic implications at a glance. *Cell Commun Signal* 18(1):59
- Bai Y, Cole K, Martinez-Morilla S, Ahmed FS, Zugazagoitia J, Staaf J, Bosch A, Ehinger A, Nimeus E, Hartman J, Acs B, Rimm DL (2021) An open source, automated tumor infiltrating lymphocyte algorithm for prognosis in triple-negative breast cancer. *Clin Cancer Res* 27(20):5557–5565
- Bianchini G, Pusztai L, Pienkowski T, Im YH, Bianchi GV, Tseng LM, Liu MC, Lluch A, Galeota E, Magazzù D, de la Haba-Rodríguez J, Oh DY, Poirier B, Pedrini JL, Semiglazov V, Valagussa P, Gianni L (2015) Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. *Ann Oncol* 26(12):2429–2436
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68(6):394–424
- Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V (2014) Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast

- cancer. *Clin Cancer Res* 20(23):5995–6005
- Burugu S, Asleh-Aburaya K, Nielsen TO (2017) Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. *Breast Cancer* 24(1):3–15
- Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L (2017) Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. *Breast Cancer Res Treat* 161(1):17–28
- Carbognin L, Pilotto S, Nortilli R, Brunelli M, Nottegar A, Sperduti I, Giannarelli D, Bria E, Tortora G (2016) Predictive and prognostic role of tumor-infiltrating lymphocytes for early breast cancer according to disease subtypes: sensitivity analysis of randomized trials in adjuvant and neoadjuvant setting. *Oncologist* 21(3):283–291
- Criscitiello C, Esposito A, Trapani D, Curigliano G (2016) Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. *Cancer Treat Rev* 50:205–207
- De Melo Gagliato D, Cortes J, Curigliano G, Loi S, Denkert C, Perez-Garcia J, Holgado E (2017) Tumor-infiltrating lymphocytes in breast cancer and implications for clinical practice. *Biochim Biophys Acta Rev Cancer* 1868(2):527–537
- Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, Muggia F, Symmans WF (2001) Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. *Clin Cancer Res* 7(10):3025–3030
- Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. *J Clin Oncol* 28(1):105–113
- Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer JU, Karn T, Pfitzner BM, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S (2018) Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet Oncol* 19(1):40–50
- Desmedt C, Salgado R, Fornili M, Pruneri G, Van den Eynden G, Zoppoli G, Rothé F, Buisseret L, Garaud S, Willard-Gallo K, Brown D, Bareche Y, Rouas G, Galant C, Bertucci F, Loi S, Viale G, Di Leo A, Green AR, Ellis IO, Rakha EA, Larsimont D, Biganzoli E, Sotiriou C (2018) Immune infiltration in invasive lobular breast cancer. *J Natl Cancer Inst* 110(7):768–776
- Dieci MV, Mathieu MC, Guarneri V, Conte P, Delaloge S, Andre F, Goubar A (2015) Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. *Ann Oncol* 26(8):1698–1704
- Dieci MV, Radošević-Robin N, Fineberg S et al. International Immuno-Oncology Biomarker Working Group on Breast Cancer (2018) Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. *Semin Cancer Biol* 52(Pt 2):16–25
- El Bairi K, Haynes HR, Blackley E et al (2018) The tale of TILs in breast cancer: a report from the International Immuno-Oncology Biomarker Working Group. *NPJ Breast Cancer* 7(1):150
- Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH, Nechaeva M, Nguyen-Duc A, Chui SY, Husain A, Winer EP, Adams S, Schmid P (2021) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion 130 study. *J Natl Cancers Inst* 113(8):1005–1016

- Global Cancer Observatory (2020) GLOBOCAN. <https://gco.iarc.fr/>
- Goto W, Kashiwagi S, Asano Y, Takada K, Takahashi K, Hatano T, Takashima T, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M (2018) Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy. *ESMO Open* 3(6):e000305
- Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothé F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart M, Sotiriou C, Willard-Gallo K (2013) CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. *J Clin Invest* 123(7):2873–2892
- Hamy AS, Pierga JY, Sabaila A, Laas E, Bonsang-Kitzis H, Laurent C, Vincent-Salomon A, Cottu P, Lerebours F, Rouzier R, Lae M, Reyat F (2017) Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. *Ann Oncol* 28(9):2233–2240
- Hendry S, Pang JB, Byrne DJ, Lakhani SR, Cummings MC, Campbell IG, Mann GB, Gorringer KL, Fox SB (2017a) Relationship of the breast ductal carcinoma in situ immune microenvironment with clinicopathological and genetic features. *Clin Cancer Res* 23(17):5210–5217
- Hendry S, Salgado R, Gevaert T et al (2017b) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. *Adv Anat Pathol* 24(5):235–251
- Horny HP, Horst HA (1986) Lymphoreticular infiltrates in invasive ductal breast cancer. A histological and immunohistological study. *Virchows Arch* 409(2):275–286
- Horst HA, Horny HP (1988) Frequency distribution of lymphoreticular infiltrates in invasive carcinoma of the female breast. *Cancer Detect Prev* 11(3–6):297–301
- Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA (2014) The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. *Breast Cancer Res Treat* 148(3):467–476
- Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, Rothé F, Maetens M, Venet D, Holgado E, McNally V, Kiermaier A, Savage HM, Wilson TR, Cortes J, Schneeweiss A, Willard-Gallo K, Biganzoli E, Sotiriou C (2019) Tumor-infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: a TRYPHAENA substudy. *J Natl Cancer Inst* 111(1):69–77
- Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, Sinn BV, Ulmer HU, Kronenwett R, Just M, Kühn T, Diebold K, Untch M, Holms F, Blohmer JU, Habeck JO, Dietel M, Overkamp F, Krabisch P, von Minckwitz G, Denkert C (2013) Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer – a substudy of the neoadjuvant GeparQuinto trial. *PLoS One* 8(12):e79775
- Krishnamurti U, Wetherilt CS, Yang J, Peng L, Li X (2017) Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers. *Hum Pathol* 64:7–12
- Lee S, Cho EY, Park YH, Ahn JS, Im YH (2013) Prognostic impact of FOXP3 expression in triple-negative breast cancer. *Acta Oncol* 52(1):73–81
- Leon-Ferre RA, Polley MY, Liu H, Gilbert JA, Cafourek V, Hillman DW, Elkhanany A, Akinhanmi M, Lilyquist J, Thomas A, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari KR,

- Couch FJ, Visscher DW, Goetz MP (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. *Breast Cancer Res Treat* 167(1):89–99
- Li JJ, Tsang JY, Tse GM (2021) Tumor microenvironment in breast cancer-updates on therapeutic implications and pathologic assessment. *Cancers (Basel)* 13(16):4233
- Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO (2012) CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. *Breast Cancer Res* 14(2):R48
- Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z, Parulekar WR, Shepherd L, Gelmon KA, Nielsen TO (2017) Role of cytotoxic tumor-infiltrating lymphocytes in predicting outcomes in metastatic HER2-positive breast cancer: a secondary analysis of a randomized clinical trial. *JAMA Oncol* 3(11):e172085
- Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ, Sotiriou C (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. *J Clin Oncol* 31(7):860–867
- Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. *Ann Oncol* 25(8):1544–1550
- Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S (2019) Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. *J Clin Oncol* 37(7):559–569
- Loi S, Michiels S, Adams S, Loibl S, Budczies J, Denkert C, Salgado R (2021) The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. *Ann Oncol* 32(10):1236–1244
- Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart M, Roblin E, Michiels S (2022) Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. *NPJ Breast Cancer* 8:3
- Lu Z, Xu S, Shao W, Wu Y, Zhang J, Han Z, Feng Q, Huang K (2020) Deep-learning-based characterization of tumor-infiltrating lymphocytes in breast cancers from histopathology images and multiomics data. *JCO Clin Cancer Inform* 4:480–490
- Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S (2017) Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. *Lancet Oncol* 18(1):52–62
- Luen SJ, Salgado R, Dieci MV, Vingiani A, Curigliano G, Gould RE, Castaneda C, D'Alfonso T, Sanchez J, Cheng E, Andreopoulou E, Castillo M, Adams S, Demaria S, Symmans WF, Michiels S, Loi S (2019) Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. *Ann Oncol* 30(2):236–242

- Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR (2011a) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. *J Clin Oncol* 29(15):1949–1955
- Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Lee AH, Ellis IO, Green AR (2011b) An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. *Breast Cancer Res Treat* 127(1):99–108
- Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR (2012) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. *Breast Cancer Res Treat* 132(2):545–553
- Mansour M, Teo ZL, Luen SJ, Loi S (2017) Advancing immunotherapy in metastatic breast cancer. *Curr Treat Options in Oncol* 18(6):35
- Miligy I, Mohan P, Gaber A, Aleskandarany MA, Nolan CC, Diez-Rodriguez M, Mukherjee A, Chapman C, Ellis IO, Green AR, Rakha EA (2017) Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. *Histopathology* 71(2):258–268
- Mohammed ZM, Going JJ, Edwards J, Elsberger B, McMillan DC (2013) The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. *Br J Cancer* 109(6):1676–1684
- Montagna E, Vingiani A, Maisonneuve P, Cancellio G, Contaldo F, Pruneri G, Colleoni M (2017) Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. *Breast* 34:83–88
- Moore OS Jr, Foote FW Jr (1949) The relatively favorable prognosis of medullary carcinoma of the breast. *Cancer* 2(4):635–642
- Ochi T, Bianchini G, Ando M, Nozaki F, Kobayashi D, Criscitiello C, Curigliano G, Iwamoto T, Niikura N, Takei H, Yoshida A, Takei J, Suzuki K, Yamauchi H, Hayashi N (2019) Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. *Eur J Cancer* 118:41–48
- Ogiya R, Niikura N, Kumaki N, Bianchini G, Kitano S, Iwamoto T, Hayashi N, Yokoyama K, Oshitani R, Terao M, Morioka T, Tsuda B, Okamura T, Saito Y, Suzuki Y, Tokuda Y (2016) Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. *Cancer Sci* 107(12):1730–1735
- Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, Baehner FL (2016) Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer. *JAMA Oncol* 2(1):56–64
- Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensz N, DeCensi A, Guerrieri-Gonzaga A, Vingiani A, Curigliano G, Zurrida S, Bassi F, Salgado R, Van den Eynden G, Loi S, Denkert C, Bonanni B, Viale G (2017) The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. *Ann Oncol* 28(2):321–328
- Ravelli A, Roviello G, Cretella D, Cavazzoni A, Biondi A, Cappelletti MR, Zanotti L, Ferrero G, Ungari M, Zanconati F, Bottini A, Alfieri R, Petronini PG, Generali D (2017) Tumor-infiltrating lymphocytes and breast cancer: beyond the prognostic and predictive utility. *Tumour Biol* 39(4):1010428317695023
- Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S (2015a) Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with Lapatinib and

- Trastuzumab: a secondary analysis of the NeoALTTO trial. *JAMA Oncol* 1(4):448–454
- Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S, International TILs Working Group 2014 (2015b) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. *Ann Oncol* 26(2):259–271
- Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, Kim YJ, Kim JH, Park SY (2013) Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. *Br J Cancer* 109(10):2705–2713
- Sobottka B, Pestalozzi B, Fink D, Moch H, Varga Z (2016) Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. *Onco Targets Ther* 5(6):e1153208
- Solinas C, Carbognin L, De Silva P, Criscitiello C, Lambertini M (2017a) Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: current state of the art. *Breast* 35:142–150
- Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M (2017b) Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: a meta-analysis of randomized controlled trials. *Cancer Treat Rev* 57:8–15
- Stanton SE, Adams S, Disis ML (2016) Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. *JAMA Oncol* 2(10):1354–1360
- Sun P, He J, Chao X, Chen K, Xu Y, Huang Q, Yun J, Li M, Luo R, Kuang J, Wang H, Li H, Hui H, Xu S (2021) A computational tumor-infiltrating lymphocyte assessment method comparable with visual reporting guidelines for triple-negative breast cancer. *EBioMedicine* 70:103492
- Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessey B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Puztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. *J Clin Oncol* 25(28):4414–4422
- Szekely B, Bossuyt V, Li X, Wali WB, Patwardhan GA, Frederick C, Silber A, Park T, Harigopal M, Pelekanou V, Zhang M, Yan Q, Rimm DL, Bianchini G, Hatzis C, Puztai L (2018) Immunological differences between primary and metastatic breast cancer. *Ann Oncol* 29(11):2232–2239
- Thomas R, Al-Khadairi G, Decock J (2021) Immune checkpoint inhibitors in triple negative breast cancer treatment: promising future prospects. *Front Oncol* 10:600573
- Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, Argani P, Cimino-Mathews A, Emens LA (2016) The immune microenvironment of breast ductal carcinoma in situ. *Mod Pathol* 29(3):249–258
- Wein L, Savas P, Luen SJ, Virassamy B, Salgado R, Loi S (2017) Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: current and future directions. *Front Oncol* 7:156
- West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH (2011) Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. *Breast Cancer Res* 13(6):R126

- West NR, Kost SE, Martin SD, Milne K, Deleeuw RJ, Nelson BH, Watson PH (2013) Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. *Br J Cancer* 108(1):155–162
- WHO Classification of Tumours Editorial Board (2019) Breast tumours. WHO classification of tumours, 5th edn. IARC Press, Lyon
- Yamaguchi R, Tanaka M, Yano A, Tse GM, Yamaguchi M, Koura K, Kanomata N, Kawaguchi A, Akiba J, Naito Y, Ohshima K, Yano H (2012) Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. *Hum Pathol* 43(10):1688–1694
- Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langan M, Shelton T, Prickett T, Gartner J, Jia L, Trebska-McGowan K, Somerville RP, Robbins PF, Rosenberg SA, Goff SL, Feldman SA (2018) Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. *Nat Med* 24(6):724–730
- Zhang W, Kong X, Ai B, Wang Z, Wang X, Wang N, Zheng S, Fang Y, Wang J (2021) Research progresses in immunological checkpoint inhibitors for breast cancer immunotherapy. *Front Oncol* 11:582664
- Zhu L, Narloch JL, Onkar S, Joy M, Broadwater G, Luedke C, Hall A, Kim R, Pogue-Geile K, Sammons S, Nayyar N, Chukwueke U, Brastianos PK, Anders CK, Soloff AC, Vignali DAA, Tseng GC, Emens LA, Lucas PC, Blackwell KL, Oesterreich S, Lee AV (2019) Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. *J Immunother Cancer* 7(1):265

第7章 从基因到康复:精准医学及其对耐多药乳腺癌的影响

- Agostinetto, E., Gligorov, J., & Piccart, M. (2022). Systemic therapy for early-stage breast cancer: learning from the past to build the future. *Nat Rev Clin Oncol*, 19(12), Article 12. <https://doi.org/10.1038/s41571-022-00687-1>
- Ahern TP, Lash TL, Damkier P, Christiansen PM, Cronin-Fenton DP (2014) Statins and breast cancer prognosis: evidence and opportunities. *Lancet Oncol* 15(10):e461–e468. [https://doi.org/10.1016/S1470-2045\(14\)70119-6](https://doi.org/10.1016/S1470-2045(14)70119-6)
- Ahn JS, Shin S, Yang S-A, Park EK, Kim KH, Cho SI, Ock C-Y, Kim S (2023) Artificial intelligence in breast cancer diagnosis and personalized medicine. *J Breast Cancer* 26(5):405. <https://doi.org/10.4048/jbc.2023.26.e45>
- Akbani R, Ng K-S, Werner HM, Zhang F, Ju Z, Liu W, Yang J-Y, Lu Y, Weinstein JN, Mills GB (2014) Abstract 4262: a pan-cancer proteomic analysis of The Cancer Genome Atlas (TCGA) project. *Cancer Res* 74(19_Supplement):4262. <https://doi.org/10.1158/1538-7445.AM2014-4262>
- Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J, Schinkel AH (2000) Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. *Cancer Res* 60(20):5761–5766
- Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. *Annu Rev Pharmacol Toxicol* 39(1):361–398
- Araki K, Miyoshi Y (2018) Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. *Breast Cancer* 25(4):392–401. <https://doi.org/10.1007/s12282-017-0812-x>
- Aronson SJ, Rehm HL (2015) Building the foundation for genomics in precision medicine. *Nature* 526(7573):336–342. <https://doi.org/10.1038/nature15816>
- Ashley EA (2016) Towards precision medicine. *Nat Rev Genet* 17(9):507–522. <https://doi.org/10.1038/nrg.2016.86>
- Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group | JNCI: Journal of the National Cancer Institute | Oxford Academic (n.d.) Retrieved November 29, 2023, from <https://academic.oup.com/jnci/article/113/7/808/6053794?login=false>
- Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E, Farahmand L (2020) Breast cancer: biology, biomarkers, and treatments. *Int Immunopharmacol* 84:106535. <https://doi.org/10.1016/j.intimp.2020.106535>
- Bauer K, Parise C, Caggiano V (2010) Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen consensus statement for early breast cancer. *BMC Cancer* 10:1–12
- Bettaieb A, Paul C, Plenchette S, Shan J, Chouchane L, Ghiringhelli F (2017) Precision medicine in breast cancer: reality or utopia? *J Transl Med* 15:1–13
- Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. *Cancer Res* 55(11):Article 11
- Bonnetterre, J., Thürlimann, B., Robertson, J. F., Krzakowski, M., Mauriac, L., Koralewski, P.,

- Vergote, I., Webster, A., Steinberg, M., & von Euler, M. (2000). Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. *J Clin Oncol*, 18(22), Article 22. <https://doi.org/10.1200/JCO.2000.18.22.3748>
- BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance—PMC (2023, November 25). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548160/>
- Buolamwini JK (1999) Novel anticancer drug discovery. *Curr Opin Chem Biol* 3(4):500–509
- Burt JR, Torosdagli N, Khosravan N, RaviPrakash H, Mortazi A, Tissavirasingham F, Hussein S, Bagci U (2018) Deep learning beyond cats and dogs: recent advances in diagnosing breast cancer with deep neural networks. *Br J Radiol* 91(1089):20170545
- Buzdar A, Howell A (2001) Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. *Clin Cancer Res* 7(9):Article 9
- Campling BG, Young LC, Baer KA, Lam Y-M, Deeley RG, Cole SP, Gerlach JH (1997) Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. *Clin Cancer Res* 3(1):115–122
- Cantley LC (2002) The phosphoinositide 3-kinase pathway. *Science* 296(5573):1655–1657. <https://doi.org/10.1126/science.296.5573.1655>
- Cardoso F, Di Leo A, Lohrisch C, Bernard C, Ferreira F, Piccart MJ (2002) Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? *Ann Oncol* 13(2):Article 2. <https://doi.org/10.1093/annonc/mdf101>
- Carpenter JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian Y-W, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S et al (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. *Nature* 448(7152):439–444. <https://doi.org/10.1038/nature05933>
- Carrick S, Parker S, Thornton C, Gherzi D, Simes J, Wilcken N (2009) Single agent versus combination chemotherapy for metastatic breast cancer. *Cochrane Database Syst Rev* 2021(5):Article 5. <https://doi.org/10.1002/14651858.CD003372.pub3>
- Casaubon JT, Kashyap S, Regan JP (2017) BRCA1 and BRCA2 mutations
- Cava C, Bertoli G, Castiglioni I (2015) Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential. *BMC Syst Biol* 9(1):62. <https://doi.org/10.1186/s12918-015-0211-x>
- Chaurasia M, Singh R, Sur S, Flora SJS (2023) A review of FDA approved drugs and their formulations for the treatment of breast cancer. *Front Pharmacol* 14:1184472
- Chen Z, Lin L, Wu C, Li C, Xu R, Sun Y (2021) Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine. *Cancer Commun* 41(11):1100–1115. <https://doi.org/10.1002/cac2.12215>
- Chiavenna SM, Jaworski JP, Vendrell A (2017) State of the art in anti-cancer mAbs. *J Biomed Sci* 24:1–12
- Cinkaya A, Akin M, Sengul A (2016) Evaluation of treatment outcomes of triple-negative breast cancer. *J Cancer Res Ther* 12(1):150–154
- Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, . . . Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. *J Clin Oncol* 17(9):2639–2639
- Collins FS, Morgan M, Patrinos A (2003) The human genome project: lessons from large-scale biology. *Science* 300(5617):Article 5617. <https://doi.org/10.1126/science.1084564>

- Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet* 384(9938):Article 9938. [https://doi.org/10.1016/S0140-6736\(13\)62422-8](https://doi.org/10.1016/S0140-6736(13)62422-8)
- Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B, Sastre-Garau X (2000) Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. *Mod Pathol* 13(11):Article 11. <https://doi.org/10.1038/modpathol.3880228>
- Cretella D, Ravelli A, Fumarola C, La Monica S, Digiacoio G, Cavazzoni A, Alfieri R, Biondi A, Generali D, Bonelli M, Petronini PG (2018) The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. *J Exp Clin Cancer Res* 37(1):72. <https://doi.org/10.1186/s13046-018-0741-3>
- Crimini E, Repetto M, Aftimos P, Botticelli A, Marchetti P, Curigliano G (2021) Precision medicine in breast cancer: from clinical trials to clinical practice. *Cancer Treat Rev* 98: 102223. <https://doi.org/10.1016/j.ctrv.2021.102223>
- Dawson S-J, Rueda OM, Aparicio S, Caldas C (2013) A new genome-driven integrated classification of breast cancer and its implications. *EMBO J* 32(5):617–628
- De Fauw J, Ledsam JR, Romera-Paredes B, Nikolov S, Tomasev N, Blackwell S, Askham H, Glorot X, O'Donoghue B, Visentin D, Van Den Driessche G, Lakshminarayanan B, Meyer C, Mackinder F, Bouton S, Ayoub K, Chopra R, King D, Karthikesalingam A et al (2018) Clinically applicable deep learning for diagnosis and referral in retinal disease. *Nat Med* 24(9):1342–1350. <https://doi.org/10.1038/s41591-018-0107-6>
- Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype—Bauer—2007—Cancer—Wiley Online Library (2023, November 25). <https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.22618>
- Domingues I, Pereira G, Martins P, Duarte H, Santos J, Abreu PH (2020) Using deep learning techniques in medical imaging: a systematic review of applications on CT and PET. *Artif Intell Rev* 53:4093–4160
- Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, Mallon E, Walker R (2000) Assessment of HER2 status in breast cancer: why, when and how? *Eur J Cancer* 36(2):170–176. [https://doi.org/10.1016/S0959-8049\(99\)00264-6](https://doi.org/10.1016/S0959-8049(99)00264-6)
- Dunlap J, Le C, Shukla A, Patterson J, Presnell A, Heinrich MC, Corless CL, Troxell ML (2010) Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. *Breast Cancer Res Treat* 120(2):409–418. <https://doi.org/10.1007/s10549-009-0406-1>
- Ehteshami Bejnordi B, Veta M, Johannes Van Diest P, Van Ginneken B, Karssemeijer N, Litjens G, Van Der Laak JAWM, the CAMELYON16 Consortium, Hermsen M, Manson QF, Balkenhol M, Geessink O, Stathonikos N, Van Dijk MC, Bult P, Beca F, Beck AH, Wang D, Khosla A et al (2017) Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. *JAMA* 318(22):2199. <https://doi.org/10.1001/jama.2017.14585>
- Esteva FJ (2004) Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. *Oncologist* 9(S3):4–9
- Fan S, Cherney B, Reinhold W, Rucker K, O'Connor PM (1998) Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine

- treatment. *Clin Cancer Res* 4(4):Article 4
- Fisher B (1979) Breast-cancer management. *N Engl J Med* 301(6):Article 6. <https://doi.org/10.1056/NEJM197908093010611>
- Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. *J Clin Oncol* 16(10):3439–3460. <https://doi.org/10.1200/JCO.1998.16.10.3439>
- Franke TF, Kaplan DR, Cantley LC (1997) PI3K: downstream AKTion blocks apoptosis. *Cell* 88(4):435–437. [https://doi.org/10.1016/S0092-8674\(00\)81883-8](https://doi.org/10.1016/S0092-8674(00)81883-8)
- Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, Amiri-Kordestani L, Ibrahim A, Sridhara R, Goldberg KB, Theoret MR, Kluetz PG, Blumenthal GM, Pazdur R, Beaver JA, Prowell TM (2020) CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. *Lancet Oncol* 21(2):250–260. [https://doi.org/10.1016/S1470-2045\(19\)30804-6](https://doi.org/10.1016/S1470-2045(19)30804-6)
- Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, De Azambuja E, Fauria K, Van Dooren V, Aktan G, Coccia-Portugal MA, Kim S-B, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart M, Flamen P, Di Cosimo S (2013) ¹⁸F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. *J Nucl Med* 54(11):Article 11. <https://doi.org/10.2967/jnumed.112.119271>
- Genetics* (n.d.) Retrieved November 9, 2023, from <https://www.breastcancer.org/risk/risk-factors/genetics>
- Genetics and risk of breast cancer* (n.d.) Retrieved January 16, 2024, from <https://www.bcna.org.au/resource-hub/articles/genetics-and-risk-of-breast-cancer/>
- Genetics as a Risk Factor for Breast Cancer (2024, January 16). <https://www.breastcancer.org/risk/risk-factors/genetics>
- Gershonovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, Buzzi F, Bodrogi I, Ludwig H, Reichardt P, O'Higgins N, Romieu G, Friederich P, Lassus M (1998) Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. *Ann Oncol* 9(6):Article 6. <https://doi.org/10.1023/A:1008226721932>
- Godet I, Gilkes DM (2017) BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. *Integr Cancer Sci Ther* 4(1):10.15761/ICST.1000228
- Gulilat M, Lamb T, Teft WA, Wang J, Dron JS, Robinson JF, Tirona RG, Hegele RA, Kim RB, Schwarz UI (2019) Targeted next generation sequencing as a tool for precision medicine. *BMC Med Genet* 12:1–17
- Haenssle HA, Fink C, Schneiderbauer R, Toberer F, Buhl T, Blum A, Kalloo A, Hassen ABH, Thomas L, Enk A, Uhlmann L, Alt C, Arenbergerova M, Bakos R, Baltzer A, Bertlich I, Blum A, Bokor-Billmann T, Bowling J et al (2018) Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists. *Ann Oncol* 29(8):1836–1842. <https://doi.org/10.1093/annonc/mdy166>
- Hamilton A, Piccart M (1999) The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. *Ann Oncol* 10(4):Article 4. <https://doi.org/10.1023/A:1008368300827>
- He J, Fortunati E, Liu D-X, Li Y (2021) Pleiotropic roles of ABC transporters in breast cancer. *Int J Mol Sci* 22(6):3199

- HER2-Positive Breast Cancer | Drugs* (n.d.) Retrieved November 29, 2023, from <https://link.springer.com/article/10.2165/00003495-200767090-00006>
- Hinz N, Jücker M (2019) Distinct functions of AKT isoforms in breast cancer: a comprehensive review. *Cell Commun Signal* 17:1–154. <https://doi.org/10.1186/s12964-019-0450-3>
- Ho A, Morrow M (2011) The evolution of the locoregional therapy of breast cancer. *Oncologist* 16(10):Article 10. <https://doi.org/10.1634/theoncologist.2011-0223>
- Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C (2002) Fulvestrant, formerly ICI 182,780, is as effective as Anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. *J Clin Oncol* 20(16):Article 16. <https://doi.org/10.1200/JCO.2002.10.057>
- Hu T, Chitnis N, Monos D, Dinh A (2021) Next-generation sequencing technologies: an overview. *Hum Immunol* 82(11):801–811. <https://doi.org/10.1016/j.humimm.2021.02.012>
- Huang C-H, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB, Amzel LM (2007) The structure of a human p110 α /p85 α complex elucidates the effects of oncogenic PI3K α mutations. *Science* 318(5857):1744–1748. <https://doi.org/10.1126/science.1150799>
- Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS (2005) Breast cancer-associated *PIK3CA* mutations are oncogenic in mammary epithelial cells. *Cancer Res* 65(23):10992–11000. <https://doi.org/10.1158/0008-5472.CAN-05-2612>
- Jassem J, Pieńkowski T, Płużańska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. *J Clin Oncol* 19(6):Article 6. <https://doi.org/10.1200/JCO.2001.19.6.1707>
- Johnston SJ, Cheung K-L (2018) Endocrine therapy for breast cancer: a model of hormonal manipulation. *Oncol Ther* 6(2):–141, 156. <https://doi.org/10.1007/s40487-018-0062-x>
- Kalinin AA, Higgins GA, Reamaroon N, Soroushmehr S, Allyn-Feuer A, Dinov ID, Najarian K, Athey BD (2018) Deep learning in pharmacogenomics: from gene regulation to patient stratification. *Pharmacogenomics* 19(7):629–650. <https://doi.org/10.2217/pgs-2018-0008>
- Karami F, Mehdipour P (2013) A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. *Biomed Res Int* 2013
- Ko BK, Kawano K, Murray JL, Disis ML, Efferson CL, Kuerer HM, Peoples GE, Ioannides CG (2003) Clinical studies of vaccines targeting breast cancer. *Clin Cancer Res* 9(9):3222–3234
- Kozegar E, Soryani M, Behnam H, Salamati M, Tan T (2020) Computer aided detection in automated 3-D breast ultrasound images: a survey. *Artif Intell Rev* 53:1919–1941
- Larry Jameson J, Longo DL (2015) Precision medicine—personalized, problematic, and promising. *Obstet Gynecol Surv* 70(10):612–614. <https://doi.org/10.1097/01.ogx.0000472121.21647.38>
- LeCun Y, Bengio Y, Hinton G (2015) Deep learning. *Nature* 521(7553):436–444
- Le Du F, Ueno NT, Gonzalez-Angulo AM (2013) Breast cancer biomarkers: utility in clinical practice. *Curr Breast Cancer Rep* 5:284–292
- Leonard R, Cervantes G, Lui W, Mauriac L, Miles D, Moiseyenko V, Chan Navarro C, Van Hazel G, Vukelja S, O'Shaughnessy J (2001) Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). *Eur J Cancer* 37:S151. [https://doi.org/10.1016/S0959-8049\(01\)81043-1](https://doi.org/10.1016/S0959-8049(01)81043-1)
- Leung JH, Leung HWC, Wang S-Y, Huang S-S, Chan ALF (2021) Efficacy and safety of CDK4/6

- and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis. *Expert Opin Drug Saf* 20(8):949–957. <https://doi.org/10.1080/14740338.2021.1931116>
- Lin E, Kuo PH, Liu YL, Yu YWY, Yang AC, Tsai SJ (2018) A deep learning approach for predicting antidepressant response in major depression using clinical and genetic biomarkers. *Front Psych* 9:367995
- Liu Y-Y, Han T-Y, Giuliano AE, Cabot MC (2001) Ceramide glycosylation potentiates cellular multidrug resistance. *FASEB J* 15(3):719–730
- Low S, Zembutsu H, Nakamura Y (2018) Breast cancer: the translation of big genomic data to cancer precision medicine. *Cancer Sci* 109(3):497–506. <https://doi.org/10.1111/cas.13463>
- Lowe SW, Ruley HE, Jacks T, Housman DE (1993) P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. *Cell* 74(6):957–967
- Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC (2020) Development of therapeutic antibodies for the treatment of diseases. *J Biomed Sci* 27:1–30
- Luminal A Breast Cancer and Molecular Assays: A Review | The Oncologist | Oxford Academic (n.d.) Retrieved November 29, 2023, from <https://academic.oup.com/oncolo/article/23/5/556/6439608?login=false>
- Mahdavi M, Nassiri M, Kooshyar MM, Vakili-Azghandi M, Avan A, Sandry R, Pillai S, Lam AK, Gopalan V (2019) Hereditary breast cancer; Genetic penetrance and current status with BRCA. *J Cell Physiol* 234(5):Article 5. <https://doi.org/10.1002/jcp.27464>
- Marrugo-Ramírez J, Mir M, Samitier J (2018) Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy. *Int J Mol Sci* 19(10):2877. <https://doi.org/10.3390/ijms19102877>
- Martinelli C, Pucci C, Ciofani G (2019) Nanostructured carriers as innovative tools for cancer diagnosis and therapy. *APL Bioeng* 3(1):011502. <https://doi.org/10.1063/1.5079943>
- McCombie WR, McPherson JD, Mardis ER (2019) Next-generation sequencing technologies. *Cold Spring Harb Perspect Med* 9(11):Article 11. <https://doi.org/10.1101/cshperspect.a036798>
- McGrath S, Ghersi D (2016) Building towards precision medicine: empowering medical professionals for the next revolution. *BMC Med Genet* 9(1):23. <https://doi.org/10.1186/s12920-016-0183-8>
- Meldrum C, Doyle MA, Tothill RW (2011) Next-generation sequencing for cancer diagnostics: a practical perspective. *Clin Biochem Rev* 32(4):177
- Miled N, Yan Y, Hon W-C, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny D, Wolfson HJ, Backer JM, Williams RL (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. *Science* 317(5835):239–242. <https://doi.org/10.1126/science.1135394>
- Miles DW, Smith IE, Coleman RE, Calvert AH, Lind MJ (2001) A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. *Eur J Cancer* 37(11):Article 11. [https://doi.org/10.1016/S0959-8049\(01\)00117-4](https://doi.org/10.1016/S0959-8049(01)00117-4)
- Moghbel M, Mashohor S (2013) A review of computer assisted detection/diagnosis (CAD) in breast thermography for breast cancer detection. *Artif Intell Rev* 39:305–313
- Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H (2017) Combination therapy in combating cancer. *Oncotarget* 8(23):38022–38043. <https://doi.org/10.18632/oncotarget.16723>
- Morash M, Mitchell H, Beltran H, Elemento O, Pathak J (2018) The role of next-generation sequencing in precision medicine: a review of outcomes in oncology. *J Personal Med* 8(3):30. <https://doi.org/10.3390/jpm8030030>

- Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B et al (2001) Superior efficacy of Letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international Letrozole breast cancer group. *J Clin Oncol* 19(10): Article 10. <https://doi.org/10.1200/JCO.2001.19.10.2596>
- Mukohara T (2015) PI3K mutations in breast cancer: prognostic and therapeutic implications. *Breast Cancer Targets Ther* 111. <https://doi.org/10.2147/BCTT.S60696>
- Murtaza G, Shuib L, Abdul Wahab AW, Mujtaba G, Mujtaba G, Nweke HF, Al-garadi MA, Zulfikar F, Raza G, Azmi NA (2020) Deep learning-based breast cancer classification through medical imaging modalities: state of the art and research challenges. *Artif Intell Rev* 53:1655–1720
- Musyuni P, Bai J, Sheikh A, Vasanthan KS, Jain GK, Abourehab MAS, Lather V, Aggarwal G, Kesharwani P, Pandita D (2022) Precision medicine: ray of hope in overcoming cancer multidrug resistance. *Drug Resist Updat* 65:100889. <https://doi.org/10.1016/j.drug.2022.100889>
- Mutant p53 in breast cancer: Potential as a therapeutic target and biomarker | Breast Cancer Research and Treatment* (n.d.) Retrieved November 29, 2023, from <https://link.springer.com/article/10.1007/s10549-018-4753-7>
- Nabholtz J-M, Senn HJ, Bezwoda WR, Melnychuk D, Deschênes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JWR, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PSGJ et al (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. *J Clin Oncol* 17(5):Article 5. <https://doi.org/10.1200/JCO.1999.17.5.1413>
- Nabieva N, Fasching PA (2021) Endocrine treatment for breast cancer patients revisited—history, standard of care, and possibilities of improvement. *Cancers* 13(22):Article 22. <https://doi.org/10.3390/cancers13225643>
- Naito Y, Urasaki T (2018) Precision medicine in breast cancer. *Chin Clin Oncol* 7(3):29–29. <https://doi.org/10.21037/cco.2018.06.04>
- Nikanjam M, Kato S, Kurzrock R (2022) Liquid biopsy: current technology and clinical applications. *J Hematol Oncol* 15(1):131. <https://doi.org/10.1186/s13045-022-01351-y>
- O'Driscoll L, Clynes M (2006) Biomarkers and multiple drug resistance in breast cancer. *Curr Cancer Drug Targets* 6(5):365–384. <https://doi.org/10.2174/156800906777723958>
- Orrantia-Borunda E, Anchondo-Núñez P, Acuña-Aguilar LE, Gómez-Valles FO, Ramírez-Valdespino CA (2022) Subtypes of breast cancer. In: Mayrovitz HN (ed) *Breast cancer*. Exon Publications. <http://www.ncbi.nlm.nih.gov/books/NBK583808/>
- Panigrahi A, Pinder S, Chan S, Paish E, Robertson J, Ellis I (2004) The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. *J Pathol* 204(1):93–100. <https://doi.org/10.1002/path.1611>
- Paridaens R, Dirix L, Beex L, Nooij M, Cufer T, Lohrisch C, Biganzoli L, Van Hoorebeeck I, Duchateau L, Lobelle J-P, Piccart M (2000) Promising results with Exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control. *Clin Breast Cancer* 1:S19–S21. <https://doi.org/10.3816/CBC.2000.s.004>
- Perez EA (2009) Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. *Breast Cancer Res Treat* 114: 195–201

- Perez EA, Pusztai L, van De Vijver M (2004) Improving patient care through molecular diagnostics. *Semin Oncol* 31:14–20
- Petric RC, Pop L-A, Jurj A, Raduly L, Dumitrascu D, Dragos N, Neagoe IB (2015) Next generation sequencing applications for breast cancer research. *Clujul Med* 88(3):Article 3. <https://doi.org/10.15386/cjmed-486>
- Pfefferle AD, Agrawal YN, Koboldt DC, Kanchi KL, Herschkowitz JI, Mardis ER, . . . Perou CM (2016) Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers. *Dis Model Mech* 9(7):749–757
- Piccart MJ, Cardoso F (2003) Progress in systemic therapy for breast cancer: an overview and perspectives. *Eur J Cancer Suppl* 1(2):Article 2. [https://doi.org/10.1016/S1359-6349\(03\)00009-0](https://doi.org/10.1016/S1359-6349(03)00009-0)
- Planes-Laine G, Rochigneux P, Bertucci F, Chrétien A-S, Viens P, Sabatier R, Gonçalves A (2019) PD-1/PD-L1 targeting in breast cancer: the first clinical evidences are emerging—a literature review. *Cancers* 11(7):1033
- Potnis KC, Ross JS, Aneja S, Gross CP, Richman IB (2022) Artificial intelligence in breast cancer screening: evaluation of FDA device regulation and future recommendations. *JAMA Intern Med* 182(12):1306–1312. <https://doi.org/10.1001/jamainternmed.2022.4969>
- Poudel P, Nyamundanda G, Patil Y, Cheang MCU, Sadanandam A (2019) Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses. *Npj Breast Cancer* 5(1):Article 1. <https://doi.org/10.1038/s41523-019-0116-8>
- Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL (2002) Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. *Oncogene* 21(50):7611–7618
- Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, Maibach R, Ruepp B, Coates AS, Goldhirsch A, Colleoni M, Gelber RD, Francis PA (2013) Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. *Breast* 22(6):1094–1100. <https://doi.org/10.1016/j.breast.2013.08.009>
- Research, C. for D. E. and (2024) Oncology (Cancer)/Hematologic Malignancies Approval Notifications. FDA. <https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications>
- Risinger JI, Hayes AK, Berchuck A, Barrett JC (1997) PTEN/MMAC1 mutations in endometrial cancers. *Cancer Res* 57(21):4736–4738
- Rizzo JM, Buck MJ (2012) Key principles and clinical applications of “next-generation” DNA sequencing. *Cancer Prev Res* 5(7):Article 7. <https://doi.org/10.1158/1940-6207.CAPR-11-0432>
- Robinson PN (2012) Deep phenotyping for precision medicine. *Hum Mutat* 33(5):777–780. <https://doi.org/10.1002/humu.22080>
- Royce M, Bachelot T, Villanueva C, Özgüroğlu M, Azevedo SJ, Cruz FM, Debled M, Hegg R, Toyama T, Falkson C, Jeong J, Srimuninnimit V, Gradishar WJ, Arce C, Ridolfi A, Lin C, Cardoso F (2018) Everolimus plus endocrine therapy for postmenopausal women with Estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a clinical trial. *JAMA Oncol* 4(7):977–984. <https://doi.org/10.1001/jamaoncol.2018.0060>
- Sachdev JC, Sandoval AC, Jahanzeb M (2019) Update on precision medicine in breast cancer. In: Von Hoff DD, Han H (eds) *Precision medicine in cancer therapy*, vol 178. Springer International Publishing, pp 45–80. https://doi.org/10.1007/978-3-030-16391-4_2
- Saha M, Chakraborty C, Racocanu D (2018) Efficient deep learning model for mitosis detection using breast histopathology images. *Comput Med Imaging Graph* 64:29–40
- Samuel AL (1959) Some studies in machine learning using the game of checkers. *IBM J Res Dev*

3(3):210–229

- Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JKV, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency of mutations of the *PIK3CA* gene in human cancers. *Science* 304(5670): 554–554. <https://doi.org/10.1126/science.1096502>
- Shah SM, Khan RA, Arif S, Sajid U (2022) Artificial intelligence for breast cancer analysis: trends & directions. *Comput Biol Med* 142:105221
- Sharma S, Mehra R (2020) Conventional machine learning and deep learning approach for multi-classification of breast cancer histopathology images—a comparative insight. *J Digit Imaging* 33:632–654
- Shen D-W, Goldenberg S, Pastan IRA, Gottesman MM (2000) Decreased accumulation of [14c] carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. *J Cell Physiol* 183(1):108–116
- Sheth D, Giger ML (2020) Artificial intelligence in the interpretation of breast cancer on MRI. *J Magn Reson Imaging* 51(5):1310–1324
- Shien T, Iwata H (2020) Adjuvant and neoadjuvant therapy for breast cancer. *Jpn J Clin Oncol* 50(3):Article 3. <https://doi.org/10.1093/jjco/hyz213>
- Shyr D, Liu Q (2013) Next generation sequencing in cancer research and clinical application. *Biol Proced Online* 15(1):4. <https://doi.org/10.1186/1480-9222-15-4>
- Simpson L, Parsons R (2001) PTEN: life as a tumor suppressor. *Exp Cell Res* 264(1):29–41. <https://doi.org/10.1006/excr.2000.5130>
- Smith BD, Jiang J, McLaughlin SS, Hurria A, Smith GL, Giordano SH, Buchholz TA (2011) Improvement in breast cancer outcomes over time: are older women missing out? *J Clin Oncol* 29(35):Article 35. <https://doi.org/10.1200/JCO.2011.35.8408>
- Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR (2012) The landscape of cancer genes and mutational processes in breast cancer. *Nature* 486(7403):400–404
- Stover DG, Wagle N (2015) Precision medicine in breast cancer: genes, genomes, and the future of Genomically driven treatments. *Curr Oncol Rep* 17(4):15. <https://doi.org/10.1007/s11912-015-0438-0>
- Syrjala KL (2018) Opportunities for improving oncology care. *Lancet Oncol* 19(4):449. [https://doi.org/10.1016/S1470-2045\(18\)30208-0](https://doi.org/10.1016/S1470-2045(18)30208-0)
- Szymczak S, Biernacka JM, Cordell HJ, González-Recio O, König IR, Zhang H, Sun YV (2009) Machine learning in genome-wide association studies. *Genet Epidemiol* 33(S1). <https://doi.org/10.1002/gepi.20473>
- Telenti A, Lippert C, Chang P-C, DePristo M (2018) Deep learning of genomic variation and regulatory network data. *Hum Mol Genet* 27(Supplement_R1):R63–R71. <https://doi.org/10.1093/hmg/ddy115>
- Thomas DC (2017) What does “precision medicine” have to say about prevention? *Epidemiology* 28(4):479–483
- Troxell ML (2012) PIK3CA/AKT1 mutations in breast carcinoma: a comprehensive review of experimental and clinical studies. *J Clin Exp Pathol* 02(01). <https://doi.org/10.4172/2161-0681.S1-002>
- Understanding Resistance to Tamoxifen in Hormone Receptor–Positive Breast Cancer | Clinical Chemistry | Oxford Academic* (n.d.) Retrieved November 29, 2023, from <https://academic.oup.com/clinchem/article/55/8/1453/5631800?login=false>
- Understanding the Basics of NGS: From Mechanism to Variant Calling | Current Genetic Medicine*

- Reports* (n.d.) Retrieved January 15, 2024, from <https://link.springer.com/article/10.1007/s40142-015-0076-8>
- van Jaarsveld MT, Wouters MD, Boersma AW, Smid M, van IJcken WF, Mathijssen RH, Hoeijmakers JH, Martens JW, van Laere S, Wiemer EA (2014) DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity. *Mol Oncol* 8(3): 458–468
- Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, . . . Baselga J (2019) Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K α inhibitors. *Science* 366(6466): 714–723
- Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase–AKT pathway in human cancer. *Nat Rev Cancer* 2(7):489–501. <https://doi.org/10.1038/nrc839>
- Wang Y, Minden A (2022) Current molecular combination therapies used for the treatment of breast cancer. *Int J Mol Sci* 23(19):11046. <https://doi.org/10.3390/ijms231911046>
- Wang J, Seebacher N, Shi H, Kan Q, Duan Z (2017) Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. *Oncotarget* 8(48):84559–84571. <https://doi.org/10.18632/oncotarget.19187>
- Wind NS, Holen I (2011) Multidrug resistance in breast cancer: from *in vitro* models to clinical studies. *Int J Breast Cancer* 2011:1–12. <https://doi.org/10.4061/2011/967419>
- Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J, . . . Spector NL (2007) Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. *Cancer Res* 67(3):1170–1175
- Xu J, Yang P, Xue S, Sharma B, Sanchez-Martin M, Wang F, Beaty KA, Dehan E, Parikh B (2019) Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives. *Hum Genet* 138(2):109–124. <https://doi.org/10.1007/s00439-019-01970-5>
- Zelli, V., Compagnoni, C., Cannita, K., Capelli, R., Capalbo, C., Di Vito Nolfi, M., Alesse, E., Zazzeroni, F., & Tessitore, A. (2020). Applications of next generation sequencing to the analysis of familial breast/ovarian cancer. *High-Throughput*, 9(1), Article 1. <https://doi.org/10.3390/ht9010001>
- Zhang W, Xia W, Lv Z, Ni C, Xin Y, Yang L (2017) Liquid biopsy for cancer: circulating tumor cells, circulating free DNA or exosomes? *Cell Physiol Biochem* 41(2):755–768. <https://doi.org/10.1159/000458736>
- Zhang, J., Späth, S. S., Marjani, S. L., Zhang, W., & Pan, X. (2018). Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment. *Precis Clin Med*, 1(1), 29–48. <https://doi.org/10.1093/pcmedi/pby007>

第8章 多药耐药和转移性乳腺癌免疫治疗的研究进展及展望

- Alavi AS, Acevedo L, Min W, Cheresch DA (2007) Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. *Cancer Res* 67(6):2766–2772
- Al-Harras MF, Houssen ME, Shaker ME, Farag K, Farouk O, Monir R, El Mahdy R, Abo-Hashem EM (2016) Polymorphisms of glutathione S-transferase π 1 and toll-like receptors 2 and 9: association with breast cancer susceptibility. *Oncol Lett* 11(3):2182–2188
- Amaral T, Meraz-Torres F, Garbe C (2017) Immunotherapy in managing metastatic melanoma: which treatment when? *Expert Opin Biol Ther* 17(12):1523–1538
- Ansell SM, Vonderheide RH (2013) Cellular composition of the tumor microenvironment. *Am Soc Clin Oncol Educ Book* 33:e91
- Ayoub NM, Al-Shami KM, Yaghan RJ (2019) Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. *Breast Cancer Targets Ther* 11:53–69
- Bonomi A, Silini A, Vertua E et al (2015) Human amniotic mesenchymal stromal cells(hAMSCs) as potential vehicles for drug delivery in cancer therapy: an in vitro study. *Stem Cell Res Ther* 6(1):155
- Borrie SC, Brems H, Legius E, Bagni C (2017) Cognitive dysfunctions in intellectual disabilities: the contributions of the Ras-MAPK and PI3K-AKT-mTOR pathways. *Annu Rev Genomics Hum Genet* 18:115–142
- Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multi-drug resistance-associated proteins. *J Natl Cancer Inst* 92(16):1295–1302
- Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways. *Am J Clin Oncol* 39:98–106
- Buonaguro L et al (2011) Translating tumor antigens into cancer vaccine. *Clin Vaccine Immunol* 18:23–34
- Chaiwun B, Sukhamwang N, Trakultivakorn H et al (2011) GSTP α -positive tumour microenvironment-associated fibroblasts are significantly associated with GSTP α -negative cancer cells in paired cases of primary invasive breast cancer and axillar lymph node metastases. *Br J Cancer* 105(8):1224–1229
- Chang H, Jeung HC, Jung JJ, Kim TS, Rha SY, Chung HC (2011) Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cell. *Breast Cancer Res Treat* 125(1):55–63
- Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK (2009) MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. *Mol Cancer Ther* 8(5):1055–1066
- Collina F, Bonito MD, Bergolis VL et al (2015) Prognostic value of cancer stem cells markers in triple-negative breast cancer. *Biomed Res Int* 2015:1–10
- Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. *Cancer Res* 62(12):3387–3394
- Dandawate PR, Subramaniam D, Jensen RA, Anant S (2016) Targeting cancer stem cells and signaling pathways by phytochemicals: novel approach for breast cancer therapy. *Semin Cancer Biol* 40–44:192–208

- Deng J, Wang ES, Jenkins RW et al (2018) CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. *Cancer Discov* 8(2):216–233
- Dougan M, Dougan SK (2017) Targeting immunotherapy to the tumor microenvironment. *J Cell Biochem* 118(10):3049–3054
- Dubensky TW Jr, Reed SG (2010) Adjuvants for cancer vaccines. *Semin Immunol* 22:155–161
- Ehata S, Johansson E, Katayama R et al (2010) Transforming growth factor- β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells. *Oncogene* 30(14):1693–1705
- Eissa IR, Bustos-Villalobos I, Ichinose T, Matsumura S, Naoe Y, Miyajima N, Morimoto D, Mukoyama N, Zhiwen W, Tanaka M et al (2018) The current status and future prospects of oncolytic viruses in clinical trials against melanoma, glioma, pancreatic, and breast cancers. *Cancers* 10:356
- Estrella V, Chen T, Lloyd M et al (2013) Acidity generated by the tumor microenvironment drives local invasion. *Cancer Res* 73(5):1524–1535
- Evans ER, Bugga P, Drezek R (2018) Metallic nanoparticles for cancer immunotherapy. *Mater Today (Kidlington)* 21(6):673
- Evseenko DA, Paxton JW, Keelan JA (2007) Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. *Drug Metab Dispos* 35(4):595–601
- Fan L, Strasser-Weippl K, Li J-J et al (2014) Breast cancer in China. *Lancet Oncol* 15(7):e279–e289
- Farkona S, Diamandis EP, Blasutig IM (2016) Cancer immunotherapy: the beginning of the end of cancer? *BMC Med* 14:73
- Frey AB (2015) Suppression of T cell responses in the tumor microenvironment. *Vaccine* 33:7393–7400
- Gao L, Yang Y, Song S, Hong H, Zhao X, Li D (2013) The association between genetic variant of MDR1 gene and breast cancer risk factors in Chinese women. *Int Immunopharmacol* 17(1):88–91
- Garcia-Aranda M, Redondo M (2019) Immunotherapy: a challenge of breast cancer treatment. *Cancers* 11:1822
- Gatenby RA, Gillies RJ, Brown JS (2010) Evolutionary dynamics of cancer prevention. *Nat Rev Cancer* 10(8):526–527
- Gattinoni L et al (2006) Adoptive immunotherapy for cancer: building on success. *Nat Rev Immunol* 6:383–393
- Ginestier C, Hur MH, Charafe-Jauffret E et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. *Cell Stem Cell* 1(5):555–567
- Guo C et al (2013) Therapeutic cancer vaccines: past, present and future. *Adv Cancer Res* 119:421–475
- Guo L, Yan DD, Yang D et al (2014) Combinatorial Photothermal and Immuno cancer therapy using chitosan-coated hollow copper sulfide nanoparticles. *ACS Nano* 8(6):5670–5681
- Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* 144:646–674
- Hartz AMS, Madole EK, Miller DS, Bauer B (2010) Estrogen receptor signaling through phosphatase and tensin homolog/phosphoinositide 3-kinase/akt/glycogen synthase kinase 3 down-regulates blood-brain barrier breast cancer resistance protein. *J Pharmacol Exp Ther* 334(2):467–476
- Hazarika M, Chuk MK, Theoret MR et al (2017) U.S. FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab. *Clin*

Cancer Res 23(14):3484–3488

- He Y-J, Wu J-Z, Ji M-H et al (2013) miR-342 is associated with estrogen receptor- α expression and response to tamoxifen in breast cancer. *Exp Ther Med* 5(3):813–818
- He X, Xiao X, Dong L, Wan N, Zhou Z, Deng H, Zhang X (2015) MiR-218 regulates Cisplatin chemosensitivity in breast cancer by targeting BRCA1. *Tumour Biol* 36(3):2065–2075
- Horn L, Mansfield AS, Szczesna A et al (2018) First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. *N Engl J Med* 379(23):2220–2229
- Huang W-C, Chen Y-J, Li L-Y et al (2011) Nuclear translocation of epidermal growth factor receptor by akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. *J Biol Chem* 286(23):20558–20568
- Huang J, Woods P, Normolle D et al (2017) Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals. *Breast Cancer Res Treat* 161(2):229–243
- Iwai Y et al (2017) Cancer immunotherapies targeting the PD-1 signaling pathway. *J Biomed Sci* 24:26
- Jain K, Paranandi KS, Sridharan S, Basu A (2013) Autophagy in breast cancer and its implications for therapy. *Am J Cancer Res* 3(3):251–265
- Ji X, Lu Y, Tian H, Meng X, Wei M, Cho WC (2019) Chemoresistance mechanisms of breast cancer and their countermeasures. *Biomed Pharmacother* 114:108800
- Kim R, Emi M, Tanabe K (2007) Cancer immunoediting from immune surveillance to immune escape. *Immunology* 121:1–14
- Kort A, Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH (2015) Brain and testis accumulation of regorafenib is restricted by breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). *Pharm Res* 32(7):2205–2216
- Kotiyal S, Bhattacharya S (2014) Breast cancer stem cells, EMT and therapeutic targets. *Biochem Biophys Res Commun* 453(1):112–116
- Kovalchuk O, Filkowski J, Meservy J et al (2008) Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. *Mol Cancer Ther* 7(7):2152–2159
- Krummel MF, Bartumeus F, Gerard A (2016) T-cell migration, search strategies and mechanisms. *Nat Rev Immunol* 16:193–201
- Landskron G et al (2014) Chronic inflammation and cytokines in the tumor microenvironment. *J Immunol Res* 2014:149185
- Li Z-W, Dalton WS (2006) Tumor microenvironment and drug resistance in hematologic malignancies. *Blood Rev* 20(6):333–342
- Liang Z, Wu H, Xia J et al (2010) Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein1. *Biochem Pharmacol* 79(6):817–824
- Lin YX, Wang Y, Blake S, Yu M, Mei L, Wang H, Shi J (2020) RNA nanotechnology-mediated cancer immunotherapy. *Theranostics* 10(1):281–299
- Liu S, Cong Y, Wang D et al (2013) Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. *Stem Cell Rep* 2(1):78–91
- Lo H-W, Hsu S-C, Xia W, Cao X, Shih J-Y, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung M-C (2007) Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. *Cancer Res* 67(19):9066–9076
- Logue SE, McGrath EP, Cleary P et al (2018) Inhibition of IRE1 RNase activity modulates the

- tumor cell secretome and enhances response to chemotherapy. *Nat Commun* 9:3267
- Luan QX, Zhang BG, Li XJ, Guo MY (2016) MiR-129-5p is downregulated in breast cancer cells partly due to promoter H3K27m3 modification and regulates epithelial-mesenchymal transition and multi-drug resistance. *Eur Rev Med Pharmacol Sci* 20(20):4257–4265
- Mao Q, Unadkat JD (2014) Role of the breast Cancer resistance protein (BCRP/ABCG2) in drug transport—an update. *AAPS J* 17(1):65–82
- Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y (2018) Next generation of immune checkpoint therapy in cancer: new developments and challenges. *J Hematol Oncol* 11(39):1–20
- Martin CM, Ferdous A, Gallardo T et al (2008) Hypoxia-inducible Factor-2 α transactivates Abcg2 and promotes cytoprotection in cardiac side population cells. *Circ Res* 102(9):1075–1081
- Mei Y, Wang R, Jiang W et al (2019) Recent progress in nanomaterials for nucleic acid delivery in cancer immunotherapy. *Biomater Sci* 7(7):2640–2651
- Mitchem JB, Brennan DJ, Knolhoff BL et al (2013) Targeting tumor-infiltrating macrophages decrease tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. *Cancer Res* 73(3):1128–1141
- Monjazez AM, Hsiao H-H, Sckisel GD, Murphy WJ (2012) The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. *J Immunotoxicol* 9:248–258
- Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C (2007) Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride(LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma, *Leuk. Lymphoma* 48(4):708–715
- Muluhngwi P, Klinge CM (2015) Roles for miRNAs in endocrine resistance in breast cancer. *Endocr Relat Cancer* 22(5):R279–R300
- Muraro E, Furlan C, Avanzo M et al (2017) Local high-dose radiotherapy induces systemic immunomodulating effects of potential therapeutic relevance in oligometastatic breast cancer. *Front Immunol* 8(1476):1–19
- Nathanson DA, Gini B, Mottahedeh J et al (2014) Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. *Science* 343(6166):72–76
- O'Bryan SM, Mathis JM (2018) Oncolytic virotherapy for breast cancer treatment. *Curr Gene Ther* 18:192–205
- Palma MD, Lewis CE (2011) Cancer: macrophages limit chemotherapy. *Nature* 472(7343):303–304
- Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. *Nat Rev Cancer* 12:265–277
- Park SY, Kim HM, Koo JS (2015) Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer. *Breast Cancer Res Treat* 149(3):727–741
- Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Rameshwar P (2010) Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF- β . *J Immunol* 184(10):5885–5894
- Pavlopoulou A, Oktay Y, Vougas K, Louka M, Vorgias CE, Georgakilas AG (2016) Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells. *Cancer Lett* 380(2):485–493
- Perica K et al (2015) Adoptive T cell immunotherapy for cancer. *Rambam Maimonides Med J* 6:e0004
- Pham CG, Bubici C, Zazzeroni F, Knabb JR, Papa S, Kuntzen C, Franzoso G (2007) Upregulation

- of Twist-1 by NF- κ B blocks cytotoxicity induced by chemotherapeutic drugs. *Mol Cell Biol* 27(11):3920–3935
- Pinto CA, Widodo E, Waltham M, Thompson EW (2013) Breast cancer stem cells and epithelial mesenchymal plasticity – implications for chemoresistance. *Cancer Lett* 341(1):56–62
- Qiu SQ, Waaijer SJH, Zwager MC, de Vries EGE, van der Vegt B, Schroder CP (2018) Tumor-associated macrophages in breast cancer: innocent bystander or important player? *Cancer Treat Rev* 70:178–189
- Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. *Nat Rev Cancer* 12:278–287
- Serda RE (2013) Particle platforms for cancer immunotherapy. *Int J Nanomedicine* 8:1683–1696
- Shao K et al (2015) Nanoparticle-based immunotherapy for cancer. *ACS Nano* 9:16–30
- Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. *Cell* 168(4):707–723
- Shuptrine C, Surana R, Weiner LM (2012) Monoclonal antibodies for the treatment of cancer. *Semin Cancer Biol* 22(1):3–13
- Sodani K, Patel A, Kathawala RJ, Chen ZS (2012) Multidrug resistance associated proteins in multidrug resistance. *Chin J Cancer* 31(2):58–72
- Spano D, Zollo M (2012) Tumor microenvironment: a main actor in the metastasis process. *Clin Exp Metastasis* 29(4):381–395
- Sun B, Roh KH, Park JR, Lee SR, Park SB, Jung JW, Kang SK, Lee YS, Kang KS (2009) Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. *Cytotherapy* 11(3):289–298
- Tai CJ, Liu CH, Pan YC, Wong SH, Tai CJ, Richardson CD, Lin LT (2019) Chemovirotherapeutic treatment using Camptothecin enhances oncolytic measles virus-mediated killing of breast cancer cells. *Sci Rep* 9:6767
- Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. *Clin Cancer Res* 15(12):4234–4241
- Tang X, Mo C, Wang Y, Wei D, Xiao H (2013) Anti-tumour strategies aiming to target tumour-associated macrophages. *Immunology* 138(2):93–104
- Thakurta DG, Sheikh NA, Fan L-Q et al (2015) Humoral immune response against nontargeted tumor antigens after treatment with Sipuleucel-T and its association with improved clinical outcome. *Clin Cancer Res* 21:3619–3630
- To KKW (2013) MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. *J Biomed Sci* 20:99
- Vannini I, Zoli W, Tesei A et al (2008) Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. *Tumour Biol* 29(3):145–151
- Véquaude E, Desplanques G, Jézéquel P, Juin P, Barillé-Nion S (2015) Survivin contributes to DNA repair by homologous recombination in breast cancer cells. *Breast Cancer Res Treat* 155(1):53–63
- Vesuna F, Lisok A, Kimble B, Domek J, Kato Y, van der Groep P, Artemov D, Kowalski J, Carraway H, van Diest P, Raman V (2011) Twist contributes to hormoneresistance in breast cancer by downregulating estrogen receptor- α . *Oncogene* 31(27):3223–3234
- Virrey JJ, Dong D, Stiles C et al (2008a) Stress chaperone GRP78/BiP confers Chemoresistance to tumor-associated endothelial cells. *Mol Cancer Res* 6(8):1268–1275
- Virrey JJ, Guan S, Li W, Schönthal AH, Chen TC, Hofman FM (2008b) Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. *Am J Pathol*

173(2):575–585

- Vtorushin SV, Khristenko KY, Zavyalova MV et al (2014) The phenomenon of multi-drug resistance in the treatment of malignant tumors. *Exp Oncol* 36(3):144–156
- Wang ZX, Cao JX, Wang M, Li D, Cui YX, Zhang XY, Liu JL, Li L (2014) Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis. *Cytotherapy* 16:934–945
- West HJ (2015) JAMA oncology patient page. Neoadjuvant therapy. *JAMA Oncol* 1:115
- Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. *Cell* 131(6):1109–1123
- Yu CJ, Ou JH, Wang ML, Jialielihan N, Liu YH (2015) Elevated survivin mediated multidrug resistance and reduced apoptosis in breast cancer stem cells. *J BUON* 20(5):1287–1294
- Zhang W, Ding W, Chen Y, Feng M, Ouyang Y, Yu Y, He Z (2011) Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. *Acta Biochim Biophys Sin Shanghai* 43(8):647–653
- Zhou J (2014) Advances and prospects in cancer immunotherapy. *New J Sci* 745808:1–13
- Zhou M, Liu Z, Zhao Y et al (2010) MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. *J Biol Chem* 285(28):21496–21507
- Zhou ZY, Wan LL, Yang QJ, Han YL, Li D, Lu J, Guo C (2016) Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model. *Toxicol Lett* 259:124–132

第9章 靶向乳腺癌中与髓系细胞相关的关键因子

- Ager EI, Kozin SV, Kirkpatrick ND, Seano G, Kodack DP, Askoxylakis V et al (2015) Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy. *J Natl Cancer Inst* 107(4):djv017. <https://doi.org/10.1093/jnci/djv017>
- Ahirwar DK, Charan M, Mishra S, Verma AK, Shilo K, Ramaswamy B et al (2021) Slit2 inhibits breast cancer metastasis by activating M1-like phagocytic and antifibrotic macrophages. *Cancer Res* 81(20):5255–5267. <https://doi.org/10.1158/0008-5472.CAN-20-3909>
- Anand P, Singh B, Jaggi AS, Singh N (2012) Mast cells: an expanding pathophysiological role from allergy to other disorders. *Naunyn Schmiedeberg's Arch Pharmacol* 385(7):657–670. <https://doi.org/10.1007/s00210-012-0757-8>
- Anderson NM, Simon MC (2020) The tumor microenvironment. *Curr Biol* 30(16):R921–R925. <https://doi.org/10.1016/j.cub.2020.06.081>
- Augimeri G, Gonzalez ME, Paoli A, Eido A, Choi Y, Burman B et al (2023) A hybrid breast cancer/mesenchymal stem cell population enhances chemoresistance and metastasis. *JCI Insight* 8(18):e164216. <https://doi.org/10.1172/jci.insight.164216>
- Balan S, Saxena M, Bhardwaj N (2019) Dendritic cell subsets and locations. *Int Rev Cell Mol Biol* 348:1–68. <https://doi.org/10.1016/bs.ircmb.2019.07.004>
- Bartosh TJ, Ullah M, Zeitouni S, Beaver J, Prockop DJ (2016) Cancer cells enter dormancy after cannibalizing mesenchymal stem/stromal cells (MSCs). *Proc Natl Acad Sci USA* 113(42):E6447–E6456. <https://doi.org/10.1073/pnas.1612290113>
- Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S et al (2020) Breast cancer: biology, biomarkers, and treatments. *Int Immunopharmacol* 84:106535. <https://doi.org/10.1016/j.intimp.2020.106535>
- Basha S, Jin-Smith B, Sun C, Pi L (2023) The SLIT/ROBO pathway in liver fibrosis and cancer. *Biomol Ther* 13(5):785. <https://doi.org/10.3390/biom13050785>
- Bergenfels C, Roxa A, Mehmeti M, Leandersson K, Larsson AM (2020) Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer. *Cancer Immunol Immunother* 69(3):435–448. <https://doi.org/10.1007/s00262-019-02472-z>
- Blaye C, Boyer T, Peyraud F, Domblides C, Larmonier N (2022) Beyond immunosuppression: the multifaceted functions of tumor-promoting myeloid cells in breast cancers. *Front Immunol* 13:838040. <https://doi.org/10.3389/fimmu.2022.838040>
- Blomberg OS, Spagnuolo L, Garner H, Voorwerk L, Isaeva OI, van Dyk E et al (2023) IL-5-producing CD4(+) T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. *Cancer Cell* 41(1):106–123 e10. <https://doi.org/10.1016/j.ccell.2022.11.014>
- Buchta Rosean C, Bostic RR, Ferey JCM, Feng TY, Azar FN, Tung KS et al (2019) Preexisting commensal Dysbiosis is a host-intrinsic regulator of tissue inflammation and tumor cell dissemination in hormone receptor-positive breast cancer. *Cancer Res* 79(14):3662–3675. <https://doi.org/10.1158/0008-5472.CAN-18-3464>
- Cai M, Huang X, Huang X, Ju D, Zhu YZ, Ye L (2023) Research progress of interleukin-15 in cancer immunotherapy. *Front Pharmacol* 14:1184703. <https://doi.org/10.3389/fphar.2023.1184703>

- Carnevale S, Di Ceglie I, Grieco G, Rigatelli A, Bonavita E, Jaillon S (2023) Neutrophil diversity in inflammation and cancer. *Front Immunol* 14:1180810. <https://doi.org/10.3389/fimmu.2023.1180810>
- Carpenco E, Ceausu RA, Cimpean AM, Gaje PN, Saptefrati L, Fulga V et al (2019) Mast cells as an indicator and prognostic marker in molecular subtypes of breast cancer. *In Vivo* 33(3):743–748. <https://doi.org/10.21873/invivo.11534>
- Castellaro AM, Rodriguez-Baili MC, Di Tada CE, Gil GA (2019) Tumor-associated macrophages induce endocrine therapy resistance in ER+ breast cancer cells. *Cancers (Basel)* 11(2):189. <https://doi.org/10.3390/cancers11020189>
- Cederberg RA, Franks SE, Wadsworth BJ, So A, Decotret LR, Hall MG et al (2022) Eosinophils decrease pulmonary metastatic mammary tumor growth. *Front Oncol* 12:841921. <https://doi.org/10.3389/fonc.2022.841921>
- Cha YJ, Koo JS (2020) Role of tumor-associated myeloid cells in breast cancer. *Cell* 9(8):1785. <https://doi.org/10.3390/cells9081785>
- Chauhan J, Stavrika C, Grandits M, Palhares L, Josephs DH, Lacy KE et al (2022) Clinical and translational significance of basophils in patients with cancer. *Cell* 11(3):438. <https://doi.org/10.3390/cells11030438>
- Chen WY, Holmes MD (2017) Role of aspirin in breast cancer survival. *Curr Oncol Rep* 19(7):48. <https://doi.org/10.1007/s11912-017-0605-6>
- Chen F, Chen J, Yang L, Liu J, Zhang X, Zhang Y et al (2019a) Extracellular vesicle-packaged HIF-1 α -stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. *Nat Cell Biol* 21(4):498–510. <https://doi.org/10.1038/s41556-019-0299-0>
- Chen YC, Gonzalez ME, Burman B, Zhao X, Anwar T, Tran M et al (2019b) Mesenchymal stem/stromal cell engulfment reveals metastatic advantage in breast cancer. *Cell Rep* 27(13):3916–3926 e5. <https://doi.org/10.1016/j.celrep.2019.05.084>
- Chen Y, Hu H, Tan S, Dong Q, Fan X, Wang Y et al (2022) The role of neutrophil extracellular traps in cancer progression, metastasis and therapy. *Exp Hematol Oncol* 11(1):99. <https://doi.org/10.1186/s40164-022-00345-3>
- Cheng H, Huang H, Guo Z, Chang Y, Li Z (2021) Role of prostaglandin E2 in tissue repair and regeneration. *Theranostics* 11(18):8836–8854. <https://doi.org/10.7150/thno.63396>
- Chirumbolo S, Bjorklund G, Sboarina A, Vella A (2018) The role of basophils as innate immune regulatory cells in allergy and immunotherapy. *Hum Vaccin Immunother* 14(4):815–831. <https://doi.org/10.1080/21645515.2017.1417711>
- Clarke R (2011) Cannibalism, cell survival, and endocrine resistance in breast cancer. *Breast Cancer Res* 13(4):311. <https://doi.org/10.1186/bcr2870>
- Cohen N, Shani O, Raz Y, Sharon Y, Hoffman D, Abramovitz L et al (2017) Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1. *Oncogene* 36(31):4457–4468. <https://doi.org/10.1038/onc.2017.65>
- Collin M, Bigley V (2018) Human dendritic cell subsets: an update. *Immunology* 154(1):3–20. <https://doi.org/10.1111/imm.12888>
- Cortesi L, Rugo HS, Jackisch C (2021) An overview of PARP inhibitors for the treatment of breast cancer. *Target Oncol* 16(3):255–282. <https://doi.org/10.1007/s11523-021-00796-4>
- Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M et al (2018) Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. *Cancer Cell* 33(3):463–479 e10. <https://doi.org/10.1016/j.ccell.2018.01.011>
- Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ (2020) Neutrophil to

- lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. *BMC Med* 18(1):360. <https://doi.org/10.1186/s12916-020-01817-1>
- de la Cruz-Merino L, Gion M, Cruz J, Alonso-Romero JL, Quiroga V, Moreno F et al (2022) Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-breast) study. *BMC Cancer* 22(1):1258. <https://doi.org/10.1186/s12885-022-10363-3>
- DeNardo DG, Galkin A, Dupont J, Zhou L, Bendell J (2021) GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors. *J Immunother Cancer* 9(8):e003005. <https://doi.org/10.1136/jitc-2021-003005>
- Doebel T, Voisin B, Nagao K (2017) Langerhans cells – the macrophage in dendritic cell clothing. *Trends Immunol* 38(11):817–828. <https://doi.org/10.1016/j.it.2017.06.008>
- El Hejjoui B, Lamrabet S, Amrani Joutei S, Senhaji N, Bouhafa T, Malhouf MA et al (2023) New biomarkers and treatment advances in triple-negative breast cancer. *Diagnostics (Basel)* 13(11):1949. <https://doi.org/10.3390/diagnostics13111949>
- Fang X, Lan H, Jin K, Gong D, Qian J (2022) Nanovaccines for cancer prevention and immunotherapy: an update review. *Cancers (Basel)* 14(16):3842. <https://doi.org/10.3390/cancers14163842>
- Feng TY, Azar FN, Dreger SA, Rosean CB, McGinty MT, Putelo AM et al (2022) Reciprocal interactions between the gut microbiome and mammary tissue mast cells promote metastatic dissemination of HR+ breast tumors. *Cancer Immunol Res* 10(11):1309–1325. <https://doi.org/10.1158/2326-6066.CIR-21-1120>
- Floroni E, Ceausu AR, Cosoroaba RM, Niculescu Talpos IC, Popovici RA, Gaje NP et al (2022) Mast cell density in the primary tumor predicts lymph node metastases in patients with breast cancer. *Romanian J Morphol Embryol* 63(1):129–135. <https://doi.org/10.47162/RJME.63.1.13>
- Gago-Dominguez M, Matabuena M, Redondo CM, Patel SP, Carracedo A, Ponte SM et al (2020) Neutrophil to lymphocyte ratio and breast cancer risk: analysis by subtype and potential interactions. *Sci Rep* 10(1):13203. <https://doi.org/10.1038/s41598-020-70077-z>
- Gao Z, Feng Y, Xu J, Liang J (2022) T-cell exhaustion in immune-mediated inflammatory diseases: new implications for immunotherapy. *Front Immunol* 13:977394. <https://doi.org/10.3389/fimmu.2022.977394>
- Geurts V, Kok M (2023) Immunotherapy for metastatic triple negative breast cancer: current paradigm and future approaches. *Curr Treat Options in Oncol* 24(6):628–643. <https://doi.org/10.1007/s11864-023-01069-0>
- Ghaffari S, Rezaei N (2023) Eosinophils in the tumor microenvironment: implications for cancer immunotherapy. *J Transl Med* 21(1):551. <https://doi.org/10.1186/s12967-023-04418-7>
- Ghallab AM, Eissa RA, El Tayebi HM (2022) CXCR2 small-molecule antagonist combats chemoresistance and enhances immunotherapy in triple-negative breast cancer. *Front Pharmacol* 13:862125. <https://doi.org/10.3389/fphar.2022.862125>
- Ghebeh H, Elshenawy MA, AlSayed AD, Al-Tweigeri T (2022) Peripheral blood eosinophil count is associated with response to chemoimmunotherapy in metastatic triple-negative breast cancer. *Immunotherapy* 14(4):189–199. <https://doi.org/10.2217/imt-2021-0149>
- Girithar HN, Staats Pires A, Ahn SB, Guillemin GJ, Gluch L, Heng B (2023) Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials. *Br J Cancer* 129(2):185–203. <https://doi.org/10.1038/s41416-023-02245-7>
- Godet I, Gilkes DM (2017) BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. *Integr Cancer Sci Ther* 4(1):10.15761. <https://doi.org/10.15761/ICST.1000228>

- Gonda K, Shibata M, Ohtake T, Matsumoto Y, Tachibana K, Abe N et al (2017) Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer. *Oncol Lett* 14(2):1766–1774. <https://doi.org/10.3892/ol.2017.6305>
- Goswami KK, Bose A, Baral R (2021) Macrophages in tumor: an inflammatory perspective. *Clin Immunol* 232:108875. <https://doi.org/10.1016/j.clim.2021.108875>
- Griesenauer B, Paczesny S (2017) The ST2/IL-33 axis in immune cells during inflammatory diseases. *Front Immunol* 8:475. <https://doi.org/10.3389/fimmu.2017.00475>
- Grisaru-Tal S, Dulberg S, Beck L, Zhang C, Itan M, Hediye-Zadeh S et al (2021) Metastasis-entrained eosinophils enhance lymphocyte-mediated antitumor immunity. *Cancer Res* 81(21):5555–5571. <https://doi.org/10.1158/0008-5472.CAN-21-0839>
- Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J et al (2019) Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. *Br J Cancer* 120(1):16–25. <https://doi.org/10.1038/s41416-018-0333-1>
- Guo Y, Zhai Y, Wu L, Wang Y, Wu P, Xiong L (2022) Mesenchymal stem cell-derived extracellular vesicles: pleiotropic impacts on breast cancer occurrence, development, and therapy. *Int J Mol Sci* 23(6):2927. <https://doi.org/10.3390/ijms23062927>
- Guo Z, Zhang H, Fu Y, Kuang J, Zhao B, Zhang L et al (2023) Cancer-associated fibroblasts induce growth and radioresistance of breast cancer cells through paracrine IL-6. *Cell Death Discov* 9(1):6. <https://doi.org/10.1038/s41420-023-01306-3>
- Hajizadeh F, Aghebati Maleki L, Alexander M, Mikhailova MV, Masjedi A, Ahmadpour M et al (2021) Tumor-associated neutrophils as new players in immunosuppressive process of the tumor microenvironment in breast cancer. *Life Sci* 264:118699. <https://doi.org/10.1016/j.lfs.2020.118699>
- He F, Antonucci L, Karin M (2020) NRF2 as a regulator of cell metabolism and inflammation in cancer. *Carcinogenesis* 41(4):405–416. <https://doi.org/10.1093/carcin/bgaa039>
- He Q, Hu H, Yang F, Song D, Zhang X, Dai X (2023) Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer. *Biomed Pharmacother* 162:114609. <https://doi.org/10.1016/j.biopha.2023.114609>
- Hollande C, Boussier J, Ziai J, Nozawa T, Bondet V, Phung W et al (2019) Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. *Nat Immunol* 20(3):257–264. <https://doi.org/10.1038/s41590-019-0321-5>
- Hong DS, Parikh A, Shapiro GI, Varga A, Naing A, Meric-Bernstam F et al (2020) First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE(2)-receptor E-type 4 (EP4), in patients with advanced cancers. *J Immunother Cancer* 8(1):e000222. <https://doi.org/10.1136/jitc-2019-000222>
- Hu S, Ma J, Su C, Chen Y, Shu Y, Qi Z et al (2021) Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis. *Acta Biomater* 135:567–581. <https://doi.org/10.1016/j.actbio.2021.09.003>
- Huang H, Li Y, Liu B (2016) Transcriptional regulation of mast cell and basophil lineage commitment. *Semin Immunopathol* 38(5):539–548. <https://doi.org/10.1007/s00281-016-0562-4>
- Jackson DJ, Akuthota P, Roufosse F (2022) Eosinophils and eosinophilic immune dysfunction in health and disease. *Eur Respir Rev* 31(163):210150. <https://doi.org/10.1183/16000617.0150-2021>
- Jacobs F, Agostinetto E, Miggianno C, De Sanctis R, Zambelli A, Santoro A (2023) Hope and hype around immunotherapy in triple-negative breast cancer. *Cancers (Basel)* 15(11):2933. <https://doi.org/10.3390/cancers15112933>

doi.org/10.3390/cancers15112933

- Javid H, Attarian F, Saadatmand T, Rezagholinejad N, Mehri A, Amiri H et al (2023) The therapeutic potential of immunotherapy in the treatment of breast cancer: rational strategies and recent progress. *J Cell Biochem* 124(4):477–494. <https://doi.org/10.1002/jcb.30402>
- Jayakumar A, Bothwell ALM (2019) Functional diversity of myeloid-derived suppressor cells: the multitasking hydra of cancer. *J Immunol* 203(5):1095–1103. <https://doi.org/10.4049/jimmunol.1900500>
- Jiang W, Xu J (2020) Immune modulation by mesenchymal stem cells. *Cell Prolif* 53(1):e12712. <https://doi.org/10.1111/cpr.12712>
- Juric V, O'Sullivan C, Stefanutti E, Kovalenko M, Greenstein A, Barry-Hamilton V et al (2018) MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors. *PLoS One* 13(11):e0207255. <https://doi.org/10.1371/journal.pone.0207255>
- Kiaei SZF, Nouralishahi A, Ghasemirad M, Barkhordar M, Ghaffari S, Kheradjoo H et al (2023) Advances in natural killer cell therapies for breast cancer. *Immunol Cell Biol* 101(8):705–726. <https://doi.org/10.1111/imcb.12658>
- Kim H, Lin Q, Yun Z (2019) BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors. *Sci Rep* 9(1):9702. <https://doi.org/10.1038/s41598-019-46210-y>
- Klion AD, Ackerman SJ, Bochner BS (2020) Contributions of eosinophils to human health and disease. *Annu Rev Pathol* 15:179–209. <https://doi.org/10.1146/annurev-pathmechdis-012419-032756>
- Komi DEA, Redegeld FA (2020) Role of mast cells in shaping the tumor microenvironment. *Clin Rev Allergy Immunol* 58(3):313–325. <https://doi.org/10.1007/s12016-019-08753-w>
- Kudo-Saito C, Ozaki Y, Imazeki H, Hayashi H, Masuda J, Ozawa H et al (2021) Targeting oncoimmune drivers of cancer metastasis. *Cancers (Basel)* 13(3):554. <https://doi.org/10.3390/cancers13030554>
- Kwantwi LB, Wang S, Zhang W, Peng W, Cai Z, Sheng Y et al (2021) Tumor-associated neutrophils activated by tumor-derived CCL20 (C-C motif chemokine ligand 20) promote T cell immunosuppression via programmed death-ligand 1 (PD-L1) in breast cancer. *Bioengineered* 12(1):6996–7006. <https://doi.org/10.1080/21655979.2021.1977102>
- Kwon MJ (2022) Matrix metalloproteinases as therapeutic targets in breast cancer. *Front Oncol* 12:1108695. <https://doi.org/10.3389/fonc.2022.1108695>
- Lavoie SS, Dumas E, Vulesevic B, Neagoe PE, White M, Sirois MG (2018) Synthesis of human neutrophil extracellular traps contributes to angiopoietin-mediated in vitro proinflammatory and proangiogenic activities. *J Immunol* 200(11):3801–3813. <https://doi.org/10.4049/jimmunol.1701203>
- Lebeau G, Ah-Pine F, Daniel M, Bedoui Y, Vagner D, Frumence E et al (2022) Perivascular mesenchymal stem/stromal cells, an immune privileged niche for viruses? *Int J Mol Sci* 23(14):8038. <https://doi.org/10.3390/ijms23148038>
- Li P, Lu M, Shi J, Gong Z, Hua L, Li Q et al (2020) Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis. *Nat Immunol* 21(11):1444–1455. <https://doi.org/10.1038/s41590-020-0783-5>
- Li H, Qiao C, Zhao L, Jing Q, Xue D, Zhang Y (2022a) Epigallocatechin-3-gallate reduces neutrophil extracellular trap formation and tissue injury in severe acute pancreatitis. *J Leukoc Biol* 112(6):1427–1443. <https://doi.org/10.1002/JLB.3A0322-151R>
- Li J, Shu X, Xu J, Su SM, Chan UI, Mo L et al (2022b) S100A9-CXCL12 activation in BRCA1-

- mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy. *Nat Commun* 13(1):1481. <https://doi.org/10.1038/s41467-022-29151-5>
- Li D, Hemati H, Park Y, Taftaf R, Zhang Y, Liu J et al (2023) ICAM-1-suPAR-CD11b axis is a novel therapeutic target for metastatic triple-negative breast cancer. *Cancers (Basel)* 15(10):2734. <https://doi.org/10.3390/cancers15102734>
- Lin Z, Radaeva M, Cherkasov A, Dong X (2022) Lin28 regulates cancer cell stemness for tumour progression. *Cancers (Basel)* 14(19):4640. <https://doi.org/10.3390/cancers14194640>
- Liu C, Qiang J, Deng Q, Xia J, Deng L, Zhou L et al (2021) ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression. *Cancer Res* 81(23):5919–5934. <https://doi.org/10.1158/0008-5472.CAN-21-1337>
- Liu Z, Shi Y, Lv L, Chen J, Jiang W, Li J et al (2022) Small molecular inhibitors reverse cancer metastasis by blockading oncogenic PITPNM3. *Adv Sci (Weinh)* 9(35):e2204649. <https://doi.org/10.1002/advs.202204649>
- Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G (2021) Breast cancer. *Lancet* 397(10286):1750–1769. [https://doi.org/10.1016/S0140-6736\(20\)32381-3](https://doi.org/10.1016/S0140-6736(20)32381-3)
- Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S et al (2019) Epcadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. *Lancet Oncol* 20(8):1083–1097. [https://doi.org/10.1016/S1470-2045\(19\)30274-8](https://doi.org/10.1016/S1470-2045(19)30274-8)
- Ma J, Cai Z, Wei H, Liu X, Zhao Q, Zhang T (2017) The anti-tumor effect of aspirin: what we know and what we expect. *Biomed Pharmacother* 95:656–661. <https://doi.org/10.1016/j.biopha.2017.08.085>
- Ma S, Guo C, Sun C, Han T, Zhang H, Qu G et al (2021) Aspirin use and risk of breast cancer: a meta-analysis of observational studies from 1989 to 2019. *Clin Breast Cancer* 21(6):552–565. <https://doi.org/10.1016/j.clbc.2021.02.005>
- Ma C, He D, Tian P, Wang Y, He Y, Wu Q et al (2022) miR-182 targeting reprograms tumor-associated macrophages and limits breast cancer progression. *Proc Natl Acad Sci USA* 119(6):e2114006119. <https://doi.org/10.1073/pnas.2114006119>
- Mahesh G, Anil Kumar K, Reddanna P (2021) Overview on the discovery and development of anti-inflammatory drugs: should the focus be on synthesis or degradation of PGE(2)? *J Inflamm Res* 14:253–263. <https://doi.org/10.2147/JIR.S278514>
- Majorini MT, Cancila V, Rigoni A, Botti L, Dugo M, Triulzi T et al (2020) Infiltrating mast cell-mediated stimulation of estrogen receptor activity in breast cancer cells promotes the luminal phenotype. *Cancer Res* 80(11):2311–2324. <https://doi.org/10.1158/0008-5472.CAN-19-3596>
- Majumder M, Nandi P, Omar A, Ugwuagbo KC, Lala PK (2018) EP4 as a therapeutic target for aggressive human breast cancer. *Int J Mol Sci* 19(4):1019. <https://doi.org/10.3390/ijms19041019>
- Malech HL, Deleo FR, Quinn MT (2014) The role of neutrophils in the immune system: an overview. *Methods Mol Biol* 1124:3–10. https://doi.org/10.1007/978-1-62703-845-4_1
- Maryam M, Naemi M, Hasani SS (2021) A comprehensive review on oncogenic miRNAs in breast cancer. *J Genet* 100:15. <https://www.ncbi.nlm.nih.gov/pubmed/33764337>
- Maurer M, Cheung DS, Theess W, Yang X, Dolton M, Guttman A et al (2022) Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis. *J Allergy Clin Immunol* 150(6):1517–1524. <https://doi.org/10.1016/j.jaci.2022.08.015>
- Mercogliano MF, Bruni S, Mauro FL, Schillaci R (2023) Emerging targeted therapies for HER2-positive breast cancer. *Cancers (Basel)* 15(7):1987. <https://doi.org/10.3390/cancers15071987>

- Mishra AK, Banday S, Bharadwaj R, Ali A, Rashid R, Kulshreshtha A et al (2022) Macrophages as a potential immunotherapeutic target in solid cancers. *Vaccines (Basel)* 11(1):55. <https://doi.org/10.3390/vaccines11010055>
- Miyake K, Ito J, Karasuyama H (2022) Role of basophils in a broad spectrum of disorders. *Front Immunol* 13:902494. <https://doi.org/10.3389/fimmu.2022.902494>
- Monteran L, Ershaid N, Doron H, Zait Y, Scharff Y, Ben-Yosef S et al (2022) Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer. *Nat Commun* 13(1):5797. <https://doi.org/10.1038/s41467-022-33598-x>
- Mousset A, Lecorgne E, Bourget I, Lopez P, Jenovai K, Cherfils-Vicini J et al (2023) Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-beta activation. *Cancer Cell* 41(4):757–775 e10. <https://doi.org/10.1016/j.ccell.2023.03.008>
- Muller L, Tunger A, Wobus M, von Bonin M, Towers R, Bornhauser M et al (2021) Immunomodulatory properties of mesenchymal stromal cells: an update. *Front Cell Dev Biol* 9:637725. <https://doi.org/10.3389/fcell.2021.637725>
- Munir MT, Kay MK, Kang MH, Rahman MM, Al-Harrasi A, Choudhury M et al (2021) Tumor-associated macrophages as multifaceted regulators of breast tumor growth. *Int J Mol Sci* 22(12):6526. <https://doi.org/10.3390/ijms22126526>
- Ness S, Lin S, Gordon JR (2021) Regulatory dendritic cells, T cell tolerance, and dendritic cell therapy for immunologic disease. *Front Immunol* 12:633436. <https://doi.org/10.3389/fimmu.2021.633436>
- Nixon BG, Kuo F, Ji L, Liu M, Capistrano K, Do M et al (2022) Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer. *Immunity* 55(11):2044–2058 e5. <https://doi.org/10.1016/j.immuni.2022.10.002>
- Nobre AR, Risson E, Singh DK, Di Martino JS, Cheung JF, Wang J et al (2021) Bone marrow NG2 (+)/nestin(+) mesenchymal stem cells drive DTC dormancy via TGFbeta2. *Nat Cancer* 2(3):327–339. <https://doi.org/10.1038/s43018-021-00179-8>
- Nordin ML, Azemi AK, Nordin AH, Nabgan W, Ng PY, Yusoff K et al (2023) Peptide-based vaccine against breast cancer: recent advances and prospects. *Pharmaceuticals (Basel)* 16(7):923. <https://doi.org/10.3390/ph16070923>
- Okano M, Oshi M, Butash AL, Katsuta E, Tachibana K, Saito K et al (2019) Triple-negative breast cancer with high levels of annexin A1 expression is associated with mast cell infiltration, inflammation, and angiogenesis. *Int J Mol Sci* 20(17):4197. <https://doi.org/10.3390/ijms20174197>
- Onesti CE, Josse C, Boulet D, Thiry J, Beaumecker B, Bours V et al (2020) Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse. *Onco Targets Ther* 9(1):1761176. <https://doi.org/10.1080/2162402X.2020.1761176>
- Orrantia-Borunda E, Anchondo-Nunez P, Acuna-Aguilar LE, Gomez-Valles FO, Ramirez-Valdespino CA (2022) Subtypes of breast cancer. In: Mayrovitz HN (ed) *Breast cancer*. Exon Publications, Brisbane (AU). <https://doi.org/10.36255/exon-publications-breast-cancer-subtypes>
- Pereira-Veiga T, Schneegans S, Pantel K, Wikman H (2022) Circulating tumor cell-blood cell crosstalk: biology and clinical relevance. *Cell Rep* 40(9):111298. <https://doi.org/10.1016/j.celrep.2022.111298>
- Perez-Tomas R, Perez-Guillen I (2020) Lactate in the tumor microenvironment: an essential molecule in cancer progression and treatment. *Cancers (Basel)* 12(11):3244. <https://doi.org/10.3390/cancers12113244>

- Piezzo M, Cocco S, Caputo R, Cianniello D, Gioia GD, Lauro VD et al (2020) Targeting cell cycle in breast cancer: CDK4/6 inhibitors. *Int J Mol Sci* 21(18):6479. <https://doi.org/10.3390/ijms21186479>
- Pittenger MF, Discher DE, Peault BM, Phinney DG, Hare JM, Caplan AI (2019) Mesenchymal stem cell perspective: cell biology to clinical progress. *NPJ Regen Med* 4:22. <https://doi.org/10.1038/s41536-019-0083-6>
- Qi M, Xia Y, Wu Y, Zhang Z, Wang X, Lu L et al (2022) Lin28B-high breast cancer cells promote immune suppression in the lung pre-metastatic niche via exosomes and support cancer progression. *Nat Commun* 13(1):897. <https://doi.org/10.1038/s41467-022-28438-x>
- Qian D, Li J, Huang M, Cui Q, Liu X, Sun K (2023) Dendritic cell vaccines in breast cancer: immune modulation and immunotherapy. *Biomed Pharmacother* 162:114685. <https://doi.org/10.1016/j.biopha.2023.114685>
- Qin S, Jiang J, Lu Y, Nice EC, Huang C, Zhang J et al (2020) Emerging role of tumor cell plasticity in modifying therapeutic response. *Signal Transduct Target Ther* 5(1):228. <https://doi.org/10.1038/s41392-020-00313-5>
- Rabe KF, Celli BR, Wechsler ME, Abdulai RM, Luo X, Boomsma MM et al (2021) Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. *Lancet Respir Med* 9(11):1288–1298. [https://doi.org/10.1016/S2213-2600\(21\)00167-3](https://doi.org/10.1016/S2213-2600(21)00167-3)
- Radisky ES, Raeeszadeh-Sarmazdeh M, Radisky DC (2017) Therapeutic potential of matrix metalloproteinase inhibition in breast cancer. *J Cell Biochem* 118(11):3531–3548. <https://doi.org/10.1002/jcb.26185>
- Raychaudhuri D, Bhattacharya R, Sinha BP, Liu CSC, Ghosh AR, Rahaman O et al (2019) Lactate induces pro-tumor reprogramming in intratumoral plasmacytoid dendritic cells. *Front Immunol* 10:1878. <https://doi.org/10.3389/fimmu.2019.01878>
- Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L et al (2019) Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer. *Cancer Immunol Res* 7(6):1025–1035. <https://doi.org/10.1158/2326-6066.CIR-18-0619>
- Reizis B (2019) Plasmacytoid dendritic cells: development, regulation, and function. *Immunity* 50(1):37–50. <https://doi.org/10.1016/j.immuni.2018.12.027>
- Rubinstein-Achiasaf L, Morein D, Ben-Yaakov H, Liubomirski Y, Meshel T, Elbaz E et al (2021) Persistent inflammatory stimulation drives the conversion of MSCs to inflammatory CAFs that promote pro-metastatic characteristics in breast cancer cells. *Cancers (Basel)* 13(6):1472. <https://doi.org/10.3390/cancers13061472>
- Salimifard S, Masjedi A, Hojjat-Farsangi M, Ghalamfarsa G, Irandoust M, Azizi G et al (2020) Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer. *Pathol Res Pract* 216(5):152915. <https://doi.org/10.1016/j.prp.2020.152915>
- Sandiford OA, Donnelly RJ, El-Far MH, Burgmeyer LM, Sinha G, Pamarthi SH et al (2021) Mesenchymal stem cell-secreted extracellular vesicles instruct stepwise dedifferentiation of breast cancer cells into dormancy at the bone marrow perivascular region. *Cancer Res* 81(6):1567–1582. <https://doi.org/10.1158/0008-5472.CAN-20-2434>
- SenGupta S, Hein LE, Xu Y, Zhang J, Konwerski JR, Li Y et al (2021) Triple-negative breast cancer cells recruit neutrophils by secreting TGF-beta and CXCR2 ligands. *Front Immunol* 12:659996. <https://doi.org/10.3389/fimmu.2021.659996>
- Shani O, Vorobyov T, Monteran L, Lavie D, Cohen N, Raz Y et al (2020) Fibroblast-derived IL33 facilitates breast cancer metastasis by modifying the immune microenvironment and driving type 2 immunity. *Cancer Res* 80(23):5317–5329. <https://doi.org/10.1158/0008-5472.CAN-20-2116>

- Shevchenko JA, Khristin AA, Kurilin VV, Kuznetsova MS, Blinova DD, Starostina NM et al (2020) Autologous dendritic cells and activated cytotoxic T-cells as combination therapy for breast cancer. *Oncol Rep* 43(2):671–680. <https://doi.org/10.3892/or.2019.7435>
- Shi Y, Du L, Lin L, Wang Y (2017) Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. *Nat Rev Drug Discov* 16(1):35–52. <https://doi.org/10.1038/nrd.2016.193>
- Shinde-Jadhav S, Mansure JJ, Rayes RF, Marcq G, Ayoub M, Skowronski R et al (2021) Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer. *Nat Commun* 12(1):2776. <https://doi.org/10.1038/s41467-021-23086-z>
- Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. *CA Cancer J Clin* 73(1):17–48. <https://doi.org/10.3322/caac.21763>
- Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB (2019) Inflammation and cancer. *Ann Afr Med* 18(3):121–126. https://doi.org/10.4103/aam.aam_56_18
- Slade D (2020) PARP and PARG inhibitors in cancer treatment. *Genes Dev* 34(5–6):360–394. <https://doi.org/10.1101/gad.334516.119>
- Spencer LA, Bonjour K, Melo RC, Weller PF (2014) Eosinophil secretion of granule-derived cytokines. *Front Immunol* 5:496. <https://doi.org/10.3389/fimmu.2014.00496>
- Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkoutela S, Landin J et al (2019) Neutrophils escort circulating tumour cells to enable cell cycle progression. *Nature* 566(7745):553–557. <https://doi.org/10.1038/s41586-019-0915-y>
- Takai K, Le A, Weaver VM, Werb Z (2016) Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. *Oncotarget* 7(50):82889–82901. <https://doi.org/10.18632/oncotarget.12658>
- Tariq M, Zhang J, Liang G, Ding L, He Q, Yang B (2017) Macrophage polarization: anti-cancer strategies to target tumor-associated macrophage in breast cancer. *J Cell Biochem* 118(9):2484–2501. <https://doi.org/10.1002/jcb.25895>
- Ullah M, Akbar A, Ng NN, Concepcion W, Thakor AS (2019) Mesenchymal stem cells confer chemoresistance in breast cancer via a CD9 dependent mechanism. *Oncotarget* 10(37):3435–3450. <https://doi.org/10.18632/oncotarget.26952>
- Vargas A, Boivin R, Cano P, Murcia Y, Bazin I, Lavoie JP (2017) Neutrophil extracellular traps are downregulated by glucocorticosteroids in lungs in an equine model of asthma. *Respir Res* 18(1):207. <https://doi.org/10.1186/s12931-017-0689-4>
- Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB et al (2021) Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. *N Engl J Med* 385(18):1656–1668. <https://doi.org/10.1056/NEJMoa2024257>
- Wei Y, Li Y, Chen Y, Liu P, Huang S, Zhang Y et al (2022) ALDH1: a potential therapeutic target for cancer stem cells in solid tumors. *Front Oncol* 12:1026278. <https://doi.org/10.3389/fonc.2022.1026278>
- Xiao M, He J, Yin L, Chen X, Zu X, Shen Y (2021a) Tumor-associated macrophages: critical players in drug resistance of breast cancer. *Front Immunol* 12:799428. <https://doi.org/10.3389/fimmu.2021.799428>
- Xiao Y, Cong M, Li J, He D, Wu Q, Tian P et al (2021b) Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation. *Cancer Cell* 39(3):423–437 e7. <https://doi.org/10.1016/j.ccell.2020.12.012>
- Xiong H, Chen Z, Lin B, Xie B, Liu X, Chen C et al (2021) Naringenin regulates FKBP4/NR3C1/NRF2 Axis in autophagy and proliferation of breast cancer and differentiation and maturation of dendritic cell. *Front Immunol* 12:745111. <https://doi.org/10.3389/fimmu.2021.745111>
- Xu M, Zhang T, Xia R, Wei Y, Wei X (2022) Targeting the tumor stroma for cancer therapy. *Mol*

- Cancer 21(1):208. <https://doi.org/10.1186/s12943-022-01670-1>
- Yan Y, Cao S, Liu X, Harrington SM, Bindeman WE, Adjei AA et al (2018) CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. *JCI Insight* 3(8):e97828. <https://doi.org/10.1172/jci.insight.97828>
- Yang L, Liu Q, Zhang X, Liu X, Zhou B, Chen J et al (2020) DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25. *Nature* 583(7814):133–138. <https://doi.org/10.1038/s41586-020-2394-6>
- Yang T, Kang L, Li D, Song Y (2023) Immunotherapy for HER-2 positive breast cancer. *Front Oncol* 13:1097983. <https://doi.org/10.3389/fonc.2023.1097983>
- Yu B, Luo F, Sun B, Liu W, Shi Q, Cheng SY et al (2021) KAT6A acetylation of SMAD3 regulates myeloid-derived suppressor cell recruitment, metastasis, and immunotherapy in triple-negative breast cancer. *Adv Sci (Weinh)* 8(20):e2100014. <https://doi.org/10.1002/advs.202100014>
- Zeng W, Xiong L, Wu W, Li S, Liu J, Yang L et al (2023) CCL18 signaling from tumor-associated macrophages activates fibroblasts to adopt a chemoresistance-inducing phenotype. *Oncogene* 42(3):224–237. <https://doi.org/10.1038/s41388-022-02540-2>
- Zhang M, Shi Y, Zhang Y, Wang Y, Alotaibi F, Qiu L et al (2020) miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy. *Cancer Immunol Immunother* 69(6):951–967. <https://doi.org/10.1007/s00262-020-02507-w>
- Zhang L, Pan J, Wang Z, Yang C, Chen W, Jiang J et al (2021) Multi-omics profiling suggesting intratumoral mast cells as predictive index of breast cancer lung metastasis. *Front Oncol* 11:788778. <https://doi.org/10.3389/fonc.2021.788778>
- Zhang W, Zhang Q, Yang N, Shi Q, Su H, Lin T et al (2022) Crosstalk between IL-15Ralpha(+) tumor-associated macrophages and breast cancer cells reduces CD8(+) T cell recruitment. *Cancer Commun (Lond)* 42(6):536–557. <https://doi.org/10.1002/cac2.12311>
- Zhang R, Dong M, Tu J, Li F, Deng Q, Xu J et al (2023) PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway. *Signal Transduct Target Ther* 8(1):97. <https://doi.org/10.1038/s41392-023-01337-3>
- Zhao T, Su Z, Li Y, Zhang X, You Q (2020) Chitinase-3 like-protein-1 function and its role in diseases. *Signal Transduct Target Ther* 5(1):201. <https://doi.org/10.1038/s41392-020-00303-7>
- Zheng X, Zhang N, Qian L, Wang X, Fan P, Kuai J et al (2020) CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils. *Int J Cancer* 146(6):1730–1740. <https://doi.org/10.1002/ijc.32829>
- Zheng Y, Li S, Tang H, Meng X, Zheng Q (2023) Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer. *Front Immunol* 14:1153990. <https://doi.org/10.3389/fimmu.2023.1153990>
- Zhou Z, Yan F, Liu O (2020) Interleukin (IL)-33: an orchestrator of immunity from host defence to tissue homeostasis. *Clin Transl Immunol* 9(6):e1146. <https://doi.org/10.1002/cti2.1146>

第 10 章 siRNA 加载到药物递送纳米系统:乳腺癌治疗的策略

- Abedi Gaballu F, Cho WCS, Dehghan G, Zarebkohan A, Baradaran B et al (2021) Silencing of HMGA2 by siRNA loaded methotrexate functionalized polyamidoamine dendrimer for human breast cancer cell therapy. *Genes* 12(7):1102
- Ahmed OAA, Badr-Eldin SM (2020) Biodegradable self-assembled nanoparticles of PEG-PLGA amphiphilic diblock copolymer as a promising stealth system for augmented vinpocetine brain delivery. *Int J Pharm* 588:119778
- Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M et al (2019) The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. *Nat Nanotechnol* 14(12):1084–1087. <https://doi.org/10.1038/s41565-019-0591-y>
- Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE (2012) Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. *Drug Resist Updat* 15(1–2):50–61
- Araújo VCS (2017) Análise de RNAs longos não codificantes do genoma de *Arabidopsis thaliana* (L.) Heynh. 2017. 80 f. Dissertação (Mestrado em Genética e Biologia Molecular) – Universidade Federal de Goiás, Goiânia
- Bahreyni A, Mohamud Y, Luo H (2020) Emerging nanomedicines for effective breast cancer immunotherapy. *J Nanobiotechnol* 18(1):1–14
- Barenholz Y (2012) Doxil® the first FDA approved nano-drug: lessons learned. *J Control Release* 160(2):117–134
- Bochicchio S, Dalmoro A, Angela Barba A, Grassi G, Lamberti G (2022) Liposomes as siRNA delivery vectors: Ingenta connect. Disponível em: <https://www.ingentaconnect.com/content/ben/cdm/2014/00000015/00000009/art00004>. Acesso em: 18 maio. 2022
- Bozzuto G, Molinari A (2015) Liposomes as nanomedical devices. *Int J Nanomedicine* 10:975–999, 2 fev
- Cao J, Wang X, Dai T, Wu Y, Zhang M et al (2018) Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1. *Theranostics* 8(10):2739–2751
- Chan JJ, Tay Y (2018) Noncoding RNA: RNA regulatory networks in cancer. *Int J Mol Sci* 19(5):1310
- Chen J, Sun X, Shao R, Xu Y, Gao J, Liang W (2017a) VEGF siRNA delivered by polycation liposome-encapsulated calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer. *Int J Nanomedicine* 12:6075, 21 ago
- Chen X, Zhang Y, Tang C, Tian C, Sun Q et al (2017b) Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis. *Int J Pharm* 529(1–2):102–115, 30 ago
- Chen M, Chen M, He J (2019) Cancer cell membrane cloaking nanoparticles for targeted co-delivery of doxorubicin and PD-L1 siRNA. *Artif Cells Nanomed Biotechnol* [Internet] 47(1):1635–1641. Available from: <https://doi.org/10.1080/21691401.2019.1608219>
- Chen Y, Li B, Chen X, Wu M, Ji Y, Tang G et al (2020) A supramolecular co-delivery strategy for combined breast cancer treatment and metastasis prevention. *Chin Chem Lett* [Internet] 31(5):1153–1158. Available from: <https://doi.org/10.1016/j.cclet.2019.06.022>
- Chen C, Guo Q, Fu H, Yu J, Wang L, Sun Y, et al (2021) Asynchronous blockade of PD-L1 and

- CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis. *Biomaterials* [Internet] 275(2020):120988. Available from: <https://doi.org/10.1016/j.biomaterials.2021.120988>
- Chis AA, Dobrea C, Morgovan C, Arseniu AM, Rus LL et al (2020) Applications and limitations of dendrimers in biomedicine. *Molecules* 25(17):3982
- Chowdhury NK, Choudhury R, Sonawane GA, Mavinamar S, Lyu X, Pandey RP, Chang CM (2021) Nanoparticles as an effective drug delivery system in COVID-19. *Biomed Pharmacother* 143:112162
- Cramer P (2020) Rosalind Franklin and the advent of molecular biology. *Cell* 182(4):787–789
- De Kruijff IE, Timmermans AM, Den Bakker MA, Trapman-Jansen AM, Foekens R et al (2018) The prevalence of CD146 expression in breast cancer subtypes and its relation to outcome. *Cancers (Basel)* 10(5):134
- Dias AP, da Silva SS, da Silva JV, Parise-Filho R, Ferreira EI, El Seud O, Giarolla J (2020) Dendrimers in the context of nanomedicine. *Int J Pharm* 573:118814
- Ding J, Liang T, Min Q, Jiang L, Zhu JJ (2018) “Stealth and fully-laden” drug carriers: self-assembled Nanogels encapsulated with epigallocatechin Gallate and siRNA for drug-resistant breast cancer therapy. *ACS Appl Mater Interfaces* 10(12):9938–9948
- Dong Y, Siegwart DJ, Anderson DG (2019) Strategies, design, and chemistry in siRNA delivery systems. *Adv Drug Deliv Rev* 144:133–147
- Feng C, Zhu D, Chen L, Lu Y, Liu J, Kim NY et al (2019) Targeted delivery of chlorin E6 via redox sensitive diselenide-containing micelles for improved photodynamic therapy in cluster of differentiation 44-overexpressing breast cancer. *Front Pharmacol* 10:369
- Finlay J, Roberts CM, Lowe G, Loeza J, Rossi JJ, Glackin CA (2015) RNA-based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis. *Biomed Res Int* 2015:382745
- Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* 391:806–811
- Franco YL, Vaidya TR, Ait-Oudhia S (2018) Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer. *Breast Cancer Targets Ther* 10:131
- Ganesan P, Narayanasamy D (2017) Lipid nanoparticles: different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. *Sustain Chem Pharm* 6(May):37–56. <https://doi.org/10.1016/j.scp.2017.07.002>
- Ganesan K, Wang Y, Gao F, Liu Q, Zhang C et al (2021) Targeting engineered nanoparticles for breast cancer therapy. *Pharmaceutics* 13(11):1829
- Gayon J (2016) From Mendel to epigenetics: history of genetics. *C R Biol* 339(7–8):225–230
- Goes ACS, Oliveira BVX (2014) Projeto Genoma Humano: um retrato da construção do conhecimento científico sob a ótica da revista *Ciência Hoje*. *Ciência Educ Bauru* 20(03): 561–577, set
- Gonçalves GAR, Paiva RMA (2017) Gene therapy: advances, challenges and perspectives. *Einstein (São Paulo)* 15(3):369–375
- Gong J et al (2012) Polymeric micelles drug delivery system in oncology. *J Control Release* 159(3): 312–323
- Gong C et al (2017) Co-delivery of autophagy inhibitor ATG7 siRNA and docetaxel for breast cancer treatment. *J Control Release* 266:272–286
- Gong C, Yu X, Zhang W, Han L, Wang R, Wang Y et al (2021) Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid

- membrane-coated nanoparticles. *J Nanobiotechnol* [Internet] 19(1):1–20. Available from: <https://doi.org/10.1186/s12951-021-00805-8>
- Gordillo-Galeano A, Mora-Huertas CE (2018) Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release. *Eur J Pharm Biopharm.* Elsevier B.V. <https://doi.org/10.1016/j.ejpb.2018.10.017>
- Haider M, Abdin SM, Kamal L, Orive G (2020) Nanostructured lipid carriers for delivery of chemotherapeutics: a review. *Pharmaceutics* 12(3). <https://doi.org/10.3390/pharmaceutics12030288>
- Han X, Li Z, Sun J, Luo C, Li L, Liu Y et al (2015) Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation. *J Control Release* 197:29–40
- Hu B et al (2020) Therapeutic siRNA: state of the art. *Signal Transduct Target Ther* 5(1):1–25
- Janaszewska A et al (2019) Cytotoxicity of dendrimers. *Biomol Ther* 9(8):330
- Jansook P, Ogawa N, Loftsson T (2018) Cyclodextrins: structure, physicochemical properties and pharmaceutical applications. *Int J Pharm* 535(1–2):272–284
- Jin W, Wang Q, Wu M, Li Y, Tang G, Ping Y et al (2017) Lanthanide-integrated supramolecular polymeric nanoassembly with multiple regulation characteristics for multidrug-resistant cancer therapy. *Biomaterials* [Internet] 129:83–97. Available from: <https://doi.org/10.1016/j.biomaterials.2017.03.020>
- Jin M, Hou Y, Quan X, Chen L, Gao Z, Huang W (2021) Smart polymeric nanoparticles with pH-responsive and Peg-detachable properties (II): co-delivery of paclitaxel and VEGF siRNA for synergistic breast cancer therapy in mice. *Int J Nanomedicine* 16(August):5479–5494
- Kars MD, Işeri ÖD, Gündüz U (2010) Drug resistant breast cancer cells overexpress ETS1 gene. *Biomed Pharmacother* 64(7):458–462
- Kaushal N, Tiruchinapally G, Durmaz YY, Bao L, Gilani R, Merajvey SD, ElSayed ME (2018) Synergistic inhibition of aggressive breast cancer cell migration and invasion by cytoplasmic delivery of anti-RhoC silencing RNA and presentation of EPPT1 peptide on “smart” particles. *J Control Release* 289(July):79–93
- Khosa A, Reddi S, Sasha RN (2018) Nanostructured lipid carriers for site-specific drug delivery. *Biomed Pharmacother* 103(February):598–613. <https://doi.org/10.1016/j.biopha.2018.04.055>
- Kuzuhara T, Sei Y, Yamaguchi K, Suganuma M, Fujiki H (2006) DNA and RNA as new binding targets of green tea catechins. *J Biol Chem* 281(25):17446–17456
- Laouini A, Jaafar-Maalej C, Limayem-Blouza I, Sfar S, Charcosset C, Fessi H (2012) Preparation, characterization and applications of liposomes: state of the art. *J Colloid Sci Biotechnol* 1(2): 147–168
- Lee SH, Mok H, Park TG (2011) Di- and triblock siRNA-PEG copolymers: PEG density effect of polyelectrolyte complexes on cellular uptake and gene silencing efficiency. *Macromol Biosci* 11(3):410–418. <https://doi.org/10.1002/mabi.201000347>
- Lewis RG, Simpson B (2021) Genetics, autosomal dominant. 2020. In: StatPearls. StatPearls Publishing, Treasure Island (FL). PMID: 32491444
- Li Y, Humphries B, Yang C, Wang Z (2018) Nanoparticle-mediated therapeutic agent delivery for treating metastatic breast cancer—challenges and opportunities. *Nanomaterials* 8(6). <https://doi.org/10.3390/nano8060361>
- Li M, Du C, Guo N, Teng Y, Meng X et al (2019) Composition design and medical application of liposomes. *Eur J Med Chem* 164:640–653, 15 fev
- Li F, Yu W, Zhang J, Dong Y, Ding X, Ruan X et al (2021) Spatiotemporally programmable cascade hybridization of hairpin DNA in polymeric nanoframework for precise siRNA delivery.

Nat Commun 12:1138

- Li M, Li S, Li Y, Li X, Yang G et al (2022) Cationic liposomes co-deliver chemotherapeutics and siRNA for the treatment of breast cancer. *Eur J Med Chem* 233:114198, 5 abr
- Lobovkina T, Jacobson GB, Gonzalez-Gonzalez E, Hickerson RP, Leake D (2011) *In vivo* sustained release of siRNA from solid lipid nanoparticles. *ACS Nano* 5(12):9977–9983. <https://doi.org/10.1021/nn203745n>
- Lopes JC, Torres MLP (2019) Nanoparticles in cancer treatment: general aspects, antineoplastic mechanisms of action and tumor applications. *Revista Brasileira de Cancerologia* 65(4):e-08592
- Marcucci F, Romeo E, Caserta CA, Rumio C, Lefoulon F (2020) Context-dependent pharmacological effects of metformin on the immune system. *Trends Pharmacol Sci* 41(3):162–171
- Meng Q, Meng J, Ran W, Wang J, Zhai Y, Zhang P et al (2018) Light-activated Core-Shell nanoparticles for spatiotemporally specific treatment of metastatic triple-negative breast cancer. *ACS Nano* 12(3):2789–2802
- Mengarda AC, Iles B, João JP, de Moraes J (2022) Recent trends in praziquantel nanoformulations for helminthiasis treatment. *Expert Opin Drug Deliv* [Internet] 19(4):1–11. Available from: <https://doi.org/10.1080/17425247.2022.2051477>
- Mennati A, Rostamizadeh K, Manjili HK, Fathi M, Danafar H (2022) Co-delivery of siRNA and lycopene encapsulated hybrid lipid nanoparticles for dual silencing of insulin-like growth factor 1 receptor in MCF-7 breast cancer cell line. *Int J Biol Macromol* 200(November 2021): 335–349. <https://doi.org/10.1016/j.ijbiomac.2021.12.197>
- Mitchell MJ, Billingsley MM, Haley RM, Wechsle ME, Peppas NA, Langer R (2021) Engineering precision nanoparticles for drug delivery. *Nat Rev Drug Discov* 20(2):101–124
- Mittal P, Saharan A, Verma R, Altalbawy F, Alfaidi MA (2021) Dendrimers: a new race of pharmaceutical nanocarriers. *Biomed Res Int* 2021:8844030
- Modi SJ, Kulkarni VM (2019) Medicine in drug discovery Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR inhibitors: medicinal chemistry perspective. *Med Drug Discov* [Internet] 2:100009. Available from: <https://doi.org/10.1016/j.medidd.2019.100009>
- Mousazadeh H, Bonabi E, Zarghami N (2022) Stimulus-responsive drug/gene delivery system based on polyethylenimine cyclodextrin nanoparticles for potential cancer therapy, 118747. *Carbohydr Polym* [Internet] 276(October 2021). Available from: <https://doi.org/10.1016/j.carbpol.2021.118747>
- Mukalel AJ, Riley RS, Zhang R, Mitchell MJ (2019) Nanoparticles for nucleic acid delivery: applications in cancer immunotherapy. *Cancer Lett* 458:102–112
- Nápoles C, Lemieux C, Jorgensen R (1990) Introduction of a chimeric Chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. *Plant Cell* 2(4): 279–289
- Okamoto A, Asai T, Kato H, Ando H, Minamino T, Mekada E, Oku N (2014) Antibody-modified lipid nanoparticles for selective delivery of siRNA to tumors expressing membrane-anchored form of HB-EGF. *Biochem Biophys Res Commun* 449(4):460–465
- Okamoto A, Asai T, Hirai Y, Shimizu K, Koide H, Minamino T, Oku N (2018) Systemic administration of siRNA with anti-HB-EGF antibody-modified lipid nanoparticles for the treatment of triple-negative breast cancer. *Mol Pharm* 15(4):1495–1504. <https://doi.org/10.1021/acs.molpharmaceut.7b01055>
- Pan J, Mendes LP, Yao M, Filipczak N, Garai S (2019) Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multi-drug resistance. *Eur J Pharm Biopharm* 136:18–28
- Piao L, Li H, Teng L, Yung BC, Sugimoto Y, Brueggemeier RW, Lee RJ (2013) Human serum

- albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer. *Nanomedicine* 9(1): 122–129. <https://doi.org/10.1016/j.nano.2012.03.008>
- Qian W, Zhao M, Wang R, Li H (2021) Fibrinogen-like protein 1 (PGL1): the next immune checkpoint target. *J Hematol Oncol* 14(147):1–17
- Salvi VR And Pawar P. (2019) ‘Nanostructured lipid carriers (NLC) system: a novel drug targeting carrier’, *J Drug Deliv Sci Technol*, 51(990), pp. 255–267. doi: <https://doi.org/10.1016/j.jddst.2019.02.017>
- Sartaj A, Qamar Z, Qizilbash FF, Annu MS, Alhakamy NA et al (2021) Polymeric nanoparticles: exploring the current drug development and therapeutic insight of breast cancer treatment and recommendations. *Polymers (Basel)* 13(24):4400
- Singh A, Trivedi P, Jain NK (2018) Advances in siRNA delivery in cancer therapy. *Artif Cells Nanomed Biotechnol* 46(2):274–283
- Singh RP, Hidalgo T, Cazade PA, Darcy R, Cronin MF, Dorin I et al (2019) Self-assembled cationic β -Cyclodextrin nanostructures for siRNA delivery. *Mol Pharm* 16(3):1358–1366
- Sumera et al (2017) Docetaxel-loaded solid lipid nanoparticles: a novel drug delivery system. *IET Nanobiotechnol* 11(6):621–629
- Sun B, Hagan CT IV, Caster J, Wang AZ (2019) Nanotechnology in radiation oncology. *Hematol Oncol Clin North Am* 33(6):1071–1093
- Toohey JM, Ismail K, Lonergan D, Lewis CR (2007) Amyloidosis of the breast mimicking recurrence in a previously treated early breast cancer. *Australas Radiol* 51(6): 594–596. <https://doi.org/10.1111/j.1440-1673.2007.01700.x>
- Triki H, Charfi S, Bouzidi L, Ben Kridis W, Daoud J, Chaabane K et al (2019) CD155 expression in human breast cancer: clinical significance and relevance to natural killer cell infiltration. *Life Sci* 231:116543
- Vallabani NVS, Singh S, Karakoti AS (2019) Magnetic nanoparticles: current trends and future aspects in diagnostics and nanomedicine. *Curr Drug Metab* 20(6):457–472
- Verma V, Ryan KM, Padrela L (2021) Production and isolation of pharmaceutical drug nanoparticles. *Int J Pharm* 603:120708
- Vieira LM (2016) Classificação de RNAs não-codificadores longos intergênicos usando máquina de vetores de suporte: um estudo de caso para a cana-de-açúcar. xii, 74 f., il. Monografia (Bacharelado em Engenharia da Computação)—Universidade de Brasília, Brasília
- Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J et al (2019) Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. *Cell [Internet]* 176(1–2):334–347.e12. Available from: <https://doi.org/10.1016/j.cell.2018.11.010>
- Wang H, Wang C, Zou Y, Hu J, Li Y, Cheng Y (2020) Natural polyphenols in drug delivery systems: current status and future challenges. *Giant [Internet]* 3:100022. Available from: <https://doi.org/10.1016/j.giant.2020.100022>
- Wu M, Liu X, Jin W, Li Y, Li Y, Hu Q et al (2017) Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy. *J Control Release [Internet]* 253:110–121. Available from: <https://doi.org/10.1016/j.jconrel.2017.03.011>
- Xu M, Huang S, Dong X, Chen Y, Li M et al (2021) A novel isoform of ATOH8 promotes the metastasis of breast cancer by regulating RhoC. *J Mol Cell Biol* 13(1):59–71
- Yin T, Wang L, Yin L, Zhou J, Huo M (2015) Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer. *Biomaterials* 61:10–25. <https://doi.org/10.1016/j.biomaterials.2015.05.022>
- Yu S, Bi X, Yang L, Wu S, Yu Y (2019) Co-delivery of paclitaxel and PLK1-targeted siRNA using aptamer-functionalized cationic liposome for synergistic anti-breast cancer effects *in vivo*. *J*

Biomed Nanotechnol 15(6):1135–1148

Zhang L, Xu B (2020) Autophagy inhibitor autophagy-related 7 small interfering RNA and doxorubicin dual-loaded nanostructured lipid carrier to combat multidrug resistance. *J Mater Res* 35(22):3136–3143. <https://doi.org/10.1557/jmr.2020.223>

Zhang Y, Li M, Gao X, Chen Y, Liu T (2019) Nanotechnology in cancer diagnosis: progress, challenges and opportunities. *J Hematol Oncol* 12(1):1–13

Zhao F, Yin H, Li J (2014) Supramolecular self-assembly forming a multifunctional synergistic system for targeted co-delivery of gene and drug. *Biomaterials* 35(3):1050–1062

Zhu Wen-jing et al (2017) Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor. *Int J Nanomedicine* 12:3375–3393. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413542/>

Zielinska A, Carreiró F, Oliveira AM, Neves A, Pires B, Venkatesh DN et al (2020) Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. *Molecules* 25:3731

第 11 章 核酸和药物双重载体纳米平台用于治疗乳腺癌

- Abedi Gaballu F, Cho WC-S, Dehghan G, Zarebkohan A, Baradaran B, Mansoori B, Abbaspour-Ravasjani S, Mohammadi A, Sheibani N, Aghanejad A (2021) Silencing of HMGA2 by siRNA loaded methotrexate functionalized Polyamidoamine dendrimer for human breast cancer cell therapy. *Genes* 12(7):1102. <https://doi.org/10.3390/genes12071102>
- Alconcel SN, Baas AS, Maynard HD (2011) FDA-approved poly (ethylene glycol)–protein conjugate drug. *Polym Chem* 2(7):1442–1448. <https://doi.org/10.1039/C1PY00034A>
- Alinejad V, Somi MH, Baradaran B, Akbarzadeh P, Atyabi F, Kazerooni H, Kafil HS, Maleki LA, Mansouri HS, Yousefi M (2016) Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells. *Biomed Pharmacother* 83:229–240. <https://doi.org/10.1016/j.biopha.2016.06.037>
- Amani A, Alizadeh MR, Yaghoubi H, Nohtani M (2021) Novel multi-targeted nanoparticles for targeted co-delivery of nucleic acid and chemotherapeutic agents to breast cancer tissues. *Mater Sci Eng C* 118:111494. <https://doi.org/10.1016/j.msec.2020.111494>
- Ansary RH, Awang MB, Rahman MM (2014) Biodegradable poly (D, L-lactic-co-glycolic acid)-based micro/nanoparticles for sustained release of protein drugs-A review. *Trop J Pharm Res* 13(7):1179–1190. <https://doi.org/10.4314/tjpr.v13i7.24>
- Asyikin binti Abdul Aziz Z, Ahmad A, Hamidah Mohd-Setapar S, Hassan H, Lokhat D, Amjad Kamal M (2017) Recent advances in drug delivery of polymeric nano-micelles. *Curr Drug Metab* 18(1):16–29. <https://doi.org/10.2174/1389200217666160921143616>
- Barenholz YC (2012) Doxil®—the first FDA-approved nano-drug: lessons learned. *J Control Release* 160(2):117–134. <https://doi.org/10.1016/j.jconrel.2012.03.020>
- Barenholz YC (2021) Doxil-the first FDA-approved nano-drug: from an idea to a product. In: Peer D (ed) *Handbook of harnessing biomaterials in nanomedicine*, 2nd edn. Jenny Stanford Publishing, pp 335–398. <https://doi.org/10.4032/9789814364270>
- Bhargava-Shah A, Foygel K, Devulapally R, Paulmurugan R (2016) Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy. *Nanomedicine* 11(3):235–247. <https://doi.org/10.2217/nnm.15.193>
- Bulbake U, Kommineni N, Bryszewska M, Ionov M, Khan W (2018) Cationic liposomes for co-delivery of paclitaxel and anti-Plk1 siRNA to achieve enhanced efficacy in breast cancer. *J Drug Deliv Sci Technol* 48:253–265. <https://doi.org/10.1016/j.jddst.2018.09.017>
- Butt AM, Amin MCIM, Katas H, Abdul Murad NA, Kesharwani JR (2016) Doxorubicin and siRNA codelivery via chitosan-coated pH-responsive mixed micellar polyplexes for enhanced cancer therapy in multidrug-resistant tumors. *Mol Pharm* 13(12):4179–4190. <https://doi.org/10.1021/acs.molpharmaceut.6b00776>
- Chen L, Wang X, Ji F, Bao Y, Wang J, Wang X, Guo L, Li Y (2015) New bifunctional-pullulan-based micelles with good biocompatibility for efficient co-delivery of cancer-suppressing p53 gene and doxorubicin to cancer cells. *RSC Adv* 5(115):94719–94731. <https://doi.org/10.1039/C5RA17139C>
- Chen L, Ji F, Bao Y, Xia J, Guo L, Wang J, Li Y (2017a) Biocompatible cationic pullulan-g-desoxycholic acid-g-PEI micelles used to co-deliver drug and gene for cancer therapy. *Mater Sci Eng C* 70:418–429. <https://doi.org/10.1016/j.msec.2016.09.019>

- Chen X, Zhang Y, Tang C, Tian C, Sun Q, Su Z, Xue L, Yin Y, Ju C, Zhang C (2017b) Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis. *Int J Pharm* 529(1–2):102–115. <https://doi.org/10.1016/j.ijpharm.2017.06.071>
- Chen Y, Li B, Chen X, Wu M, Ji Y, Tang G, Ping Y (2020) A supramolecular co-delivery strategy for combined breast cancer treatment and metastasis prevention. *Chin Chem Lett* 31(5): 1153–1158. <https://doi.org/10.1016/j.ccllet.2019.06.022>
- Chen C, Shen M, Liao H, Guo Q, Fu H, Yu J, Duan Y (2021) A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer. *J Nanobiotechnol* 19(1):55. <https://doi.org/10.1186/s12951-021-00800-z>
- Chibon F (2013) Cancer gene expression signatures—the rise and fall? *Eur J Cancer* 49(8): 2000–2009. <https://doi.org/10.1016/j.ejca.2013.02.021>
- Dai X, Tan C (2015) Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers. *Adv Drug Deliv Rev* 81:184–197. <https://doi.org/10.1016/j.addr.2014.09.010>
- Deng ZJ, Morton SW, Ben-Akiva E, Dreaden EC, Shropsowitz KE, Hammond PT (2013) Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. *ACS Nano* 7(11):9571–9584. <https://doi.org/10.1021/nn4047925>
- Deng X, Cao M, Zhang J, Hu K, Yin Z, Zhou Z, Xiao X, Yang Y, Sheng W, Wu Y (2014) Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. *Biomaterials* 35(14):4333–4344. <https://doi.org/10.1016/j.biomaterials.2014.02.006>
- Devulapally R, Sekar TV, Paulmurugan R (2015) Formulation of anti-miR-21 and 4-hydroxytamoxifen co-loaded biodegradable polymer nanoparticles and their antiproliferative effect on breast cancer cells. *Mol Pharm* 12(6):2080–2092. <https://doi.org/10.1021/mp500852s>
- Ding J, Liang T, Min Q, Jiang L, Zhu J-J (2018) “Stealth and fully-laden” drug carriers: self-assembled nanogels encapsulated with epigallocatechin gallate and siRNA for drug-resistant breast cancer therapy. *ACS Appl Mater Interfaces* 10(12):9938–9948. <https://doi.org/10.1021/acsami.7b19577>
- Dong D, Gao W, Liu Y, Qi X-R (2015) Therapeutic potential of targeted multifunctional nanocomplex co-delivery of siRNA and low-dose doxorubicin in breast cancer. *Cancer Lett* 359(2):178–186. <https://doi.org/10.1016/j.canlet.2015.01.011>
- Dönmez Y, Gündüz U (2011) Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. *Biomed Pharmacother* 65(2):85–89. <https://doi.org/10.1016/j.biopha.2010.12.007>
- Ebrahimian M, Taghavi S, Mokhtarzadeh A, Ramezani M, Hashemi M (2017) Co-delivery of doxorubicin encapsulated PLGA nanoparticles and Bcl-xL shRNA using alkyl-modified PEI into breast cancer cells. *Appl Biochem Biotechnol* 183(1):126–136. <https://doi.org/10.1007/s12010-017-2434-3>
- Eivazy P, Atyabi F, Jadidi-Niaragh F, Aghebati Maleki L, Miahipour A, Abdolalizadeh J, Yousefi M (2017) The impact of the codelivery of drug-siRNA by trimethyl chitosan nanoparticles on the efficacy of chemotherapy for metastatic breast cancer cell line (MDA-MB-231). *Artif Cells Nanomed Biotechnol* 45(5):889–896. <https://doi.org/10.1080/21691401.2016.1185727>
- El Founi M, Laroui H, Canup BS, Ametepe JS, Vanderesse R, Acherar S, Babin J, Ferji K, Chevalot I, Six J-L (2021) Doxorubicin intracellular release via external UV irradiation of dextran-g-poly (o-nitrobenzyl acrylate) photosensitive nanoparticles. *ACS Appl Bio Mater.*

<https://doi.org/10.1021/acsabm.0c01644>

- Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001a) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* 411(6836):494–498. <https://doi.org/10.1038/35078107>
- Elbashir SM, Lendeckel W, Tuschl T (2001b) RNA interference is mediated by 21-and 22-nucleotide RNAs. *Genes Dev* 15(2):188–200. <https://doi.org/10.1101/gad.862301>
- Essa D, Kondiah PP, Choonara YE, Pillay V (2020) The design of poly (lactide-co-glycolide) nanocarriers for medical applications. *Front Bioeng Biotechnol* 8:48. <https://doi.org/10.3389/fbioe.2020.00048>
- Feng Q, Yu M-Z, Wang J-C, Hou W-J, Gao L-Y, Ma X-F, Pei X-W, Niu Y-J, Liu X-Y, Qiu C (2014) Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vaporeotide-modified core-shell nanoparticles. *Biomaterials* 35(18):5028–5038. <https://doi.org/10.1016/j.biomaterials.2014.03.012>
- Feng L, Yan S, Zhu Q, Chen J, Deng L, Zheng Y, Xue W, Guo R (2018) Targeted multifunctional redox-sensitive micelle co-delivery of DNA and doxorubicin for the treatment of breast cancer. *J Mater Chem B* 6(20):3372–3386. <https://doi.org/10.1039/C8TB00748A>
- Fu Y, Chen J, Huang Z (2019) Recent progress in microRNA-based delivery systems for the treatment of human disease. *ExRNA* 1(1):24. <https://doi.org/10.1186/s41544-019-0024-y>
- García-Pinel B, Porras-Alcalá C, Ortega-Rodríguez A, Sarabia F, Prados J, Melguizo C, López-Romero JM (2019) Lipid-based nanoparticles: application and recent advances in cancer treatment. *Nanomaterials* 9(4):638. <https://doi.org/10.3390/nano9040638>
- Gong C, Hu C, Gu F, Xia Q, Yao C, Zhang L, Qiang L, Gao S, Gao Y (2017) Co-delivery of autophagy inhibitor ATG7 siRNA and docetaxel for breast cancer treatment. *J Control Release* 266:272–286. <https://doi.org/10.1016/j.jconrel.2017.09.042>
- Gong C, Tian J, Wang Z, Gao Y, Wu X, Ding X, Qiang L, Li G, Han Z, Yuan Y (2019) Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy. *J Nanobiotechnol* 17(1):1–18. <https://doi.org/10.1186/s12951-019-0526-7>
- Gong C, Yu X, Zhang W, Han L, Wang R, Wang Y, Gao S, Yuan Y (2021) Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles. *J Nanobiotechnol* 19(1):1–20. <https://doi.org/10.1186/s12951-021-00805-8>
- Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez-Barajas D, Gonzalez-Guerrero JF, Rodriguez-Fernandez IA, Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF (2018) Epidermal growth factor receptor overexpression and outcomes in early breast cancer: a systematic review and a meta-analysis. *Cancer Treat Rev* 62:1–8. <https://doi.org/10.1016/j.ctrv.2017.10.008>
- Gu Y, Guo Y, Wang C, Xu J, Wu J, Kirk TB, Ma D, Xue W (2017) A polyamidoamine dendrimer functionalized graphene oxide for DOX and MMP-9 shRNA plasmid co-delivery. *Mater Sci Eng C* 70:572–585. <https://doi.org/10.1016/j.msec.2016.09.035>
- Guo P, Fang Q, Tao H-Q, Schafer CA, Fenton BM, Ding I, Hu B, Cheng S-Y (2003) Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo. *Cancer Res* 63(15):4684–4691
- Guo D, Ji X, Peng F, Zhong Y, Chu B, Su Y, He Y (2019) Photostable and biocompatible fluorescent silicon nanoparticles for imaging-guided co-delivery of siRNA and doxorubicin to drug-resistant cancer cells. *Nano-Micro Lett* 11(1):1–13. <https://doi.org/10.1007/s40820-019-0257-1>

- He W, Turkeshi A, Li X, Zhang H (2020) Progress in systemic co-delivery of microRNAs and chemotherapeutics for cancer treatment by using lipid-based nanoparticles. *Ther Deliv* 11(9): 591–603. <https://doi.org/10.4155/tde-2020-0052>
- Hong S, Choi DW, Kim HN, Park CG, Lee W, Park HH (2020) Protein-based nanoparticles as drug delivery systems. *Pharmaceutics* 12(7):604. <https://doi.org/10.3390/pharmaceutics12070604>
- Jafari R, Zolbanin NM, Majidi J, Atyabi F, Yousefi M, Jadidi-Niaragh F, Aghebati-Maleki L, Shanebandi D, Zangbar M-SS, Rafatpanah H (2019a) Anti-mucin1 aptamer-conjugated chitosan nanoparticles for targeted co-delivery of docetaxel and IGF-1R siRNA to SKBR3 metastatic breast cancer cells. *Iran Biomed J* 23(1):21. <https://doi.org/10.29252/23.1.21>
- Jafari S, Derakhshankhah H, Alaei L, Fattahi A, Varnamkhasti BS, Saboury AA (2019b) Mesoporous silica nanoparticles for therapeutic/diagnostic applications. *Biomed Pharmacother* 109:1100–1111. <https://doi.org/10.1016/j.biopha.2018.10.167>
- Jafari M, Sriram V, Xu Z, Harris GM, Lee J-Y (2020) Fucoidan-doxorubicin nanoparticles targeting P-selectin for effective breast cancer therapy. *Carbohydr Polym* 249:116837. <https://doi.org/10.1016/j.carbpol.2020.116837>
- Jeong D, Ham J, Kim HW, Kim H, Ji HW, Yun SH, Park JE, Lee KS, Jo H, Han JH (2021) ELOVL2: a novel tumor suppressor attenuating tamoxifen resistance in breast cancer. *Am J Cancer Res* 11(6):2568–2589
- Jia L, Li Z, Zheng D, Li Z, Zhao Z (2021) A targeted and redox/pH-responsive chitosan oligosaccharide derivatives based nanohybrids for overcoming multidrug resistance of breast cancer cells. *Carbohydr Polym* 251:117008. <https://doi.org/10.1016/j.carbpol.2020.117008>
- Jin M, Hou Y, Quan X, Chen L, Gao Z, Huang W (2021) Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties (II): co-delivery of paclitaxel and VEGF siRNA for synergistic breast cancer therapy in mice. *Int J Nanomedicine* 16:5479. <https://doi.org/10.2147/IJN.S313339>
- Ju L, Zhang G, Zhang C, Sun L, Jiang Y, Yan C, Duerksen-Hughes PJ, Zhang X, Zhu X, Chen FF (2013) Quantum dot-related genotoxicity perturbation can be attenuated by PEG encapsulation. *Mutat Res Genet Toxicol Environ Mutagen* 753(1):54–64. <https://doi.org/10.1016/j.mrgentox.2013.01.006>
- Kahraman E, Güngör S, Özsoy Y (2017) Potential enhancement and targeting strategies of polymeric and lipid-based nanocarriers in dermal drug delivery. *Ther Deliv* 8(11):967–985. <https://doi.org/10.4155/tde-2017-0075>
- Kang L, Gao Z, Huang W, Jin M, Wang Q (2015) Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment. *Acta Pharm Sin B* 5(3):169–175. <https://doi.org/10.1016/j.apsb.2015.03.001>
- Khan A, Rashid R, Murtaza G, Zahra A (2014) Gold nanoparticles: synthesis and applications in drug delivery. *Trop J Pharm Res* 13:1169–1177. <https://doi.org/10.4314/tjpr.v13i7.23>
- Khesht AMS, Karpisheh V, Gilan PS, Melnikova LA, Zekiy AO, Mohammadi M, Hojjat-Farsangi-M, Zolbanin NM, Mahmoodpoor A, Hassannia H (2021) Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo. *Int J Biol Macromol* 186:849–863. <https://doi.org/10.1016/j.ijbiomac.2021.07.034>
- Lee E, Oh C, Kim I-S, Kwon IC, Kim S (2015) Co-delivery of chemosensitizing siRNA and an anticancer agent via multiple monocomplexation-induced hydrophobic association. *J Control Release* 210:105–114. <https://doi.org/10.1016/j.jconrel.2015.05.262>
- Li M, Li Y, Huang X, Lu X (2015) Captopril-polyethyleneimine conjugate modified gold nanoparticles for co-delivery of drug and gene in anti-angiogenesis breast cancer therapy.

- J Biomater Sci Polym Ed 26(13):813–827. <https://doi.org/10.1080/09205063.2015.1057991>
- Li J, Cai C, Li J, Li J, Li J, Sun T, Wang L, Wu H, Yu G (2018) Chitosan-based nanomaterials for drug delivery. *Molecules* 23(10):2661. <https://doi.org/10.3390/molecules23102661>
- Li G, Meng F, Lu T, Wei L, Pan X, Nong Z, Wei M, Liao C, Li X (2021) Functionalised molybdenum disulfide nanosheets for co-delivery of doxorubicin and siRNA for combined chemo/gene/photothermal therapy on multidrug-resistant cancer. *J Pharm Pharmacol* 73(8): 1128–1135. <https://doi.org/10.1093/jpp/rgab059>
- Linardi RL, Natalini CC (2006) Multi-drug resistance (MDR1) gene and P-glycoprotein influence on pharmacokinetic and pharmacodynamic of therapeutic drugs. *Ciência Rural* 36(1):336–341. <https://doi.org/10.1590/S0103-84782006000100056>
- Liu Z, Sun Q, Wang X (2017) PLK1, a potential target for cancer therapy. *Transl Oncol* 10(1): 22–32. <https://doi.org/10.1016/j.tranon.2016.10.003>
- Liu Y, Sun J, Huang Y, Chen Y, Li J, Liang L, Xu J, Wan Z, Zhang B, Li Z (2021) Metformin-conjugated micellar system with intratumoral pH responsive de-shielding for co-delivery of doxorubicin and nucleic acid. *Biochem Pharmacol* 189:114453. <https://doi.org/10.1016/j.bcp.2021.114453>
- Loh H-Y, Norman BP, Lai K-S, Rahman NMANA, Alitheen NBM, Osman MA (2019) The regulatory role of microRNAs in breast cancer. *Int J Mol Sci* 20(19):4940. <https://doi.org/10.3390/ijms20194940>
- Lü J-M, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, Chen C (2009) Current advances in research and clinical applications of PLGA-based nanotechnology. *Expert Rev Mol Diagn* 9(4): 325–341. <https://doi.org/10.1586/erm.09.15>
- Luo K, Gao Y, Yin S, Yao Y, Yu H, Wang G, Li J (2021) Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer. *Acta Biomater* 134:649–663. <https://doi.org/10.1016/j.actbio.2021.07.029>
- Mahapatro A, Singh DK (2011) Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. *J Nanobiotechnol* 9(1):1–11. <https://doi.org/10.1186/1477-3155-9-55>
- Makarova JA, Shkurnikov MU, Wicklein D, Lange T, Samatov TR, Turchinovich AA, Tonevitsky AG (2016) Intracellular and extracellular microRNA: an update on localization and biological role. *Prog Histochem Cytochem* 51(3–4):33–49. <https://doi.org/10.1016/j.proghi.2016.06.001>
- Meng H, Mai WX, Zhang H, Xue M, Xia T, Lin S, Wang X, Zhao Y, Ji Z, Zink JI (2013) Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. *ACS Nano* 7(2):994–1005. <https://doi.org/10.1021/nn3044066>
- Misra R, Das M, Sahoo BS, Sahoo SK (2014) Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly (lactide-co-glycolide) nanoformulation. *Int J Pharm* 475(1–2):372–384. <https://doi.org/10.1016/j.ijpharm.2014.08.056>
- Morry J, Ngamcherdtrakul W, Gu S, Reda M, Castro DJ, Sangvanich T, Gray JW, Yantasee W (2017) Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform. *Mol Cancer Ther* 16(4):763–772. <https://doi.org/10.1158/1535-7163.MCT-16-0644>
- Nagini S (2017) Breast cancer: current molecular therapeutic targets and new players. *Anti Cancer Agents Med Chem* 17(2):152–163
- Nasab SH, Amani A, Ebrahimi HA, Hamidi AA (2021) Design and preparation of a new multi-targeted drug delivery system using multifunctional nanoparticles for co-delivery of siRNA and

- paclitaxel. *J Pharm Anal* 11(2):163–173. <https://doi.org/10.1016/j.jpha.2020.04.005>
- Norouzi M, Yathindranath V, Thliveris JA, Kopec BM, Siahaan TJ, Miller DW (2020) Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles. *Sci Rep* 10:11292. <https://doi.org/10.1038/s41598-020-68017-y>
- Norouzi P, Motasadizadeh H, Atyabi F, Dinarvand R, Gholami M, Farokhi M, Shokrgozar MA, Mottaghitalab F (2021) Combination therapy of breast cancer by Codelivery of doxorubicin and Survivin siRNA using Polyethylenimine modified silk fibroin nanoparticles. *ACS Biomater Sci Eng* 7(3):1074–1087. <https://doi.org/10.1021/acsbiomaterials.0c01511>
- Pan Q-S, Chen T-T, Nie C-P, Yi J-T, Liu C, Hu Y-L, Chu X (2018) In situ synthesis of ultrathin ZIF-8 film-coated MSNs for codelivering Bcl 2 siRNA and doxorubicin to enhance chemotherapeutic efficacy in drug-resistant cancer cells. *ACS Appl Mater Interfaces* 10(39):33070–33077. <https://doi.org/10.1021/acsami.8b13393>
- Pan J, Mendes LP, Yao M, Filipczak N, Garai S, Thakur GA, Sarisozen C, Torchilin VP (2019) Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance. *Eur J Pharm Biopharm* 136:18–28. <https://doi.org/10.1016/j.ejpb.2019.01.006>
- Parveen S, Sahoo SK (2008) Polymeric nanoparticles for cancer therapy. *J Drug Target* 16(2): 108–123. <https://doi.org/10.1080/10611860701794353>
- Patra JK, Das G, Fraceto LF, Campos EVR, del Pilar R-TM, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S (2018) Nano based drug delivery systems: recent developments and future prospects. *J Nanobiotechnol* 16(1):1–33. <https://doi.org/10.1186/s12951-018-0392-8>
- Paul S, Bravo Vázquez LA, Pérez Uribe S, Roxana Reyes-Pérez P, Sharma A (2020) Current status of microRNA-based therapeutic approaches in neurodegenerative disorders. *Cell* 9(7):1698. <https://doi.org/10.3390/cells9071698>
- Pednekar PP, Godiyal SC, Jadhav KR, Kadam VJ (2017) Mesoporous silica nanoparticles: a promising multifunctional drug delivery system. In: Grumezescu AM, Ficaí A (eds) *Nanostructures for cancer therapy*. Elsevier, pp 593–621. <https://doi.org/10.1016/B978-0-323-46144-3.00023-4>
- Polyak K (2007) Breast cancer: origins and evolution. *J Clin Invest* 117(11):3155–3163. <https://doi.org/10.1172/JCI33295>
- Qian J, Xu M, Suo A, Xu W, Liu T, Liu X, Yao Y, Wang H (2015) Folate-decorated hydrophilic three-arm star-block terpolymer as a novel nanovehicle for targeted co-delivery of doxorubicin and Bcl-2 siRNA in breast cancer therapy. *Acta Biomater* 15:102–116. <https://doi.org/10.1016/j.actbio.2014.12.018>
- Rajani C, Borisa P, Karanwad T, Borade Y, Patel V, Rajpoot K, Tekade RK (2020) Cancer-targeted chemotherapy: emerging role of the folate anchored dendrimer as drug delivery nanocarrier. In: Chauhan AS, Kulhari H (eds) *Pharmaceutical applications of dendrimers*. Elsevier, pp 151–198. <https://doi.org/10.1016/B978-0-12-814527-2.00007-X>
- Redig AJ, McAllister SS (2013) Breast cancer as a systemic disease: a view of metastasis. *J Intern Med* 274(2):113–126. <https://doi.org/10.1111/joim.12084>
- Rivenbark AG, O'Connor SM, Coleman WB (2013) Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. *Am J Pathol* 183(4):1113–1124. <https://doi.org/10.1016/j.ajpath.2013.08.002>
- Samson AAS, Park S, Kim S-Y, Min D-H, Jeon NL, Song JM (2019) Liposomal co-delivery-based quantitative evaluation of chemosensitivity enhancement in breast cancer stem cells by knock-down of GRP78/CLU. *J Liposome Res* 29(1):44–52. <https://doi.org/10.1080/08982104.2017.>

- Seidel ZP, Zhang X, MacMullan MA, Graham NA, Wang P, Lee CT Jr (2020) Photo-triggered delivery of siRNA and paclitaxel into breast cancer cells using Catanionic vesicles. *ACS Appl Bio Mater* 3(11):7388–7398. <https://doi.org/10.1021/acsabm.0c00503>
- Sgroi DC (2010) Preinvasive breast cancer. *Annu Rev Pathol* 5:193–221. <https://doi.org/10.1146/annurev.pathol.4>
- Sharma GN, Dave R, Sanadya J, Sharma P, Sharma K (2010) Various types and management of breast cancer: an overview. *J Adv Pharm Technol Res* 1(2):109
- Sharma S, Pukale S, Sahel DK, Singh P, Mittal A, Chitkara D (2021) Folate targeted hybrid Lipopolymeric Nanoplexes containing Docetaxel and miRNA-34a for breast cancer treatment. *Mater Sci Eng C* 128:112305. <https://doi.org/10.1016/j.msec.2021.112305>
- Shen J, Sun H, Xu P, Yin Q, Zhang Z, Wang S, Yu H, Li Y (2013) Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles. *Biomaterials* 34(5):1581–1590. <https://doi.org/10.1016/j.biomaterials.2012.10.057>
- Shrestha B, Wang L, Zhang H, Hung CY, Tang L (2020) Gold nanoparticles mediated drug-gene combinational therapy for breast cancer treatment. *Int J Nanomedicine* 15:8109. <https://doi.org/10.2147/IJN.S258625>
- Sun Y-S, Zhao Z, Yang Z-N, Xu F, Lu H-J, Zhu Z-Y, Shi W, Jiang J, Yao P-P, Zhu H-P (2017) Risk factors and preventions of breast cancer. *Int J Biol Sci* 13(11):1387. <https://doi.org/10.7150/ijbs.21635>
- Sun X, Xu H, Huang T, Zhang C, Wu J, Luo S (2021) Simultaneous delivery of anti-miRNA and docetaxel with supramolecular self-assembled “chitosome” for improving chemosensitivity of triple negative breast cancer cells. *Drug Deliv Transl Res* 11(1):192–204. <https://doi.org/10.1007/s13346-020-00779-4>
- Suo A, Qian J, Zhang Y, Liu R, Xu W, Wang H (2016) Comb-like amphiphilic polypeptide-based copolymer nanomicelles for co-delivery of doxorubicin and P-gp siRNA into MCF-7 cells. *Mater Sci Eng C* 62:564–573. <https://doi.org/10.1016/j.msec.2016.02.007>
- Suo A, Qian J, Xu M, Xu W, Zhang Y, Yao Y (2017) Folate-decorated PEGylated triblock copolymer as a pH/reduction dual-responsive nanovehicle for targeted intracellular co-delivery of doxorubicin and Bcl-2 siRNA. *Mater Sci Eng C* 76:659–672. <https://doi.org/10.1016/j.msec.2017.03.124>
- Swami R, Kumar Y, Chaudhari D, Katiyar SS, Kuche K, Katore PB, Banerjee SK, Jain S (2020) pH sensitive liposomes assisted specific and improved breast cancer therapy using co-delivery of SIRT1 shRNA and Docetaxel. *Mater Sci Eng C* 120:111664. <https://doi.org/10.1016/j.msec.2020.111664>
- Sztandera K, Gorzkiewicz M, Klajnert-Maculewicz B (2018) Gold nanoparticles in cancer treatment. *Mol Pharm* 16(1):1–23. <https://doi.org/10.1021/acs.molpharmaceut.8b00810>
- Tang S, Yin Q, Zhang Z, Gu W, Chen L, Yu H, Huang Y, Chen X, Xu M, Li Y (2014) Co-delivery of doxorubicin and RNA using pH-sensitive poly (β -amino ester) nanoparticles for reversal of multidrug resistance of breast cancer. *Biomaterials* 35(23):6047–6059. <https://doi.org/10.1016/j.biomaterials.2014.04.025>
- Tang S, Yin Q, Su J, Sun H, Meng Q, Chen Y, Chen L, Huang Y, Gu W, Xu M (2015) Inhibition of metastasis and growth of breast cancer by pH-sensitive poly (β -amino ester) nanoparticles co-delivering two siRNA and paclitaxel. *Biomaterials* 48:1–15. <https://doi.org/10.1016/j.biomaterials.2015.01.049>
- Tashima T (2018) Effective cancer therapy based on selective drug delivery into cells across their

- membrane using receptor-mediated endocytosis. *Bioorg Med Chem Lett* 28(18):3015–3024. <https://doi.org/10.1016/j.bmcl.2018.07.012>
- Taxman DJ, Moore CB, Guthrie EH, Huang MT-H (2010) Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown. In: Sioud M (ed) *RNA therapeutics: methods in molecular biology*. Humana Press, pp 139–156. https://doi.org/10.1007/978-1-60761-657-3_10
- Waks AG, Winer EP (2019) Breast cancer treatment: a review. *JAMA* 321(3):288–300. <https://doi.org/10.1001/jama.2018.19323>
- Wang D, Wang T, Xu Z, Yu H, Feng B, Zhang J, Guo C, Yin Q, Zhang Z, Li Y (2016a) Cooperative treatment of metastatic breast cancer using host–guest nanoplatform coloaded with docetaxel and siRNA. *Small* 12(4):488–498. <https://doi.org/10.1002/smll.201502913>
- Wang S, Zhang J, Wang Y, Chen M (2016b) Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy. *Nanomomed Nanotechnol Biol Med* 12(2):411–420. <https://doi.org/10.1016/j.nano.2015.09.014>
- Wang S, Liu X, Chen S, Liu Z, Zhang X, Liang X-J, Li L (2018a) Regulation of Ca²⁺ signaling for drug-resistant breast cancer therapy with mesoporous silica nanocapsule encapsulated doxorubicin/siRNA cocktail. *ACS Nano* 13(1):274–283. <https://doi.org/10.1021/acsnano.8b05639>
- Wang W, Chen K, Su Y, Zhang J, Li M, Zhou J (2018b) Lysosome-independent intracellular drug/gene codelivery by lipoprotein-derived nanovector for synergistic apoptosis-inducing cancer-targeted therapy. *Biomacromolecules* 19(2):438–448. <https://doi.org/10.1021/acs.biomac.7b01549>
- Weigelt B, Geyer FC, Reis-Filho JS (2010) Histological types of breast cancer: how special are they? *Mol Oncol* 4(3):192–208. <https://doi.org/10.1016/j.molonc.2010.04.004>
- Xie X, Chen Y, Chen Z, Feng Y, Wang J, Li T, Li S, Qin X, Wu C, Zheng C (2019) Polymeric hybrid nanomicelles for cancer theranostics: an efficient and precise anticancer strategy for the codelivery of doxorubicin/miR-34a and magnetic resonance imaging. *ACS Appl Mater Interfaces* 11(47):43865–43878. <https://doi.org/10.1021/acsami.9b14908>
- Xu J, Chen Y, Olopade OI (2010) MYC and breast cancer. *Genes Cancer* 1(6):629–640. <https://doi.org/10.1177/1947601910378691>
- Xu M, Qian J, Suo A, Cui N, Yao Y, Xu W, Liu T, Wang H (2015) Co-delivery of doxorubicin and P-glycoprotein siRNA by multifunctional triblock copolymers for enhanced anticancer efficacy in breast cancer cells. *J Mater Chem B* 3(10):2215–2228. <https://doi.org/10.1039/C5TB00031A>
- Xu J, Sun J, Ho PY, Luo Z, Ma W, Zhao W, Rathod SB, Fernandez CA, Venkataramanan R, Xie W (2019a) Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis. *Biomaterials* 210:25–40. <https://doi.org/10.1016/j.biomaterials.2019.04.025>
- Xu X, Liu A, Bai Y, Li Y, Zhang C, Cui S, Piao Y, Zhang S (2019b) Co-delivery of resveratrol and p53 gene via peptide cationic liposomal nanocarrier for the synergistic treatment of cervical cancer and breast cancer cells. *J Drug Deliv Sci Technol* 51:746–753. <https://doi.org/10.1016/j.jddst.2018.05.008>
- Yadav D, Sandeep K, Pandey D, Dutta RK (2017) Liposomes for drug delivery. *J Biotechnol Biomater* 7(4):276. <https://doi.org/10.4172/2155-952X.1000276>
- Yaghoobi E, Shojaee S, Ramezani M, Alibolandi M, Charbgoos F, Nameghi MA, Khatami F, Ashjaei MS, Abnous K, Taghdisi SM (2021) A novel targeted co-delivery system for transfer of epirubicin and anti-miR-10b into cancer cells through a linear DNA nanostructure consisting of FOXM1 and AS1411 aptamers. *J Drug Deliv Sci Technol* 63:102521. <https://doi.org/10.1016/j.jddst.2021.102521>
- Yang H, Deng L, Li T, Shen X, Yan J, Zuo L, Wu C, Liu Y (2015) Multifunctional PLGA

- nanobubbles as theranostic agents: combining doxorubicin and P-gp siRNA co-delivery into human breast cancer cells and ultrasound cellular imaging. *J Biomed Nanotechnol* 11(12): 2124–2136. <https://doi.org/10.1166/jbn.2015.2168>
- Yang L, Tian Y, Leong WS, Song H, Yang W, Wang M, Wang X, Kong J, Shan B, Song Z (2018) Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro. *Breast Cancer Res* 20(1):1–13
- Yin T, Wang L, Yin L, Zhou J, Huo M (2015) Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer. *Biomaterials* 61:10–25. <https://doi.org/10.1016/j.biomaterials.2015.05.022>
- Yin PT, Pongkulapa T, Cho H-Y, Han J, Pasquale NJ, Rabie H, Kim J-H, Choi J-W, Lee K-B (2018) Overcoming chemoresistance in cancer via combined microRNA therapeutics with anticancer drugs using multifunctional magnetic core-shell nanoparticles. *ACS Appl Mater Interfaces* 10(32):26954–26963. <https://doi.org/10.1021/acsami.8b09086>
- Yu D, Lu J (2011) Breast cancer multistep development. In: Schwab M (ed) *Encyclopedia of cancer*. Springer, Berlin Heidelberg, pp 522–526
- Yu D, Li W, Zhang Y, Zhang B (2016a) Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment. *Biomed Pharmacother* 83:1428–1435. <https://doi.org/10.1016/j.biopha.2016.08.061>
- Yu H, Guo C, Feng B, Liu J, Chen X, Wang D, Teng L, Li Y, Yin Q, Zhang Z (2016b) Triple-layered pH-responsive micelleplexes loaded with siRNA and cisplatin prodrug for NF-Kappa B targeted treatment of metastatic breast cancer. *Theranostics* 6(1):14. <https://doi.org/10.7150/thno.13515>
- Yu S, Bi X, Yang L, Wu S, Yu Y, Jiang B, Zhang A, Lan K, Duan S (2019) Co-delivery of paclitaxel and PLK1-targeted siRNA using aptamer-functionalized cationic liposome for synergistic anti-breast cancer effects in vivo. *J Biomed Nanotechnol* 15(6):1135–1148. <https://doi.org/10.1166/jbn.2019.2751>
- Zhang D, Xu H, Hu M, Deng Y (2015) “PEG dilemma” for liposomes and its solving approaches. *Acta Pharm Sin* 50(3):252–260
- Zhang N, Huang Y, Wu F, Zhao Y, Li X, Shen P, Yang L, Luo Y, Yang L, He G (2016) Codelivery of a miR-124 mimic and obatoclax by cholesterol-penetratin micelles simultaneously induces apoptosis and inhibits autophagic flux in breast cancer in vitro and in vivo. *Mol Pharm* 13(7): 2466–2483. <https://doi.org/10.1021/acs.molpharmaceut.6b00211>
- Zhang L, Yang X, Lv Y, Xin X, Qin C, Han X, Yang L, He W, Yin L (2017a) Cytosolic co-delivery of miRNA-34a and docetaxel with core-shell nanocarriers via caveolae-mediated pathway for the treatment of metastatic breast cancer. *Sci Rep* 7(1):46186. <https://doi.org/10.1038/srep46186>
- Zhang L, Yang X, Li Y, Zheng W, Jiang X (2017b) Hollow carbon nanospheres as a versatile platform for co-delivery of siRNA and chemotherapeutics. *Carbon* 121:79–89. <https://doi.org/10.1016/j.carbon.2017.05.084>
- Zhang Q, Wang L, Jiang Y, Gao W, Wang Y, Yang X, Yang X, Liu Z (2017c) Gold nanorods with silica shell and PAMAM dendrimers for efficient photothermal therapy and low toxic codelivery of anticancer drug and siRNA. *Adv Mater Interfaces* 4(24):1701166. <https://doi.org/10.1002/admi.201701166>
- Zhao L, Zhao W, Liu Y, Chen X, Wang Y (2017) Nano-hydroxyapatite-derived drug and gene co-delivery system for anti-angiogenesis therapy of breast cancer. *Med Sci Monit* 23:4723–4732. <https://doi.org/10.12659/MSM.902538>
- Zhao Z, Li Y, Liu H, Jain A, Patel PV, Cheng K (2020) Co-delivery of IKBKE siRNA and

- cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer. *Sci Adv* 6(29):eabb0616. <https://doi.org/10.1126/sciadv.abb0616>
- Zhou X, Chen L, Nie W, Wang W, Qin M, Mo X, Wang H, He C (2016) Dual-responsive mesoporous silica nanoparticles mediated codelivery of doxorubicin and Bcl-2 SiRNA for targeted treatment of breast cancer. *J Phys Chem C* 120(39):22375–22387. <https://doi.org/10.1021/acs.jpcc.6b06759>
- Zhou Z, Kennell C, Lee J-Y, Leung Y-K, Tarapore P (2017) Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and miR-221/222 inhibitors. *Nanomed Nanotechnol Biol Med* 13(2):403–410. <https://doi.org/10.1016/j.nano.2016.07.016>
- Zhu W-j, C-xQ S-d Y, Zhu Q-I, Chen W-I, Li F, Yuan Z-q, Liu Y, You B-g, Zhang X-n (2017) Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor. *Int J Nanomedicine* 12:3375. <https://doi.org/10.2147/IJN.S126310>
- Zhuang J, Chen S, Hu Y, Yang F, Huo Q, Xie N (2021) Tumour-targeted and redox-responsive mesoporous silica nanoparticles for controlled release of doxorubicin and an siRNA against metastatic breast cancer. *Int J Nanomedicine* 16:1961. <https://doi.org/10.2147/IJN.S278724>
- Zolbanin NM, Jafari R, Majidi J, Atyabi F, Yousefi M, Jadidi-Niaragh F, Aghebati-Maleki L, Shanehbandi D, Zangbar M-SS, Nayebi AM (2018) Targeted co-delivery of docetaxel and cMET siRNA for treatment of mucin1 overexpressing breast cancer cells. *Adv Pharm Bull* 8(3): 383–393. <https://doi.org/10.15171/apb.2018.045>

第 12 章 针对乳腺癌的溶瘤病毒疗法

- Achard C, Surendran A, Wedge M-E, Ungerechts G, Bell J, Ilkow CS (2018) Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. *EBioMedicine* 31:17–24
- Admoun C, Mayrovitz HN (2022) The etiology of breast cancer. Exon Publications, pp 21–30
- Akhtar J, Shukla D (2009) Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. *FEBS J* 276:7228–7236
- Alberts P, Tilgase A, Rasa A, Bandere K, Venskus D (2018) The advent of oncolytic virotherapy in oncology: the Rigvir[®] story. *Eur J Pharmacol* 837:117–126
- Ang L, Guo L, Wang J, Huang J, Lou X, Zhao M (2020) Oncolytic virotherapy armed with an engineered interfering lncRNA exhibits antitumor activity by blocking the epithelial mesenchymal transition in triple-negative breast cancer. *Cancer Lett* 479:42–53
- Arulanandam R, Taha Z, Garcia V, Selman M, Chen A, Varette O, Jirovec A, Sutherland K, Macdonald E, Tzelepis F (2020) The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy. *Commun Biol* 3:254
- Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. *Nat Rev Cancer* 2:420–430
- Askari FS, Mohebbi A, Moradi A, Javid N (2021) The role of vesicular stomatitis virus matrix protein in autophagy in the breast cancer. *Asian Pac J Cancer Prevent APJCP* 22:249
- Au GG, Lincz LF, Enno A, Shafren DR (2007) Oncolytic coxsackievirus A21 as a novel therapy for multiple myeloma. *Br J Haematol* 137:133–141
- Balachandran S, Barber GN (2000) Vesicular stomatitis virus (VSV) therapy of tumors. *IUBMB Life* 50:135–138
- Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, Porten M, Herrmann I, Ristimäki A, Virkkunen P, Tarkkanen M (2008) Tissue-specific promoters active in CD44+ CD24–/low breast cancer cells. *Cancer Res* 68:5533–5539
- Bell JC, Lichty B, Stojdl D (2003) Getting oncolytic virus therapies off the ground. *Cancer Cell* 4: 7–11
- Bellanger M, Zeinomar N, Tehranifar P, Terry MB (2018) Are global breast cancer incidence and mortality patterns related to country-specific economic development and prevention strategies? *J Glob Oncol* 4:1
- Bergman I, Whitaker-Dowling P, Gao Y, Griffin JA (2004) Preferential targeting of vesicular stomatitis virus to breast cancer cells. *Virology* 330:24–33
- Bernstein V, Ellard S, Dent S, Tu D, Mates M, Dhesy-Thind S, Panasci L, Gelmon K, Salim M, Song X (2018) A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND. 213. *Breast Cancer Res Treat* 167:485–493
- Berry JT, Muñoz LE, Stewart RMR, Selvaraj P, Mainou BA (2020) Doxorubicin conjugation to reovirus improves oncolytic efficacy in triple-negative breast cancer. *Mol Ther -Oncolyt* 18: 556–572
- Bieler A, Mantwill K, Holzmüller R, Jürchott K, Kaszubiak A, Stärk S, Glockzin G, Lage H, Grosu A-L, Gansbacher B (2008) Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblastoma. *Radiother Oncol* 86:419–427

- Bourgeois-Daigneault M-C, St-Germain LE, Roy DG, Pelin A, Aitken AS, Arulanandam R, Falls T, Garcia V, Diallo J-S, Bell JC (2016) Combination of paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment. *Breast Cancer Res* 18:1–10
- Bourgeois-Daigneault M-C, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD (2018) Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. *Sci Transl Med* 10: eaao1641
- Bramante S, Koski A, Liikanen I, Vassilev L, Oksanen M, Siurala M, Heiskanen R, Hakonen T, Joensuu T, Kanerva A (2016) Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer. *Onco Targets Ther* 5:e1078057
- Breitbach CJ, Lichty BD, Bell JC (2016) Oncolytic viruses: therapeutics with an identity crisis. *EBioMedicine* 9:31–36
- Carter ME, Koch A, Lauer UM, Hartkopf AD (2021) Clinical trials of oncolytic viruses in breast cancer. *Front Oncol* 11:803050
- Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R (2006) Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. *Biochim Biophys Acta (BBA)-Rev Cancer* 1766:63–78
- Chalikonda S, Kivlen MH, O'Malley ME, McCart J, Gorry M, Yin X, Brown C, Zeh H, Guo Z, Bartlett D (2008) Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. *Cancer Gene Ther* 15:115–125
- Chaurasiya S, Fong Y (2021) Viroimmunotherapy for breast cancer: promises, problems and future directions. *Cancer Gene Ther* 28:757–768
- Chaurasiya S, Yang A, Kang S, Lu J, Kim S-I, Park AK, Sivanandam V, Zhang Z, Woo Y, Warner SG (2020) Oncolytic poxvirus CF33-hNIS- Δ F14. 5 favorably modulates tumor immune micro-environment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model. *Onco Targets Ther* 9:1729300
- Chen S, Li YQ, Yin XZ, Li SZ, Zhu YL, Fan YY, Li WJ, Cui YL, Zhao J, Li X (2019) Recombinant adenoviruses expressing apoptin suppress the growth of MCF-7 breast cancer cells and affect cell autophagy. *Oncol Rep* 41:2818–2832
- Cheng P-H, Lian S, Zhao R, Rao X-M, McMasters KM, Zhou HS (2013) Combination of autophagy inducer rapamycin and oncolytic adenovirus improves antitumor effect in cancer cells. *Virol J* 10:1–13
- Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, Ross BD, Rehemtulla A (2000) Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. *Proc Natl Acad Sci* 97:1754–1759
- Cody JJ, Hurst DR (2015) Promising oncolytic agents for metastatic breast cancer treatment. *Oncolyt Virother*:63–73
- De Matos AL, Franco LS, McFadden G (2020) Oncolytic viruses and the immune system: the dynamic duo. *Mol Ther -Methods Clin Dev* 17:349–358
- Denton NL, Chen C-Y, Scott TR, Cripe TP (2016) Tumor-associated macrophages in oncolytic virotherapy: friend or foe? *Biomedicine* 4:13
- Denton NL, Chen C-Y, Hutzen B, Currier MA, Scott T, Nartker B, Leddon JL, Wang P-Y, Srinivas R, Cassady KA (2018) Myelolytic treatments enhance oncolytic herpes virotherapy in models of Ewing sarcoma by modulating the immune microenvironment. *Mol Ther -Oncolyt* 11:62–74
- Dong X, Qu W, Ma S, Zhu Z, Zheng C, He A, Karlsson A, Xu K, Zheng X (2013) Potent

- antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo. *Cancer Lett* 328:95–103
- Ejaz M, Syed MA (2022) Therapeutic cancer vaccines; past, present, and future aspects. In: Rezaei N (ed) *Handbook of cancer and immunology*. Springer, Cham, pp 1–21
- Ejaz M, Javed S, Hamza M, Tabassum S, Abubakar M, Ullah I (2020) Fungal endophytes are effective alternatives and novel sources of anticancer drugs. *Punjab Univ J Zool* 35:13–24
- Engeland CE, Ungerechts G (2021) Measles virus as an oncolytic immunotherapy. *Cancers* 13:544
- Ferguson MS, Dunmall LSC, Gangeswaran R, Marelli G, Tysome JR, Burns E, Whitehead MA, Aksoy E, Alusi G, Hiley C (2020) Transient inhibition of PI3K δ enhances the therapeutic effect of intravenous delivery of oncolytic vaccinia virus. *Mol Ther* 28:1263–1275
- Fernandez M, Porosnicu M, Markovic D, Barber GN (2002) Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. *J Virol* 76: 895–904
- Filley AC, Dey M (2017) Immune system, friend or foe of oncolytic virotherapy? *Front Oncol* 7: 106
- Frazier VN, Holl E, Brown M, Boczkowski D, Landa K, Hwang S, Gromeier M, Nair SK (2020) Oncolytic poliovirus immunotherapy for breast cancer. *J Immunol* 204:249.225
- Gazit Y (1999) TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. *Leukemia* 13:1817–1824
- Gentshev I, Stritzker J, Hofmann E, Weibel S, Yu Y, Chen N, Zhang Q, Bullerdiek J, Nolte I, Szalay A (2009) Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent. *Cancer Gene Ther* 16:320–328
- Gholami S, Marano A, Chen NG, Aguilar RJ, Frentzen A, Chen C-H, Lou E, Fujisawa S, Eveno C, Belin L (2014) A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer. *Breast Cancer Res Treat* 148:489–499
- Ghouse SM, Nguyen H-M, Bommarreddy PK, Guz-Montgomery K, Saha D (2020) Oncolytic herpes simplex virus encoding IL12 controls triple-negative breast cancer growth and metastasis. *Front Oncol* 10:384
- Gil M, Seshadri M, Komorowski MP, Abrams SI, Kozbor D (2013) Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. *Proc Natl Acad Sci* 110:E1291–E1300
- Gonzalez-Angulo A, Blumenschein G Jr (2013) Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. *Cancer Treat Rev* 39:313–320
- Graat H, Witlox M, Schagen F, Kaspers G, Helder M, Bras J, Schaap G, Gerritsen W, Wuisman P, Van Beusechem V (2006) Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. *Br J Cancer* 94:1837–1844
- Guo ZS, Liu Z, Kowalsky S, Feist M, Kalinski P, Lu B, Storkus WJ, Bartlett DL (2017) Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives. *Front Immunol* 8:555
- Hanahan D, Weinberg RA (2000) The hallmarks of cancer. *Cell* 100:57–70
- Hartkopf AD, Fehm T, Wallwiener D, Lauer UM (2011) Oncolytic virotherapy of breast cancer. *Gynecol Oncol* 123:164–171
- Hartkopf A, Fehm T, Wallwiener M, Lauer U (2012) Oncolytic viruses to treat ovarian cancer patients – a review of results from clinical trials. *Tumor Diagnostik Ther* 33:279–283
- Hata Y, Etoh T, Inomata M, Shiraishi N, Nishizono A, Kitano S (2008) Efficacy of oncolytic reovirus against human breast cancer cells. *Oncol Rep* 19:1395–1398
- Hemminki O, Dos Santos JM, Hemminki A (2020) Oncolytic viruses for cancer immunotherapy.

- J Hematol Oncol 13:1–15
- Higginson IJ, Costantini M (2008) Dying with cancer, living well with advanced cancer. *Eur J Cancer* 44:1414–1424
- Hou F, Sun L, Zheng H, Skaug B, Jiang Q-X, Chen ZJ (2011) MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. *Cell* 146:448–461
- Iankov ID, Kurokawa CB, D’Assoro AB, Ingle JN, Domingo-Musibay E, Allen C, Crosby CM, Nair AA, Liu MC, Aderca I (2015) Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy. *Cancer Gene Ther* 22:438–444
- Ilkow CS, Swift SL, Bell JC, Diallo J-S (2014) From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer. *PLoS Pathog* 10:e1003836
- Jardé T, Perrier S, Vasson M-P, Caldefie-Chézet F (2011) Molecular mechanisms of leptin and adiponectin in breast cancer. *Eur J Cancer* 47:33–43
- Jin S, Wang Q, Wu H, Pang D, Xu S (2021) Oncolytic viruses for triple negative breast cancer and beyond. *Biomarker Res* 9:1–16
- Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. *Nat Rev Drug Discov* 14:642–662
- Kelly E, Russell SJ (2007) History of oncolytic viruses: genesis to genetic engineering. *Mol Ther* 15:651–659
- Kleibl Z, Kristensen VN (2016) Women at high risk of breast cancer: molecular characteristics, clinical presentation and management. *Breast* 28:136–144
- Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M (2021a) Macrophages mediate the antitumor effects of the oncolytic virus HSV1716 in mammary tumors. *Mol Cancer Ther* 20:589–601
- Kwan A, Winder N, Muthana M (2021b) Oncolytic virotherapy treatment of breast cancer: barriers and recent advances. *Viruses* 13:1128
- Lal G, Rajala MS (2019) Combination of oncolytic measles virus armed with BNiP3, a pro-apoptotic gene and paclitaxel induces breast cancer cell death. *Front Oncol* 8:676
- Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A, Reid TR (2015) Going viral: a review of replication-selective oncolytic adenoviruses. *Oncotarget* 6:19976
- Lawler SE, Speranza M-C, Cho C-F, Chiocca EA (2017) Oncolytic viruses in cancer treatment: a review. *JAMA Oncol* 3:841–849
- Lei S, Zheng R, Zhang S, Wang S, Chen R, Sun K, Zeng H, Zhou J, Wei W (2021) Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. *Cancer Commun* 41:1183–1194
- Leoni V, Gatta V, Palladini A, Nicoletti G, Ranieri D, Dall’Ora M, Grosso V, Rossi M, Alviano F, Bonsi L (2015) Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases. *Oncotarget* 6:34774
- Leveille S, Samuel S, Goulet M, Hiscott J (2011) Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. *Cancer Gene Ther* 18:435–443
- Li Y, Xiao F, Zhang A, Zhang D, Nie W, Xu T, Han B, Seth P, Wang H, Yang Y (2020) Oncolytic adenovirus targeting TGF- β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer. *Cell Immunol* 348:104041
- Liikanen I, Tähtinen S, Guse K, Gutmann T, Savola P, Oksanen M, Kanerva A, Hemminki A (2016) Oncolytic adenovirus expressing monoclonal antibody trastuzumab for treatment of HER2-positive cancer. *Mol Cancer Ther* 15:2259–2269
- Lin Y, Wang W, Wan J, Yang Y, Fu W, Pan D, Cai L, Cheng T, Huang X, Wang Y (2018) Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines. *Virol J*

15:1–12

- Liu R, Varghese S, Rabkin SD (2005) Oncolytic herpes simplex virus vector therapy of breast cancer in C3 (1)/SV40 T-antigen transgenic mice. *Cancer Res* 65:1532–1540
- Liu T-C, Galanis E, Kim D (2007) Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. *Nat Clin Pract Oncol* 4:101–117
- Marcato P, Dean CA, Giacomantonio CA, Lee PW (2009) Oncolytic reovirus effectively targets breast cancer stem cells. *Mol Ther* 17:972–979
- Marchini A, Daeffler L, Pozdeev VI, Angelova A, Rommelaere J (2019) Immune conversion of tumor microenvironment by oncolytic viruses: the protoparvovirus H-1PV case study. *Front Immunol* 10:1848
- Marelli G, Howells A, Lemoine NR, Wang Y (2018) Oncolytic viral therapy and the immune system: a double-edged sword against cancer. *Front Immunol* 9:866
- Marra A, Viale G, Curigliano G (2019) Recent advances in triple negative breast cancer: the immunotherapy era. *BMC Med* 17:1–9
- Martini V, D'Avanzo F, Maggiora PM, Varughese FM, Sica A, Gennari A (2020) Oncolytic virotherapy: new weapon for breast cancer treatment. *ecancermedicallscience* 14:14
- Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. *Science* 252:854–856
- Matveeva OV, Chumakov PM (2018) Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses. *Rev Med Virol* 28:e2008
- McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, Moss B, Bartlett DL (2001) Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. *Cancer Res* 61:8751–8757
- McCart JA, Mehta N, Scollard D, Reilly RM, Carrasquillo JA, Tang N, Deng H, Miller M, Xu H, Libutti SK (2004) Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using ¹¹¹In-pentetreotide. *Mol Ther* 10:553–561
- McDonald CJ, Erlichman C, Ingle JN, Rosales GA, Allen C, Greiner SM, Harvey ME, Zollman PJ, Russell SJ, Galanis E (2006) A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. *Breast Cancer Res Treat* 99:177–184
- Menotti L, Cerretani A, Hengel H, Campadelli-Fiume G (2008) Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. *J Virol* 82:10153–10161
- Mohamed Amin Z, Che Ani MA, Tan SW, Yeap SK, Alitheen NB, Syed Najmuddin SUF, Kalyanasundram J, Chan SC, Veerakumarasivam A, Chia SL (2019) Evaluation of a recombinant Newcastle disease virus expressing human IL12 against human breast cancer. *Sci Rep* 9:13999
- Mostafa AA, Meyers DE, Thirukkumaran CM, Liu PJ, Gratton K, Spurrell J, Shi Q, Thakur S, Morris DG (2018) Oncolytic reovirus and immune checkpoint inhibition as a novel immunotherapeutic strategy for breast cancer. *Cancers* 10:205
- Mühlebach MD, Mateo M, Sinn PL, Prüfer S, Uhlig KM, Leonard VH, Navaratnarajah CK, Frenzke M, Wong XX, Sawatsky B (2011) Adherens junction protein nectin-4 is the epithelial receptor for measles virus. *Nature* 480:530–533
- Nemunaitis J, Senzer N, Sarmiento S, Zhang Y, Arzaga R, Sands B, Maples P, Tong A (2007) A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients. *Cancer Gene Ther* 14:885–893
- Niavarani S-R, Lawson C, Boudaud M, Simard C, Tai L-H (2020) Oncolytic vesicular stomatitis virus – based cellular vaccine improves triple-negative breast cancer outcome by enhancing

- natural killer and CD8+ T-cell functionality. *J Immunother Cancer* 8
- Nielsen LL, Dell J, Maxwell E, Armstrong L, Maneval D, Catino JJ (1997) Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. *Cancer Gene Ther* 4:129–138
- Niemann J, Woller N, Brooks J, Fleischmann-Mundt B, Martin NT, Kloos A, Knocke S, Ernst AM, Manns MP, Kubicka S (2019) Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy. *Nat Commun* 10:3236
- Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, Strong JE, Lee PW (2002) Reovirus oncolysis of human breast cancer. *Hum Gene Ther* 13:641–652
- O'Bryan SM, Mathis JM (2018) Oncolytic virotherapy for breast cancer treatment. *Curr Gene Ther* 18:192–205
- Otani Y, Yoo JY, Shimizu T, Kurozumi K, Date I, Kaur B (2022) Implications of immune cells in oncolytic herpes simplex virotherapy for glioma. *Brain Tumor Pathol* 39:57–64
- Ottolino-Perry K, Diallo J-S, Lichty BD, Bell JC, McCart JA (2010) Intelligent design: combination therapy with oncolytic viruses. *Mol Ther* 18:251–263
- Pak-Wittel MA, Yang L, Sojka DK, Rivenbark JG, Yokoyama WM (2013) Interferon- γ mediates chemokine-dependent recruitment of natural killer cells during viral infection. *Proc Natl Acad Sci* 110:E50–E59
- Paplomata E, O'Regan R (2014) The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. *Therapeutic advances in medical oncology* 6:154–166
- Perez MC, Miura JT, Naqvi SMH, Kim Y, Holstein A, Lee D, Sarnaik AA, Zager JS (2018) Talimogene laherparepvec (TVEC) for the treatment of advanced melanoma: a single-institution experience. *Ann Surg Oncol* 25:3960–3965
- Printz C (2016) FDA approves new treatment of metastatic melanoma. *Cancer* 122:1149–1149
- Redig AJ, McAllister SS (2013) Breast cancer as a systemic disease: a view of metastasis. *J Intern Med* 274:113–126
- Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RH, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E (2017) Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. *Cell* 170:1109–1119.e1110
- Roberts KL, Smith GL (2008) Vaccinia virus morphogenesis and dissemination. *Trends Microbiol* 16:472–479
- Roth JA (2006) Adenovirus p53 gene therapy. *Expert Opin Biol Ther* 6:55–61
- Russell SJ, Peng K-W (2007) Viruses as anticancer drugs. *Trends Pharmacol Sci* 28:326–333
- Russell SJ, Peng K-W, Bell JC (2012) Oncolytic virotherapy. *Nat Biotechnol* 30:658–670
- Sahin TT, Kasuya H, Nomura N, Shikano T, Yamamura K, Gewen T, Kanzaki A, Fujii T, Sugae T, Imai T (2012) Impact of novel oncolytic virus HF10 on cellular components of the tumor microenvironment in patients with recurrent breast cancer. *Cancer Gene Ther* 19:229–237
- Sarkar D, Su Z-z, Vozhilla N, Park ES, Gupta P, Fisher PB (2005) Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. *Proc Natl Acad Sci* 102:14034–14039
- Schneeweiss A, Ruckhäberle E, Huober J (2015) Chemotherapy for metastatic breast cancer—an anachronism in the era of personalised and targeted oncological therapy? *Geburtshilfe Frauenheilkd* 75:574–583
- Seubert C, Stritzker J, Hess M, Donat U, Sturm J, Chen N, von Hof JM, Krewer B, Tietze LF, Gentschev I (2011) Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β -galactosidase-activatable prodrug seco-analog of duocarmycin SA. *Cancer Gene Ther* 18:42–52

- Shin DH, Nguyen T, Ozpolat B, Lang F, Alonso M, Gomez-Manzano C, Fueyo J (2021) Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy. *J Immunother Cancer* 9:e002086
- Skelding KA, Barry RD, Shafren DR (2009) Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21. *Breast Cancer Res Treat* 113:21–30
- Smith GL, Vanderplasschen A, Law M (2002) The formation and function of extracellular enveloped vaccinia virus. *J Gen Virol* 83:2915–2931
- Smolarz B, Nowak AZ, Romanowicz H (2022) Breast cancer – epidemiology, classification, pathogenesis and treatment (review of literature). *Cancers* 14:2569
- Sugiyama T, Yoneda M, Kuraishi T, Hattori S, Inoue Y, Sato H, Kai C (2013) Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment. *Gene Ther* 20:338–347
- Sun Y-S, Zhao Z, Yang Z-N, Xu F, Lu H-J, Zhu Z-Y, Shi W, Jiang J, Yao P-P, Zhu H-P (2017) Risk factors and preventions of breast cancer. *Int J Biol Sci* 13:1387
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 71:209–249
- Suryawanshi YR, Zhang T, Essani K (2017) Oncolytic viruses: emerging options for the treatment of breast cancer. *Med Oncol* 34:1–11
- Tan G, Kasuya H, Sahin TT, Yamamura K, Wu Z, Koide Y, Hotta Y, Shikano T, Yamada S, Kanzaki A (2015) Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft. *Int J Cancer* 136:1718–1730
- Tatsuo H, Ono N, Tanaka K, Yanagi Y (2000) SLAM (CDw150) is a cellular receptor for measles virus. *Nature* 406:893–897
- Teshigahara O, Goshima F, Takao K, Kohno S, Kimata H, Nakao A, Nishiyama Y (2004) Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10. *J Surg Oncol* 85: 42–47
- Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, Wold WS (2008) Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. *Mol Ther* 16:1665–1673
- Tian Y, Xie D, Yang L (2022) Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. *Signal Transduct Target Ther* 7:117
- Umer BA, Noyce RS, Franczak BC, Shenouda MM, Kelly RG, Favis NA, Desaulniers M, Baldwin TA, Hitt MM, Evans DH (2020) Deciphering the immunomodulatory capacity of oncolytic vaccinia virus to enhance the immune response to breast cancer. *Cancer Immunol Res* 8:618–631
- Wang H, Chen NG, Minev BR, Szalay AA (2012) Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells. *J Transl Med* 10:1–15
- Wang G, Kang X, Chen KS, Jehng T, Jones L, Chen J, Huang XF, Chen S-Y (2020) An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. *Nat Commun* 11:1395
- Wu Y, He J, An Y, Wang X, Liu Y, Yan S, Ye X, Qi J, Zhu S, Yu Q (2016) Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy. *J Pharmacol Sci* 132:24–30
- Wu S, Zhu W, Thompson P, Hannun YA (2018) Evaluating intrinsic and non-intrinsic cancer risk

- factors. *Nat Commun* 9:3490
- Xu W, Yang Y, Hu Z, Head M, Mangold KA, Sullivan M, Wang E, Saha P, Gulukota K, Helseth DL (2020) LyP-1-modified oncolytic adenoviruses targeting transforming growth factor β inhibit tumor growth and metastases and augment immune checkpoint inhibitor therapy in breast cancer mouse models. *Hum Gene Ther* 31:863–880
- Yan Y, Xu H, Wang J, Wu X, Wen W, Liang Y, Wang L, Liu F, Du X (2019) Inhibition of breast cancer cells by targeting E2F-1 gene and expressing IL15 oncolytic adenovirus. *Biosci Rep* 39: BSR20190384
- Yang W, Senger D, Lun X, Muzik H, Shi Z, Dyck R, Norman K, Brasher P, Rewcastle N, George D (2004) Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. *Gene Ther* 11:1579–1589
- Yu W, Fang H (2007) Clinical trials with oncolytic adenovirus in China. *Curr Cancer Drug Targets* 7:141–148
- Yu J, Mu Q, Fung M, Xu X, Zhu L, Ho RJ (2022) Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. *Pharmacol Ther* 236:108108
- Zhang J, Ramesh N, Chen Y, Li Y, Dilley J, Working P, Yu D-C (2002) Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. *Cancer Res* 62:3743–3750
- Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, Marincola FM, Szalay AA (2007) Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. *Cancer Res* 67:10038–10046
- Zhu W, Wei L, Zhang H, Chen J, Qin X (2012) Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo. *J Exp Clin Cancer Res* 31:1–10
- Zhu W, Zhang H, Shi Y, Song M, Zhu B, Wei L (2013) Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer. *Cancer Biol Ther* 14:1016–1023
- Zou H, Mou XZ, Zhu B (2023) Combining of oncolytic Virotherapy and other immunotherapeutic approaches in cancer: a powerful functionalization tactic. *Global Chall* 7:2200094

第 13 章 克服乳腺癌对靶向、化疗和免疫疗法的耐药性:克服耐药性和促进药物开发的机制与策略

- Abbasian MH, Ardekani AM, Sobhani N, Roudi R (2022) The role of genomics and proteomics in lung cancer early detection and treatment. *Cancers (Basel)* 14:5144
- Abu Samaan TM, Samec M, Liskova A, Kubatka P, Büsselberg D (2019) Paclitaxel's mechanistic and clinical effects on breast cancer. *Biomol Ther* 9:789
- Adachi A, Yamashita T, Kanaya S, Kosugi Y (2023) Ensemble machine learning approaches based on molecular descriptors and graph convolutional networks for predicting the efflux activities of MDR1 and BCRP transporters. *AAPS J* 25:88
- Adrienne GW, Tanya EK, Tianyu L, Nabihah T, Gerburg MW, Edward TR III, Victoria A, Leilani A, Elizabeth AM, Beth O, Eric PW, Ian EK, Judith A, Eliezer MVA, Sara MT (2022) Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. *J Immunother Cancer* 10:e005119
- Ajabnoor GMA, Crook T, Coley HM (2012) Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells. *Cell Death Dis* 3:e260–e260
- Ali S, Rasool M, Chaoudhry H, Pushparaj PN, Jha P, Hafiz A, Mahfooz M, Abdus Sami G, Azhar Kamal M, Bashir S, Ali A, Sarwar Jamal M (2016) Molecular mechanisms and mode of tamoxifen resistance in breast cancer. *Bioinformation* 12:135–139
- Aman NA, Doukoure B, Koffi KD, Kouli BS, Traore ZC, Kouyate M, Effi AB (2019) HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women. *BMC Clin Pathol* 19:1
- Andrahennadi S, Sami A, Haider K, Chalchal HI, Le D, Ahmed O, Manna M, El-Gayed A, Wright P, Ahmed S (2021) Efficacy of Fulvestrant in women with hormone-resistant metastatic breast cancer (mBC): a Canadian Province experience. *Cancers (Basel)* 13:4163
- André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, Rubovszky G, Yamashita T, Kaufman B, Lu YS, Inoue K, Pápai Z, Takahashi M, Ghaznawi F, Mills D, Kaper M, Miller M, Conte PF, Iwata H, Rugo HS (2021) Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. *Ann Oncol* 32:208–217
- André F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, Lima JP, Aksoy S, Gavila Gregori J, De Laurentiis M, Bianchini G, Roylance R, Miyoshi Y, Armstrong A, Sinha R, Ruiz Borrego M, Lim E, Ettl J, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Gambhire D, Cathcart J, Wu C, Chu C, Egorov A, Krop I (2023) Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. *Lancet* 401:1773–1785
- Arcaro A, Guerreiro AS (2007) The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. *Curr Genomics* 8:271–306
- Arpino G, Wiechmann L, Osborne CK, Schiff R (2008) Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. *Endocr Rev* 29:217–233
- Azzahra SNA, Hanif N, Hermawan A (2022) MDM2 is a potential target gene of glycyrrhizic acid for circumventing breast cancer resistance to tamoxifen: integrative bioinformatics analysis. *Asian Pac J Cancer Prev* 23:2341–2350

- Bachelot T, Garcia-Saenz JA, Verma S, Gutierrez M, Pivot X, Kozloff MF, Prady C, Huang X, Khosravan R, Wang Z, Cesari R, Tassell V, Kern KA, Blay JY, Lluch A (2014) Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. *BMC Cancer* 14:166
- Baird RD, van Rossum AGJ, Oliveira M, Beelen K, Gao M, Schrier M, Mandjes IAM, Garcia-Corbacho J, Vallier AL, Dougall G, van Werkhoven E, Linossi C, Kumar S, van Tinteren H, Callari M, Beddowes E, Perez-Garcia JM, Rosing H, Platte E, Nederlof P, Schot M, de Vries SA, Bernards R, Saura C, Gallagher W, Cortès J, Caldas C, Linn SC (2019) POSEIDON trial phase 1b results: safety, efficacy and circulating tumor DNA response of the beta isoform-sparing PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor positive metastatic breast cancer patients. *Clin Cancer Res* 25:6598–6605
- Ballhausen A, Wheler JJ, Karp DD, Piha-Paul SA, Fu S, Pant S, Tsimberidou AM, Hong DS, Subbiah V, Holley VR, Huang HJ, Brewster AM, Koenig KB, Ibrahim NK, Meric-Bernstam F, Janku F (2021) Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors. *Clin Cancer Res* 27:1247–1255
- Baselga J, Im S-A, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiello-Gruszczyk A, Pistilli B, Tseng L-M (2015) PIK3CA status in circulating tumor DNA predicts efficacy of buparlisib plus fulvestrant in postmenopausal women with endocrine-resistant HR+/HER2–advanced breast cancer: first results from the randomized, phase III BELLE-2 trial. *Proceedings of the 38th annual San Antonio breast cancer symposium, San Antonio*
- Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiello-Gruszczyk A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M (2017) Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 18:904–916
- Basu A, Krishnamurthy S (2010) Cellular responses to cisplatin-induced DNA damage. *J Nucleic Acids* 2010:201367
- Bellmunt J, Paz-Ares L, Cuello M, Cecere F, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, De la Cruz J (2007) Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. *Ann Oncol* 18:522–528
- Blackwell KL, Zaman K, Qin S, Tkaczuk KHR, Campone M, Hunt D, Bryce R, Goldstein LJ (2019) Neratinib in combination with trastuzumab for the treatment of patients with advanced HER2-positive breast cancer: a phase I/II study. *Clin Breast Cancer* 19:97–104.e104
- Bomane A, Gonçalves A, Ballester PJ (2019) Paclitaxel response can be predicted with interpretable multi-variate classifiers exploiting DNA-methylation and miRNA data. *Front Genet* 10:1041
- Bos MK, Lam SW, Motta G, Helmijs JCA, Beaufort CM, de Jonge E, Martens JWM, Boven E, Jansen M, Jager A, Sleijfer S (2023) Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer. *Breast Cancer Res Treat* 200:271–279
- Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, Fornander T, Nordenskjöld B, Stål O (2013) Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. *Breast Cancer Res Treat* 137:397–406
- Brabec V (2002) DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. *Prog Nucleic Acid Res Mol Biol* 71:1
- Braun L, Mietzsch F, Seibold P, Schneeweiss A, Schirmacher P, Chang-Claude J, Sinn HP,

- Aulmann S (2013) Intrinsic breast cancer subtypes defined by estrogen receptor signalling—prognostic relevance of progesterone receptor loss. *Mod Pathol* 26:1161–1171
- Breugom AJ, Swets M, Bosset J-F, Collette L, Sainato A, Cionini L, Glynne-Jones R, Counsell N, Bastiaannet E, van den Broek CB (2015) Adjuvant chemotherapy after preoperative (chemo) radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. *Lancet Oncol* 16:200–207
- Brown A, Kumar S, Tchounwou PB (2019) Cisplatin-based chemotherapy of human cancers. *J Cancer Sci Ther* 11(4):97
- Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. *Am J Clin Oncol* 39:98–106
- Bydoun M, Marcato P, Dellaire G (2014) Breast cancer genomics. Elsevier, Cancer genomics, pp 213–232
- Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J (2018) Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: overall survival results from BELLE-2. *Eur J Cancer* 103:147–154
- Cappetta D, De Angelis A, Sapio L, Prezioso L, Illiano M, Quaini F, Rossi F, Berrino L, Naviglio S, Urbanek K (2017) Oxidative stress and cellular response to doxorubicin: a common factor in the complex milieu of anthracycline cardiotoxicity. *Oxidative Med Cell Longev* 2017:1521020
- Cha HK, Cheon S, Kim H, Lee KM, Ryu HS, Han D (2022) Discovery of proteins responsible for resistance to three chemotherapy drugs in breast cancer cells using proteomics and bioinformatics analysis. *Molecules* 27(6):1762
- Chaganty BKR, Qiu S, Gest A, Lu Y, Ivan C, Calin GA, Weiner LM, Fan Z (2018) Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN γ secretion. *Cancer Lett* 430:47–56
- Chia SK, Ellard SL, Mates M, Welch S, Mihalcioiu C, Miller WH Jr, Gelmon K, Lohrisch C, Kumar V, Taylor S, Hagerman L, Goodwin R, Wang T, Sakashita S, Tsao MS, Eisenhauer E, Bradbury P (2017) A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. *Breast Cancer Res* 19:54
- Chia SKL, Bedard PL, Hilton J, Amir E, Gelmon KA, Goodwin RA, Villa D, Cabanero M, Ritter H, Tu D, Tsao MS, Seymour L (2018) A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686]. *J Clin Oncol* 36:1029–1029
- Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, Leahy DJ (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. *Nature* 421:756–760
- Christowitz C, Davis T, Isaacs A, van Niekerk G, Hattingh S, Engelbrecht AM (2019) Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model. *BMC Cancer* 19:757
- Ciruelos E, Villagrasa P, Pascual T, Oliveira M, Pernas S, Paré L, Escrivá-de-Romaní S, Manso L, Adamo B, Martínez E, Cortés J, Vazquez S, Perelló A, Garau I, Melé M, Martínez N, Montaña A, Bermejo B, Morales S, Echarri MJ, Vega E, González-Farré B, Martínez D, Galván P, Canes J, Nuciforo P, Gonzalez X, Prat A (2020) Palbociclib and trastuzumab in HER2-positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA trial.

Clin Cancer Res 26:5820–5829

- Ciszewski WM, Tavecchio M, Dastyh J, Curtin NJ (2014) DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. *Breast Cancer Res Treat* 143:47–55
- Clarke R, Tyson JJ, Dixon JM (2015) Endocrine resistance in breast cancer—an overview and update. *Mol Cell Endocrinol* 418:220–234
- Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn H-J, Members P, André F (2015) Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015. *Ann Oncol* 26:1533–1546
- Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P, Investigators K (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. *Lancet* 396:1817–1828
- Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im S-A, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol* 17:425–439
- Cui S, Feng J, Tang X, Lou S, Guo W, Xiao X, Li S, Chen X, Huan Y, Zhou Y, Xiao L (2023) The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients. *Eur J Med Res* 28:90
- Curigliano G, Dunton K, Rosenlund M, Janek M, Cathcart J, Liu Y, Fasching PA, Iwata H (2023) Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study. *Ann Oncol* 34:569–577
- deGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW, Weiss GR (2004) NF- κ B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. *Ann Oncol* 15:885–890
- Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Ware JA (2016) A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC). *Am Soc Clin Oncol* 34:520
- DiMarco AV, Qin X, McKinney BJ, Garcia NMG, Van Alsten SC, Mendes EA, Force J, Hanks BA, Troester MA, Owzar K, Xie J, Alvarez JV (2022) APOBEC mutagenesis inhibits breast cancer growth through induction of T cell-mediated antitumor immune responses. *Cancer Immunol Res* 10:70–86
- Droog M, Beelen K, Linn S, Zwart W (2013) Tamoxifen resistance: from bench to bedside. *Eur J Pharmacol* 717:47–57
- Dusenbery AC, Maniaci JL, Hillerson ND, Dill EA, Bullock TN, Mills AM (2021) MHC class I loss in triple-negative breast cancer: a potential barrier to PD-1/PD-L1 checkpoint inhibitors. *Am J Surg Pathol* 45:701–707
- Duz MB, Karatas OF (2021) Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for paclitaxel resistance in human epithelial type 2 cells. *Mol Biol Rep* 48:1393–1400
- Dziadyk JM, Sui M, Zhu X, Fan W (2004) Paclitaxel-induced apoptosis may occur without a prior

G2/M-phase arrest. *Anticancer Res* 24:27–36

- Egelston CA, Guo W, Yost SE, Ge X, Lee JS, Frankel PH, Cui Y, Ruel C, Schmolze D, Murga M, Tang A, Martinez N, Karimi M, Somlo G, Lee PP, Waisman JR, Yuan Y (2023) Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer. *Cancer Immunol Immunother* 72:3013–3027
- Entwistle RA, Winefield RD, Foland TB, Lushington GH, Himes RH (2008) The paclitaxel site in tubulin probed by site-directed mutagenesis of *Saccharomyces cerevisiae* β -tubulin. *FEBS Lett* 582:2467–2470
- Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O’Leary P, Holmes FA, Espina V, Liotta LA, O’Shaughnessy J, Gallagher C, O’Driscoll L, Rani S, Madden SF, O’Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O’Donovan N, Crown J (2018) Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclox and TRAIL. *BMC Cancer* 18:965
- Fan W, Chang J, Fu P (2015) Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. *Future Med Chem* 7:1511–1519
- Fang X, Cao J, Shen A (2020) Advances in anti-breast cancer drugs and the application of nano-drug delivery systems in breast cancer therapy. *J Drug Deliv Sci Technol* 57:101662
- Fasching PA, Hein A, Kolberg HC, Häberle L, Uhrig S, Rübner M, Belleville E, Hack CC, Fehm TN, Janni W, Hartmann A, Erber R, Theuser AK, Brucker SY, Hartkopf AD, Untch M (2023) Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – a single-arm phase II trial (NeoImmunoboost, AGO-B-041). *Eur J Cancer* 184:1–9
- Fattori S, Le Roy A, Houacine J, Robert L, Abes R, Gorvel L, Granjeaud S, Rouviere MS, Ben Amara A, Boucherit N, Tarpin C, Pakradouni J, Charafe-Jauffret E, Houvenaeghel G, Lambaudie E, Bertucci F, Rochigneux P, Goncalves A, Foussat A, Chretien AS, Olive D (2023) CD25high effector regulatory T cells hamper responses to PD-1 blockade in triple-negative breast cancer. *Cancer Res* 83:3026–3044
- Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, Ji X, Liu W, Huang B, Luo W (2018) Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis* 5:77–106
- Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. *Biochemistry* 24:707–713
- Fisusi FA, Akala EO (2019) Drug combinations in breast cancer therapy. *Pharm Nanotechnol* 7: 3–23
- Fribbens C, O’Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S (2016) Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer
- Fumoleau P, Koch KM, Brain E, Lokiec F, Rezai K, Awada A, Hayward L, Werutsky G, Bogaerts J, Marréaud S, Cardoso F (2014) A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study). *Breast* 23:663–669
- Gadgeel SM, Lew DL, Synold TW, LoRusso P, Chung V, Christensen SD, Smith DC, Kingsbury L, Hoering A, Kurzrock R (2013) Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. *Cancer Chemother Pharmacol* 72:1089–1096
- Gajria D, Chandarlapaty S (2011) HER2-amplified breast cancer: mechanisms of trastuzumab

- resistance and novel targeted therapies. *Expert Rev Anticancer Ther* 11:263–275
- Gala K, Chandarlapaty S (2014) Molecular pathways: HER3 targeted therapy. *Clin Cancer Res* 20:1410–1416
- Gao C, Li H, Liu C, Xu X, Zhuang J, Zhou C, Liu L, Feng F, Sun C (2021) Tumor mutation burden and immune invasion characteristics in triple negative breast cancer: genome high-throughput data analysis. *Front Immunol* 12:650491
- Gautam P, Jaiswal A, Aittokallio T, Al-Ali H, Wennerberg K (2019) Phenotypic screening combined with machine learning for efficient identification of breast cancer-selective therapeutic targets. *Cell Chem Biol* 26:970–979.e974
- Giessrigl B, Schmidt WM, Kalipciyan M, Jeitler M, Bilban M, Gollinger M, Krieger S, Jäger W, Mader RM, Krupitza G (2013) Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. *Br J Cancer* 109:2751–2762
- Giuliano M, Trivedi MV, Schiff R (2013) Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. *Breast Care (Basel)* 8:256–262
- Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, Contreras A, Gutierrez C, Wang T, Hilsenbeck SG, De Angelis C, Wang NJ, Heiser LM, Gray JW, Lopez-Tarruella S, Pavlick AC, Trivedi MV, Chamness GC, Chang JC, Osborne CK, Rimawi MF, Schiff R (2015) Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy. *Clin Cancer Res* 21:3995–4003
- Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N (2009) Triple-negative breast cancer—current status and future directions. *Ann Oncol* 20:1913–1927
- Gluz O, Nitz UA, Christgen M, Kuemmel S, Holtschmidt J, Schumacher J, Hartkopf A, Potenberg J, Lüdtke-Heckenkamp K, Just M, Schem C, von Schumann R, Kolberg-Liedtke C, Eulenburg CZ, Schinköthe T, Graeser M, Wuerstlein R, Kates RE, Kreipe HH, Harbeck N (2023) Efficacy of endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy in patients with hormone receptor-positive/ERBB2-positive early breast cancer: the neoadjuvant WSG-TP-II randomized clinical trial. *JAMA Oncol* 9:946–954
- Goetz MP, Okera M, Wildiers H, Campone M, Grischke EM, Manso L, André VAM, Chouaki N, San Antonio B, Toi M, Sledge GW Jr (2021) Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. *Breast Cancer Res Treat* 186:417–428
- Goldenson B, Crispino JD (2015) The aurora kinases in cell cycle and leukemia. *Oncogene* 34:537–545
- Gomes I, de Almeida BP, Dâmaso S, Mansinho A, Correia I, Henriques S, Cruz-Duarte R, Vilhais G, Félix P, Alves P, Corredeira P, Barbosa-Morais NL, Costa L, Casimiro S (2020) Expression of receptor activator of NFκB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer. *Oncotarget* 11:1714
- Gómez Tejeda Zañudo J, Mao P, Alcon C, Kowalski K, Johnson GN, Xu G, Baselga J, Scaltriti M, Letai A, Montero J, Albert R, Wagle N (2021) Cell line-specific network models of ER(+) breast cancer identify potential PI3Kα inhibitor resistance mechanisms and drug combinations. *Cancer Res* 81:4603–4617
- Graham PJ, Brar MS, Foster T, McCall M, Bouchard-Fortier A, Temple W, Quan ML (2015) Neoadjuvant chemotherapy for breast cancer, is practice changing? A population-based review of current surgical trends. *Ann Surg Oncol* 22:3376–3382

- Grandits M, Ecker GF (2023) Ligand- and structure-based approaches for transmembrane transporter modeling. *Curr Drug Res Rev* 15
- Guarneri V, Dieci MV, Griguolo G, Miglietta F, Girardi F, Bisagni G, Generali DG, Cagossi K, Sarti S, Frassoldati A, Gianni L, Cavanna L, Pinotti G, Musolino A, Piacentini F, Cinieri S, Prat A, Conte P (2021) Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: survival analyses of the CHER-Lob trial. *Eur J Cancer* 153:133–141
- Guo S, Sonenshein GE (2004) Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. *Mol Cell Biol* 24:8681–8690
- Gutierrez C, Schiff R (2011) HER2: biology, detection, and clinical implications. *Arch Pathol Lab Med* 135:55–62
- Haddad TC, Suman VJ, D’Assoro AB, Carter JM, Giridhar KV, McMenomy BP, Santo K, Mayer EL, Karuturi MS, Morikawa A, Marcom PK, Isaacs CJ, Oh SY, Clark AS, Mayer IA, Keyomarsi K, Hobday TJ, Peethambaram PP, O’Sullivan CC, Leon-Ferre RA, Liu MC, Ingle JN, Goetz MP (2023) Evaluation of alisertib alone or combined with fulvestrant in patients with endocrine-resistant advanced breast cancer: the phase 2 TBCRC041 randomized clinical trial. *JAMA Oncol* 9:815–824
- Haley B, Batra K, Sahoo S, Froehlich T, Klemow D, Unni N, Ahn C, Rodriguez M, Hullings M, Frankel AE (2021) A phase I/Ib trial of PD 0332991 (palbociclib) and T-DM1 in HER2-positive advanced breast cancer after trastuzumab and taxane therapy. *Clin Breast Cancer* 21:417–424
- Hanna K, Mayden K (2021) Chemotherapy treatment considerations in metastatic breast cancer. *J Adv Pract Oncol* 12:6–12
- Hanusch C, Schneeweiss A, Loibl S, Untch M, Paepke S, Kümmel S, Jackisch C, Huober J, Hilfrich J, Gerber B, Eidtmann H, Denkert C, Costa S, Blohmer JU, Engels K, Burchardi N, von Minckwitz G (2015) Dual blockade with Afatinib and trastuzumab as NEOadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy-DAFNE (GBG-70). *Clin Cancer Res* 21:2924–2931
- Hany D, Zoetemelk M, Bhattacharya K, Nowak-Sliwinska P, Picard D (2023) Network-informed discovery of multidrug combinations for ER α +/HER2-/PI3K α -mutant breast cancer. *Cell Mol Life Sci* 80:80
- Hari M, Loganzo F, Annable T, Tan X, Musto S, Morilla DB, Nettles JH, Snyder JP, Greenberger LM (2006) Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β -tubulin (Asp26Glu) and less stable microtubules. *Mol Cancer Ther* 5:270–278
- Hermawan A, Wagner E, Roidl A (2016) Consecutive salinomycin treatment reduces doxorubicin resistance of breast tumor cells by diminishing drug efflux pump expression and activity. *Oncol Rep* 35:1732–1740
- Hermawan A, Putri H, Utomo RY (2020) Comprehensive bioinformatics study reveals targets and molecular mechanism of hesperetin in overcoming breast cancer chemoresistance. *Mol Divers* 24:933–947
- Hermawan A, Putri H, Utomo R (2021) Exploration of targets and molecular mechanisms of cinnamaldehyde in overcoming fulvestrant-resistant breast cancer: a bioinformatics study. *Network Model Anal Health Inf Bioinf* 10:30
- Hermawan A, Putri H, Hanif N, Fatimah N, Prasetyo HH (2022) Identification of potential target genes of honokiol in overcoming breast cancer resistance to tamoxifen. *Front Oncol* 12:1019025
- Herrmann F, Lehr HA, Drexler I, Sutter G, Hengstler J, Wollscheid U, Seliger B (2004) HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. *Cancer Res* 64:215–220

- Hickish T, Mehta A, Liu MC, Huang CS, Arora RS, Chang YC, Yang Y, Vladimirov V, Jain M, Tsang J, Pemberton K, Sadrolhefazi B, Jin X, Tseng LM (2022) Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial. *Breast Cancer Res Treat* 192:593–602
- Holzer AK, Manorek GH, Howell SB (2006) Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. *Mol Pharmacol* 70: 1390–1394
- Howell SJ, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, Meissner M, Bale C, Bezecny P, Moon S, Twelves C, Venkitaraman R, Waters S, de Bruin EC, Schiavon G, Foxley A, Jones RH (2022) Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. *Lancet Oncol* 23:851–864
- Hsu JL, Hung MC (2016) The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. *Cancer Metastasis Rev* 35:575–588
- Huang BE, Mulyasasmita W, Rajagopal G (2016) The path from big data to precision medicine. *Expert Rev Precis Med Drug Dev* 1:129–143
- Huang D, Yang F, Wang Y, Guan X (2017) Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer. *Biochimica et Biophysica Acta (BBA) – Reviews on Cancer* 1868:148–156
- Huang JF, Wen CJ, Zhao GZ, Dai Y, Li Y, Wu LX, Zhou HH (2018) Overexpression of ABCB4 contributes to acquired doxorubicin resistance in breast cancer cells in vitro. *Cancer Chemother Pharmacol* 82:199–210
- Huang D, Tang L, Yang F, Jin J, Guan X (2019) PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer. *Am J Transl Res* 11:6055–6065
- Huang S, Hu P, Lakowski TM (2021) Predicting breast cancer drug response using a multiple-layer cell line drug response network model. *BMC Cancer* 21:648
- Hudis CA (2007) Trastuzumab--mechanism of action and use in clinical practice. *N Engl J Med* 357:39–51
- Huzil JT, Chen K, Kurgan L, Tuszynski JA (2007) The roles of beta-tubulin mutations and isotype expression in acquired drug resistance. *Cancer Inform* 3:159–181
- Hwang S-Y, Park S, Kwon Y (2019) Recent therapeutic trends and promising targets in triple negative breast cancer. *Pharmacol Ther* 199:30–57
- Ibadurrahman W, Hanif N, Hermawan A (2022) Functional network analysis of p85 and PI3K as potential gene targets and mechanism of oleanolic acid in overcoming breast cancer resistance to tamoxifen. *J Genet Eng Biotechnol* 20:66
- Imyanitov E, Sokolenko A (2021) Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors. *World J Clin Oncol* 12:544
- Infante T, Del Viscovo L, De Rimini ML, Padula S, Caso P, Napoli C (2020) Network medicine: a clinical approach for precision medicine and personalized therapy in coronary heart disease. *J Atheroscler Thromb* 27:279–302
- Inoue M, Mimura K, Izawa S, Shiraishi K, Inoue A, Shiba S, Watanabe M, Maruyama T, Kawaguchi Y, Inoue S, Kawasaki T, Choudhury A, Katoh R, Fujii H, Kiessling R, Kono K (2012) Expression of MHC class I on breast cancer cells correlates inversely with HER2 expression. *Onco Targets Ther* 1:1104–1110
- Jia Y, Zhang C, Zhou L, Xu H, Shi Y, Tong Z (2015) Micheliolide overcomes KLF4-mediated

- cisplatin resistance in breast cancer cells by downregulating glutathione. *Onco Targets Ther* 8: 2319–2327
- Jiang D, Lei T, Wang Z, Shen C, Cao D, Hou T (2020) ADMET evaluation in drug discovery. 20. Prediction of breast cancer resistance protein inhibition through machine learning. *J Cheminform* 12:16
- Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, Press MF, Tjulandin S, Iwata H, Simon SD, Kenny S, Sarp S, Izquierdo MA, Williams LS, Gradishar WJ (2021) Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE. *J Clin Oncol* 39:79–89
- Juric D, Janku F, Rodón J, Burris HA, Mayer IA, Schuler M, Seggewiss-Bernhardt R, Gil-Martin M, Middleton MR, Baselga J, Bootle D, Demanse D, Blumenstein L, Schumacher K, Huang A, Quadt C, Rugo HS (2019) Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial. *JAMA Oncol* 5:e184475
- Kaklamani VG, Gradishar WJ (2003) Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? *Clin Breast Cancer* 4:S26–S33
- Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. *J Clin Invest* 112:1776–1784
- Kaminska K, Akrap N, Staaf J, Alves C, Ehinger A, Ebbesson A, Hedenfalk I, Beumers L, Veerla S, Harbst K, Ehmsen S, Borgquist S, Borg A, Perez-Fidalgo JA, Ditzel H, Bosch A, Honeth G (2021) Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. *Breast Cancer Res* 23:26
- Kaneko K, Ishigami S, Kijima Y, Funasako Y, Hirata M, Okumura H, Shinchi H, Koriyama C, Ueno S, Yoshinaka H, Natsugoe S (2011) Clinical implication of HLA class I expression in breast cancer. *BMC Cancer* 11:454
- Kanthala S, Mill CP, Riese DJ 2nd, Jaiswal M, Jois S (2016) Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells. *Protein Expr Purif* 125:26–33
- Kaplan BL, Norell H, Callender GG, Ohlum T, Kiessling R, Nishimura MI (2006) Interferon-gamma renders tumors that express low levels of her-2/neu sensitive to cytotoxic T cells. *Cancer Immunol Immunother* 55:653–662
- Kasaian J, Mosaffa F, Behravan J, Masullo M, Piacente S, Iranshahi M (2016) Modulation of multidrug resistance protein 2 efflux in the cisplatin resistance human ovarian carcinoma cells A2780/RCIS by sesquiterpene coumarins. *Phytother Res* 30:84–89
- Keenan TE, Li T, Vallius T, Guerriero JL, Tayob N, Kochupurakkal B, Davis J, Pastorello R, Tahara RK, Anderson L, Conway J, He MX, Shannon E, Godin RE, Sorger PK, D'Andrea A, Overmoyer B, Winer EP, Mittendorf EA, Van Allen EM, Shapiro GI, Tolane SM (2021) Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer. *Clin Cancer Res* 27: 983–991
- Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, Park J, Lee JH, Oh DY, Im SA, Bang YJ, Kim TY (2009) Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. *PLoS One* 4:e5933
- Koca E, Niravath PA, Ensor J, Patel TA, Li X, Hemati P, Wong H, Qian W, Boone T, Zhao J, Ramshesh PV, Cohen AL, Murthy A, Nair S, Darcourt JG, Belcheva A, Kaklamani VG, Chang

- JCN (2021) ANETT: PhAse II trial of NEoadjuvant TAK-228 plus tamoxifen in patients with hormone receptor-positive breast cancer. *Breast Cancer Res Treat* 188:433–439
- Kornblum N, Manola J, Klein P, Ramaswamy B, Brufsky A, Stella P (2017) PrECOG 0102: a randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy. *Cancer Res* 77:S1–02
- Kumar R, George B, Campbell MR, Verma N, Paul AM, Melo-Alvim C, Ribeiro L, Pillai MR, da Costa LM, Moasser MM (2020) HER family in cancer progression: from discovery to 2020 and beyond. *Adv Cancer Res* 147:109–160
- Kutuk O, Letai A (2008) Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. *Cancer Res* 68:7985–7994
- Latorre E, Tebaldi T, Viero G, Spartà AM, Quattrone A, Provenzani A (2012) Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells. *Mol Cancer* 11:13
- Lavasani SM, Somlo G, Yost SE, Frankel PH, Ruel C, Cui Y, Murga M, Tang A, Martinez N, Kruper L, Tumyan L, Schmolze D, Yeon C, Yuan Y, Waisman JR, Mortimer J (2023) Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer. *Cancer* 129:740–749
- Le DT, Bui LT, Nguyen CV, Do KH, Tran GL, Do TA (2023) Neoadjuvant doxorubicin-paclitaxel combined chemotherapy in patients with inoperable stage III breast cancer: a retrospective cohort study with 10 years of follow-up in Vietnam. *Oncol Ther* 11:327–341
- Ledys F, Kalfeist L, Galland L, Limagne E, Ladoire S (2021) Therapeutic associations comprising anti-PD-1/PD-L1 in breast cancer: clinical challenges and perspectives. *Cancers (Basel)* 13:5999
- Leenhardt F, Alexandre M, Jacot W (2021) Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer. *Expert Opin Pharmacother* 22:667–675
- Li G, Zhao L, Li W, Fan K, Qian W, Hou S, Wang H, Dai J, Wei H, Guo Y (2014) Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. *Oncotarget* 5:8317–8329
- Li S, Li C, Jin S, Liu J, Xue X, Eltahan AS, Sun J, Tan J, Dong J, Liang X-J (2017) Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo. *Biomaterials* 144:119–129
- Li K, Du Y, Li L, Wei D-Q (2020) Bioinformatics approaches for anti-cancer drug discovery. *Curr Drug Targets* 21:3–17
- Li CL, Moi SH, Lin HS, Hou MF, Chen FM, Shih SL, Kan JY, Kao CN, Wu YC, Kao LC, Chen YH, Lee YC, Chiang CP (2022) Comprehensive transcriptomic and proteomic analyses identify a candidate gene set in cross-resistance for endocrine therapy in breast cancer. *Int J Mol Sci* 23(18):10539
- Li Y, Qi L, Wang Y, Zhao X, Lv S, Feng Y, Liu C, Li P, Xiong B, Guo Y, Lv D, Liu Y, Mao T, Yuan K, Cheng X, Li Y, Wang X (2023a) Safety, tolerability, pharmacokinetics and immunogenicity of an antibody-drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study. *Anti-Cancer Drugs* 34:763–774
- Li R, Sant S, Brown E, Caramia F, Nikolic B, Clarke K, Byrne A, Lara Gonzalez LE, Savas P, Luen SJ, Teo ZL, Virassamy B, Neeson PJ, Darcy PK, Loi S (2023b) Tucatinib promotes immune activation and synergizes with programmed cell death-1 and programmed cell death-ligand 1 inhibition in HER2-positive breast cancer. *J Natl Cancer Inst* 115:805–814
- Liu PC, Liu X, Li Y, Covington M, Wynn R, Huber R, Hillman M, Yang G, Ellis D, Marando C,

- Katiyar K, Bradley J, Abremski K, Stow M, Rupar M, Zhuo J, Li YL, Lin Q, Burns D, Xu M, Zhang C, Qian DQ, He C, Sharief V, Weng L, Agrios C, Shi E, Metcalf B, Newton R, Friedman S, Yao W, Scherle P, Hollis G, Burn TC (2006) Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. *Cancer Biol Ther* 5:657–664
- Liu Z, Shi A, Song D, Han B, Zhang Z, Ma L, Liu D, Fan Z (2017) Resistin confers resistance to doxorubicin-induced apoptosis in human breast cancer cells through autophagy induction. *Am J Cancer Res* 7:574–583
- Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, Andre F, International Breast Cancer Study G, the Breast International G (2019) Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. *Lancet Oncol* 20:371–382
- Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA, Masuda N, Loi S, André F, Harbeck N, Verma S, Folkert E, Puyana Theall K, Hoffman J, Zhang K, Bartlett CH, Dowsett M (2017) Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. *Oncologist* 22:1028–1038
- Lollini PL, Nicoletti G, Landuzzi L, De Giovanni C, Rossi I, Di Carlo E, Musiani P, Muller WJ, Nanni P (1998) Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. *Int J Cancer* 77:937–941
- Lovitt CJ, Shelper TB, Avery VM (2018) Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins. *BMC Cancer* 18:41
- Lu YS, Im SA, Colleoni M, Franke F, Bardia A, Cardoso F, Harbeck N, Hurvitz S, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, O'Regan R, Gasch C, Solovieff N, Wang C, Wang Y, Chakravarty A, Ji Y, Tripathy D (2022) Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR +/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. *Clin Cancer Res* 28:851–859
- Łukasiewicz S, Czezelewski M, Forma A, Baj J, Sitarz R, Stanisławek A (2021) Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. *Cancers (Basel)* 13:4287
- Luque-Cabal M, García-Tejido P, Fernández-Pérez Y, Sánchez-Lorenzo L, Palacio-Vázquez I (2016) Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it. *Clin Med Insights Oncol* 10:21–30
- Ma CX, Sanchez C, Gao F, Crowder R, Naughton M, Pluard T, Creekmore A, Guo Z, Hoog J, Lockhart AC, Doyle A, Erlichman C, Ellis MJ (2016) A phase I study of the AKT inhibitor MK-2206 in combination with hormonal therapy in postmenopausal women with estrogen receptor-positive metastatic breast cancer. *Clin Cancer Res* 22:2650–2658
- Ma J, Chen C, Liu S, Ji J, Wu D, Huang P, Wei D, Fan Z, Ren L (2022) Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis. *Cancer Gene Ther* 29:1578–1589
- Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla J-P, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T (2013) Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. *Lancet Oncol* 14:72–80

- Mao Y, Lv M, Zhang Y, Nie G, Cui J, Wang Y, Wang Y, Cao W, Liu X, Wang X, Wang H (2020) APOBEC3B expression and its prognostic potential in breast cancer. *Oncol Lett* 19:3205–3214
- Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E (2014) PI3K/AKT signaling pathway and cancer: an updated review. *Ann Med* 46:372–383
- Matikas A, Johansson H, Grybäck P, Bjöhle J, Acs B, Boyaci C, Lekberg T, Fredholm H, Elinder E, Margolin S, Isaksson-Friman E, Bosch A, Lindman H, Adra J, Andersson A, Agartz S, Hellström M, Zerdes I, Hartman J, Bergh J, Hatschek T, Foukakis T (2023) Survival outcomes, digital TILs, and on-treatment PET/CT during neoadjuvant therapy for HER2-positive breast cancer: results from the randomized PREDIX HER2 trial. *Clin Cancer Res* 29:532–540
- Maximov PY, Lee TM, Jordan VC (2013) The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. *Curr Clin Pharmacol* 8:135–155
- McCart Reed AE, Kalita-De Croft P, Kutasovic JR, Saunus JM, Lakhani SR (2019) Recent advances in breast cancer research impacting clinical diagnostic practice. *J Pathol* 247:552–562
- Medina MA, Oza G, Sharma A, Arriaga L, Hernández Hernández JM, Rotello VM, Ramirez JT (2020) Triple-negative breast cancer: a review of conventional and advanced therapeutic strategies. *Int J Environ Res Public Health* 17:2078
- Mercogliano MF, De Martino M, Venturutti L, Rivas MA, Proietti CJ, Inurrigarro G, Frahm I, Allemand DH, Deza EG, Ares S, Gercovich FG, Guzmán P, Roa JC, Elizalde PV, Schillaci R (2017) TNF α -induced mucin 4 expression elicits trastuzumab resistance in HER2-positive breast cancer. *Clin Cancer Res* 23:636–648
- Meredith A-M, Dass CR (2016) Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism. *J Pharm Pharmacol* 68:729–741
- Miller TW, Balko JM, Arteaga CL (2011a) Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. *J Clin Oncol* 29:4452
- Miller TW, Rexer BN, Garrett JT, Arteaga CL (2011b) Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. *Breast Cancer Res* 13:1–12
- Mitra D, Mitra D, Bensaad MS, Sinha S, Pant K, Pant M, Priyadarshini A, Singh P, Dassamiour S, Hambaba L (2022) Evolution of bioinformatics and its impact on modern bio-science in the twenty-first century: special attention to pharmacology, plant science and drug discovery. *Comput Toxicol* 24:100248
- Moerkens M, Zhang Y, Wester L, van de Water B, Meerman JH (2014) Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation. *BMC Cancer* 14:283
- Moo TA, Sanford R, Dang C, Morrow M (2018) Overview of breast cancer therapy. *PET Clin* 13:339–354
- Mottini C, Napolitano F, Li Z, Gao X, Cardone L (2019) Computer-aided drug repurposing for cancer therapy: approaches and opportunities to challenge anticancer targets, vol 68. *Semin Cancer Biol*, p 59
- Muhammad J, Khan A, Ali A, Fang L, Yanjing W, Xu Q, Wei D-Q (2018) Network pharmacology: exploring the resources and methodologies. *Curr Top Med Chem* 18:949–964
- Mukherjee A, Dhadda A, Shehata M, Chan S (2007) Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer. *Expert Opin Pharmacother* 8:2189–2204
- Munzone E, Colleoni M (2018) Optimal management of luminal breast cancer: how much endocrine therapy is long enough? *Ther Adv Med Oncol* 10:1758835918777437
- Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C (2012) Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. *Cancer Treat*

- Musolino A, Boggiani D, Pellegrino B, Zanoni D, Sikokis A, Missale G, Silini EM, Maglietta G, Frassoldati A, Michiara M (2020) Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer. *Crit Rev Oncol Hematol* 149: 102927
- Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung M-C, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. *Cancer Cell* 6: 117–127
- Němcová-Fürstová V, Kopperová D, Balušíková K, Ehrlichová M, Brynychová V, Václavíková R, Daniel P, Souček P, Kovář J (2016) Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters. *Toxicol Appl Pharmacol* 310:215–228
- Nguyen LC, Naulaerts S, Bruna A, Ghislat G, Ballester PJ (2021) Predicting cancer drug response in vivo by learning an optimal feature selection of tumour molecular profiles. *Biomedicines* 9:1319
- Nicolini A, Ferrari P, Kotlarova L, Rossi G, Biava M (2015) The PI3K-AKt-mTOR pathway and new tools to prevent acquired hormone resistance in breast cancer. *Curr Pharm Biotechnol* 16: 804–815
- Nicolini A, Ferrari P, Duffy MJ (2018) Prognostic and predictive biomarkers in breast cancer: past, present and future, *Seminars in cancer biology*, vol 52. Elsevier, p 56
- Nikolai BC, Lanz RB, York B, Dasgupta S, Mitsiades N, Creighton CJ, Tsimelzon A, Hilsenbeck SG, Lonard DM, Smith CL, O'Malley BW (2016) HER2 signaling drives DNA anabolism and proliferation through SRC-3 phosphorylation and E2F1-regulated genes. *Cancer Res* 76: 1463–1475
- Niu B, Zhou Y, Liao K, Wen T, Lao S, Quan G, Pan X, Wu C (2022) “Pincer movement”: reversing cisplatin resistance based on simultaneous glutathione depletion and glutathione S-transferases inhibition by redox-responsive degradable organosilica hybrid nanoparticles. *Acta Pharm Sin B* 12:2074–2088
- Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. *Annu Rev Med* 62:233–247
- Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M (2011) Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. *Clin Cancer Res* 17:1147–1159
- Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC (2007) Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. *Int J Oncol* 30:509–520
- Paananen J, Fortino V (2020) An omics perspective on drug target discovery platforms. *Brief Bioinform* 21:1937–1953
- Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, Kurek R, Vega-Valle E, Feigenbaum L, Halverson D, Vortmeyer AO, Steinberg SM, Aldape K, Steeg PS (2007) Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. *Cancer Res* 67:4190–4198
- Pandolfi PP (2004) Breast cancer—loss of PTEN predicts resistance to treatment. *N Engl J Med* 351:2337–2338
- Pang H, Hu Z (2023) Metabolomics in drug research and development: the recent advances in technologies and applications. *Acta Pharm Sin B* 13:3238–3251
- Pang X, Fu W, Wang J, Kang D, Xu L, Zhao Y, Liu AL, Du GH (2018) Identification of estrogen

- receptor α antagonists from natural products via in vitro and in silico approaches. *Oxidative Med Cell Longev* 2018:6040149
- Park JH, Kang MJ, Ahn JH, Kim JE, Jung KH, Gong G, Lee HJ, Son BH, Ahn SH, Kim HH, Shin HJ, Moon DH, Kim SB (2016) Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [neo-ALL-IN]: highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers. *Cancer Chemother Pharmacol* 78:685–695
- Park YH, Kim TY, Kim GM, Kang SY, Park IH, Kim JH, Lee KE, Ahn HK, Lee MH, Kim HJ, Kim HJ, Lee JI, Koh SJ, Kim JY, Lee KH, Sohn J, Kim SB, Ahn JS, Im YH, Jung KH, Im SA (2019) Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. *Lancet Oncol* 20:1750–1759
- Patel L, Shukla T, Huang X, Ussery DW, Wang S (2020) Machine learning methods in drug discovery. *Molecules* 25:5277
- Patil S, Gupta AD (2022) Bioinformatics and its application in computing biological data. *Information retrieval in bioinformatics: a practical approach*. Springer, pp 133–154
- Perez EA (1998) Paclitaxel in breast cancer. *Oncologist* 3:373–389
- Pircher M, Mlineritsch B, Fridrik MA, Dittrich C, Lang A, Petru E, Weltermann A, Thaler J, Hufnagl C, Gampenrieder SP, Rinnerthaler G, Ressler S, Ulmer H, Greil R (2015) Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial. *Anticancer Res* 35:517–521
- Poornima P, Kumar JD, Zhao Q, Blunder M, Efferth T (2016) Network pharmacology of cancer: from understanding of complex interactomes to the design of multi-target specific therapeutics from nature. *Pharmacol Res* 111:290–302
- Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, Díez M, Viladot M, Arance A, Muñoz M (2015) Clinical implications of the intrinsic molecular subtypes of breast cancer. *Breast* 24: S26–S35
- Qian T, Zhu S, Hoshida Y (2019) Use of big data in drug development for precision medicine: an update. *Expert Rev Precis Med Drug Dev* 4:189–200
- Rago RP, Einstein A Jr, Lush R, Beer TM, Ko YJ, Henner WD, Bubley G, Merica EA, Garg V, Ette E, Harding MW, Dalton WS (2003) Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. *Cancer Chemother Pharmacol* 51:297–305
- Rahman MH, Rana HK, Peng S, Kibria MG, Islam MZ, Mahmud SH, Moni MA (2021) Bioinformatics and system biology approaches to identify pathophysiological impact of COVID-19 to the progression and severity of neurological diseases. *Comput Biol Med* 138:104859
- Reel PS, Reel S, Pearson E, Trucco E, Jefferson E (2021) Using machine learning approaches for multi-omics data analysis: a review. *Biotechnol Adv* 49:107739
- Reslan L, Dalle S, Dumontet C (2009) Understanding and circumventing resistance to anticancer monoclonal antibodies. *MAbs* 1:222–229
- Riggins RB, Zwart A, Nehra R, Clarke R (2005) The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. *Mol Cancer Ther* 4:33–41
- Rimawi MF, Niravath P, Wang T, Rexer BN, Forero A, Wolff AC, Nanda R, Storniolo AM, Krop I, Goetz MP, Nangia JR, Jiralerspong S, Pavlick A, Veeraraghavan J, De Angelis C, Gutierrez C,

- Schiff R, Hilsenbeck SG, Osborne CK (2020) TBCRC023: a randomized phase II neoadjuvant trial of lapatinib plus trastuzumab without chemotherapy for 12 versus 24 weeks in patients with HER2-positive breast cancer. *Clin Cancer Res* 26:821–827
- Rinkenbaugh AL, Baldwin AS (2016) The NF- κ B pathway and cancer stem cells. *Cells* 5:16
- Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, Harris S, Shah RR, Resnick MA, Getz G, Gordenin DA (2013) An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. *Nat Genet* 45:970–976
- Rocca A, Maltoni R, Bravaccini S, Donati C, Andreis D (2018) Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence. *Cancer Manag Res* 10:3083–3099
- Rocha CRR, Silva MM, Quinet A, Cabral-Neto JB, Menck CFM (2018) DNA repair pathways and cisplatin resistance: an intimate relationship. *Clinics* 73:e478s
- Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, Goldstein L, Tripathy D, Brown-Glaberman UA, Huynh TT, Szyarto CS, Godwin AK, Pathak HB, Swisher EM, Radke MR, Timms KM, Lew DL, Miao J, Pusztai L, Hayes DF, Hortobagyi GN (2023) Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol* 24:162–174
- Røssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Falk RS, Russnes HG, Jahr T, Mathiesen RR, Lømo J, Garred Ø, Chauhan SK, Lereim RR, Dunn C, Naume B, Kyte JA (2022) Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. *Nat Med* 28:2573–2583
- Rossi L, McCartney A, De Santo I, Risi E, Moretti E, Malorni L, Biganzoli L, Di Leo A (2019) The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: a concise review. *Cancer Treat Rev* 74:29–34
- Safaei R, Otani S, Larson BJ, Rasmussen ML, Howell SB (2008) Transport of cisplatin by the copper efflux transporter ATP7B. *Mol Pharmacol* 73:461–468
- Saha Detroja T, Detroja R, Mukherjee S, Samson AO (2022) Identifying hub genes associated with neoadjuvant chemotherapy resistance in breast cancer and potential drug repurposing for the development of precision medicine. *Int J Mol Sci* 23(20):12628
- Saha T, Lukong KE (2022) Breast cancer stem-like cells in drug resistance: a review of mechanisms and novel therapeutic strategies to overcome drug resistance. *Front Oncol* 12:856974
- Sahu R, Pattanayak SP (2020) Strategic developments & future perspective on gene therapy for breast cancer: role of mTOR and Brk/PTK6 as molecular targets. *Curr Gene Ther* 20:237–258
- Santa-Maria CA, Kato T, Park JH, Kiyotani K, Rademaker A, Shah AN, Gross L, Blanco LZ, Jain S, Flaum L, Tellez C, Stein R, Uthe R, Gradishar WJ, Cristofanilli M, Nakamura Y, Giles FJ (2018) A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. *Oncotarget* 9:18985–18996
- Saxon ML, Lee DC (1999) Mutagenesis reveals a role for epidermal growth factor receptor extracellular subdomain IV in ligand binding. *J Biol Chem* 274(40):28356–28362. <https://doi.org/10.1074/jbc.274.40.28356>
- Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J, Baselga J (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. *J Natl Cancer Inst* 99:628–638
- Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green SR, Mai S,

- Rosen N, Hudis C, Baselga J (2011) Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. *Proc Natl Acad Sci USA* 108: 3761–3766
- Schärer OD (2005) DNA interstrand crosslinks: natural and drug-induced DNA adducts that induce unique cellular responses. *Chembiochem* 6:27–32
- Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA, Investigators IMT (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med* 379:2108–2121
- Schoeberl A, Gutmann M, Theiner S, Corte-Rodríguez M, Braun G, Vician P, Berger W, Koellensperger G (2022) The copper transporter CTR1 and cisplatin accumulation at the single-cell level by LA-ICP-TOFMS. *Front Mol Biosci* 9:1055356
- Schöffski P, Cresta S, Mayer IA, Wildiers H, Damian S, Gendreau S, Rooney I, Morrissey KM, Spoerke JM, Ng VW, Singel SM, Winer E (2018) A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. *Breast Cancer Res* 20:109
- Schoumacher M, Burbridge M (2017) Key roles of AXL and MER receptor tyrosine kinases in resistance to multiple anticancer therapies. *Curr Oncol Rep* 19:1–14
- Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J (2011) PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. *Oncogene* 30:2547–2557
- Shah D, Osipo C (2016) Cancer stem cells and HER2 positive breast cancer: the story so far. *Genes Dis* 3:114–123
- Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. *Cell* 168:707–723
- Shi X, Wang J, Lei Y, Cong C, Tan D, Zhou X (2019) Research progress on the PI3K/AKT signaling pathway in gynecological cancer (review). *Mol Med Rep* 19:4529–4535
- Siddiqui AJ, Jahan S, Patel M, Abdelgadir A, Alturaiki W, Bardakci F, Sachidanandan M, Badraoui R, Snoussi M, Adnan M (2023) Identifying novel and potent inhibitors of EGFR protein for the drug development against the breast cancer. *J Biomol Struct Dyn* 41:1–13
- Singh V, Afshan T, Tyagi P, Varadwaj PK, Sahoo AK (2023) Recent development of multi-targeted inhibitors of human topoisomerase II enzyme as potent cancer therapeutics. *Int J Biol Macromol* 226:473–484
- Skolastika S, Hanif N, Ikawati M, Hermawan A (2022) Comprehensive computational analysis of honokiol targets for cell cycle inhibition and immunotherapy in metastatic breast cancer stem cells. *Evid Based Complement Alternat Med* 2022:4172531
- Sleire L, Forde HE, Netland IA, Leiss L, Skeie BS, Enger PO (2017) Drug repurposing in cancer. *Pharmacol Res* 124:74–91
- Smart E, Semina SE, Frasor J (2020) Update on the role of NFκB in promoting aggressive phenotypes of estrogen receptor-positive breast cancer. *Endocrinology* 161(10):bqaa152
- Smith BN, Bhowmick NA (2016) Role of EMT in metastasis and therapy resistance. *J Clin Med* 5(2):17
- Stefanski CD, Keffler K, McClintock S, Milac L, Prosperi JR (2019) APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells. *Neoplasia* 21:1143–1150
- Stine ZE, Schug ZT, Salvino JM, Dang CV (2022) Targeting cancer metabolism in the era of precision oncology. *Nat Rev Drug Discov* 21:141–162

- Sui M, Huang Y, Park BH, Davidson NE, Fan W (2007) Estrogen receptor α mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. *Cancer Res* 67:5337–5344
- Sun R, Ge W, Zhu Y, Sayad A, Luna A, Lyu M, Liang S, Tobalina L, Rajapakse VN, Yu C, Zhang H, Fang J, Wu F, Xie H, Saez-Rodriguez J, Ying H, Reinhold WC, Sander C, Pommier Y, Neel BG, Aebersold R, Guo T (2023) Proteomic dynamics of breast cancer cell lines identifies potential therapeutic protein targets. *Mol Cell Proteomics* 22:100602
- Takeda K, Nakayama M, Hayakawa Y, Kojima Y, Ikeda H, Imai N, Ogasawara K, Okumura K, Thomas DM, Smyth MJ (2017) IFN-gamma is required for cytotoxic T cell-dependent cancer genome immunoediting. *Nat Commun* 8:14607
- Taylor BC, Sun X, Gonzalez-Ericsson PI, Sanchez V, Sanders ME, Wescott EC, Opalenik SR, Hanna A, Chou ST, Van Kaer L, Gomez H, Isaacs C, Ballinger TJ, Santa-Maria CA, Shah PD, Dees EC, Lehmann BD, Abramson VG, Pietenpol JA, Balko JM (2023) NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous triple negative breast cancer. *Cancer Discov* 14(2):290
- Teven CM, Schmid DB, Sisco M, Ward J, Howard MA (2017) Systemic therapy for early-stage breast cancer: what the plastic surgeon should know. *Eplasty* 17:e7
- Thery J-C, Spano J-P, Azria D, Raymond E, Llorca FP (2014) Resistance to human epidermal growth factor receptor type 2-targeted therapies. *Eur J Cancer* 50:892–901
- Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SR, Chan A, Goel S, Catron K, Chapman SC, Price GL, Yang Z, Gainford MC, André F (2020) Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarchHER): a randomised, open-label, phase 2 trial. *Lancet Oncol* 21:763–775
- Treilleux I, Arnedos M, Cropet C, Wang Q, Ferrero JM, Abadie-Lacourtoisie S, Levy C, Legouffe E, Lortholary A, Pujade-Lauraine E, Bourcier AV, Eymard JC, Spaeth D, Bachelot T (2015) Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. *Ann Oncol* 26:120–125
- Trowe T, Boukouvala S, Calkins K, Cutler RE Jr, Fong R, Funke R, Gendreau SB, Kim YD, Miller N, Woolfrey JR (2008) EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. *Clin Cancer Res* 14:2465–2475
- Tsang RY, Sadeghi S, Finn RS (2011) Lapatinib, a dual-targeted small molecule inhibitor of EGFR and HER2, in HER2-amplified breast cancer: from bench to bedside. *Clin Med Insights Ther* 3: CMT.S3783
- Tsimberidou AM, Shaw JV, Juric D, Verschraegen C, Weise AM, Sarantopoulos J, Lopes G, Nemunaitis J, Mita M, Park H, Eilers-Lenz B, Tian H, Xiong W, Kaleta R, Kurzrock R (2021) Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. *J Hematol Oncol* 14:127
- Van Swearingen AED, Siegel MB, Deal AM, Sambade MJ, Hoyle A, Hayes DN, Jo H, Little P, Dees EC, Muss H, Jolly T, Zagar TM, Patel N, Miller CR, Parker JS, Smith JK, Fisher J, Shah N, Nabell L, Nanda R, Dillon P, Abramson V, Carey LA, Anders CK (2018) LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. *Breast Cancer Res Treat* 171:637–648
- Vassilopoulos A, Xiao C, Chisholm C, Chen W, Xu X, Lahusen TJ, Bewley C, Deng CX (2014) Synergistic therapeutic effect of cisplatin and phosphatidylinositol 3-kinase (PI3K) inhibitors in cancer growth and metastasis of Brca1 mutant tumors. *J Biol Chem* 289:24202–24214

- Veglia F, Perego M, Gabrilovich D (2018) Myeloid-derived suppressor cells coming of age. *Nat Immunol* 19:108–119
- Viedma-Rodríguez R, Baiza-Gutman L, Salamanca-Gómez F, Diaz-Zaragoza M, Martínez-Hernández G, Ruiz Esparza-Garrido R, Velázquez-Flores MA, Arenas-Aranda D (2014) Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer. *Oncol Rep* 32:3–15
- Wahba HA, El-Hadaad HA (2015) Current approaches in treatment of triple-negative breast cancer. *Cancer Biol Med* 12:106–116
- Wang H, Mao X (2020) Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer. *Drug Des Devel Ther* 14:2423–2433
- Wang Y, Zhou BP (2011) Epithelial-mesenchymal transition in breast cancer progression and metastasis. *Chin J Cancer* 30:603–611
- Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. *Cancer Cell* 10:25–38
- Wang X, Hui R, Chen Y, Wang W, Chen Y, Gong X, Jin J (2019) Discovery of novel doxorubicin metabolites in MCF7 doxorubicin-resistant cells. *Front Pharmacol* 10:1434. <https://doi.org/10.3389/fphar.2019.01434>
- Wang H, Guo S, Kim SJ, Shao F, Ho JWK, Wong KU, Miao Z, Hao D, Zhao M, Xu J, Zeng J, Wong KH, Di L, Wong AH, Xu X, Deng CX (2021) Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel. *Theranostics* 11:2442–2459
- Weiss A, Li T, Desai NV, Tung NM, Poorvu PD, Partridge AH, Nakhlis F, Dominici L, Sinclair N, Spring LM, Faggen M, Constantine M, Krop IE, DeMeo M, Wrabel E, Alberti J, Chikarmane S, Tayob N, King TA, Tolane SM, Winer EP, Mittendorf EA, Waks AG (2023) Impact of neoadjuvant paclitaxel/trastuzumab/pertuzumab on breast tumor downsizing for patients with HER2+ breast cancer: single-arm prospective clinical trial. *J Am Coll Surg* 237:247–256
- Wen C, Fu L, Huang J, Dai Y, Wang B, Xu G, Wu L, Zhou H (2019) Curcumin reverses doxorubicin resistance via inhibition the efflux function of ABCB4 in doxorubicin-resistant breast cancer cells. *Mol Med Rep* 19:5162–5168
- Wibowo MA, Nugroho EP, Hermawan A (2021) Genomic understanding reveals the important role of FGFR2 as paeoniflorin target for circumventing breast cancer resistance to tamoxifen. *Asian Pac J Cancer Prev* 22:3949–3958
- Wisinski KB, Tevaarwerk AJ, Burkard ME, Rampurwala M, Eickhoff J, Bell MC, Kolesar JM, Flynn C, Liu G (2016) Phase I study of an AKT inhibitor (MK-2206) combined with lapatinib in adult solid tumors followed by dose expansion in advanced HER2+ breast cancer. *Clin Cancer Res* 22:2659–2667
- Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao Q (2006) Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. *Cancer Res* 66:1640–1647
- Xie XF, Zhang QY, Huang JY, Chen LP, Lan XF, Bai X, Song L, Xiong SL, Guo SJ, Du CW (2023) Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial. *Breast Cancer Res Treat* 197:93–101
- Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on

- p27, cyclin D1, and antitumor action. *Cancer Res* 62:4132–4141
- Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK (2023) A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. *Breast Cancer Res Treat* 199:457–469
- Yang F, Teves SS, Kemp CJ, Henikoff S (2014) Doxorubicin, DNA torsion, and chromatin dynamics. *Biochimica et Biophysica Acta (BBA) – Reviews on Cancer* 1845:84–89
- Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X (2017) Triple-negative breast cancer: is there a treatment on the horizon? *Oncotarget* 8:1913–1924
- Yardley DA, Arrowsmith ER, Daniel BR, Eakle J, Brufsky A, Drosick DR, Kudrik F, Bosserman LD, Keaton MR, Goble SA, Bubis JA, Priego VM, Pendergrass K, Manalo Y, Bury M, Gravenor DS, Rodriguez GI, Inhorn RC, Young RR, Harwin WN, Silver C, Hainsworth JD, Burris HA 3rd (2017) TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. *Breast Cancer Res Treat* 164:649–658
- Yin S, Bhattacharya R, Cabral F (2010) Human mutations that confer paclitaxel resistance. *Mol Cancer Ther* 9:327–335
- Yin W, Xiang D, Wang T, Zhang Y, Pham CV, Zhou S, Jiang G, Hou Y, Zhu Y, Han Y (2021) The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells. *Sci Rep* 11:10791
- Yoshida R, Tazawa H, Hashimoto Y, Yano S, Onishi T, Sasaki T, Shirakawa Y, Kishimoto H, Uno F, Nishizaki M, Kagawa S, Fujiwara T (2012) Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells. *Cancer Immunol Immunother* 61:1905–1916
- Zafar I, Saba M, Raza MA, Rather MA, Rayan RA, Fatima M, Ain Q, Ishneiwra RM (2021) Roles of bioinformatics in reproductive science. In: *Recent updates in molecular endocrinology and reproductive physiology of fish: an imperative step in aquaculture*, pp 203–228
- Zhang X, Diaz MR, Yee D (2013) Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells. *Breast Cancer Res Treat* 139:351–360
- Zheng M (2022) Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better. *J Immunother Cancer* 10:e003087